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THE BIRTH AND RE-BIRTH OF VITAMIN D3 
Rickets is a bone disease associated with vitamin D3 deficiency that was first described by 
Daniel Whistle in 1645. The Cambridge physician Francis Glisson gave a detailed account of 
rickets in 1650 through his comprehensive investigations (1). However, it was only in the 
early 20'h century that a better understanding of the causative factors of rickets emerged; the 
disease being attributed to a lack of vitamin D3. In 1919, Mellanby's theory of rickets 
resulting from a nutritional disorder (2) had initiated further work that lead to its association 
with vitamin D3. In 1922, a major breakthrough was achieved when Harriette Chick showed 
that whole milk and cod liver oil reduced the prevalence of rickets in children in Vienna (3). 
By 1930s, the use of cod liver oil in the prevention and treatment of rickets became 
widespread (4). 
During the same period, the discovery of vitamin D3 and its biosynthesis pathway was 
elucidated from the work of various researchers in North-Western Europe and North America 
(Figure 1). In 1914, McCollum and Davis were credited for the discovery of the first 
accessory food substance to be recognized as vitamin; they called it 'fat-soluble A'. Cod liver 
oil containing 'fat-soluble A' was first believed to be a single vitamin capable of curing 
xerophthalmia (eye condition resulting from vitamin A deficiency) and rickets. In 1922, 
McCollum showed that cod liver oil heated at the temperature of boiling water for 12 to 20 
hours retained its antirachitic activity in rats but was no longer effective against 
xerophthalmia. It was apparent that two factors were present in 'fat-soluble A' and they were 
later named as vitamin A and vitamin D (5). While McCollum demonstrated that rickets could 
be treated with cod liver oil, Huldshinsky adopted a new approach by exposing rachitic 
children to an ultraviolet (UV)-emitting lamp for two months and observing great 
improvement. This dichotomy was deciphered by Steenbock and Hess who demonstrated 
that UV light induced vitamin D in the fatty portions of diet and of the skin (6). The bridging of 
the knowledge that photosynthesized vitamin D and vitamin D in cod liver oil were similar set 
the platform for a new wave of research leading to the discovery of the biosynthesis pathway 
of vitamin D3. In 1926, Hess (from New York) started working with Windaus (from Göttingen) 
and tested 30 different steroids from various plant sources for antirachitic activity upon 
radiation. Together with Rosenheim (from London), they managed to identify ergosterol as 
the cholesterol which can be converted to vitamin D (7). The ultraviolet irradiation product of 
ergosterol, known as calciferol or vitamin D2, was chemically characterized in 1931 by 
Windaus and its structure was established in 1936 (8). Windaus played a major role in the 
identification, purification and understanding of the chemical properties of vitamin D. He was 
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awarded the Nobel Prize for chemistry in 1928 for his work on the constitution of sterols (9). 
In 1955, the steps involved in the photochemical conversion from ergosterol to calciferol 
(vitamin D2) was reported in French. The complete sequence of steps, from the conversion 
of 7-dehydrocholestrol to pre-vitamin D3 synthesis in the skin, leading to the production of 
1,25(OH)2D3 was illustrated by Holick in 1980 (10). 
Almost a century after the discovery of vitamin D3 (The Birth), vitamin D3 has re-invented its 
role in human health (The Re-birth). Currently, the research interest concerning vitamin D3 is 
focused primarily on its effects on the immune system, cardiovascular system and as anti-
tumor therapy; these are often referred to as the non-classical actions. Two pivotal concepts 
which fuel this heightened interest are: 1 ) sub-optimal vitamin D status is more common than 
previously recognised and 2) new perspectives on the non-hormonal impact of its active 
metabolite, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) are known. 
Until the late 1990s, the criterion for adequate vitamin Da status was simply the absence of 
rickets or osteomalacia. Circulating serum 25-hydroxyvitamin D3 (25(OH)D3) concentration 
has now been accepted as an appropriate marker of vitamin D3 status. The International 
Osteoporosis Foundation states that a serum 25(OH)D3 concentration greater than 75 
nmol/L (30 ng/ml) should be targeted (11). A serum 25(OH)D3 concentration of less than 25 
nmol/L (10 ng/ml) is defined as deficient, while concentrations less than 50 or 75 nmol/L are 
generally considered as insufficient. Vitamin D3 insufficiency is increasingly being recognized 
as a prevalent health problem and affects an estimated 1 billion people worldwide. Across 
the world, individuals at risk of vitamin D3 deficiency include those with dark skin tone, young 
children, pregnant women and the elderly (12). Vieth has given an interesting insight on 
human evolution and vitamin D3 deficiency, with the latter condition leading to natural 
selection for lighter skin tone (13). Through evolution, clothing and shelter minimize the 
biosynthesis of vitamin Da by the skin. Ultraviolet exposure of the entire skin surface of an 
adult is equivalent to 10 000 IU vitamin D (14). Exposure of the face and arms constitutes 
only 5% of the skin surface area. Moreover even for those who live in sunny conditions, they 
are not assured of a desirable 25(OH)D3 concentration due to their way of life as compared 
to their non-human primate counterparts. 
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Figure 1. Summary of the significant events leading to the discovery of vitamin D3 and its non-classical actions 
In modern times, people generally stay indoors most of the time due to a shift from 
agriculture to an industrial and technological society. Moreover, the increased use of 
sunscreen and decreased outdoor activities may also have contributed to the widespread 
prevalence of vitamin D3 insufficiency during the last decades. As mankind migrated out of 
Africa, the vitamin D3 store declined because of a reduced ultraviolet exposure at higher 
latitudes. Skin tone does not impact the amount of 1,25(OH)2D3 being produced, but darker 
skin tone does require longer exposure. Therefore, vitamin D3 deficiency favors natural 
selection for lighter skin tone in geographical areas with lower exposure to ultraviolet light. 
Epidemiological data have established a relationship between vitamin D3 deficiency with 
various health conditions such as infectious diseases (15-18), autoimmune disorders (19), 
cardiovascular diseases (20) and cancer. 
Traditionally, vitamin D3 is known for its function in regulating calcium and phosphate 
homeostasis by enhancing their intestinal absorption, and maintaining bone mineralization 
by mobilizing osteoclastic stem cells to mature and increasing bone resorption (21). A 
completely novel area of interest emerged in the 1980s when several studies suggested a 
link between vitamin D3 and the immune response. One of the initial observations was the 
extra-renal synthesis of 1,25(OH)2D3 in patients with the granulomatous disease sarcoidosis 
(22). Vitamin D3 is first hydroxylated into 25(OH)D3 by 25-hydroxylase (CYP27A1) in the liver 
and further converted by 1 α-hydroxylase (CYP27B1) in the kidney into the biologically active 
form of vitamin D, 1,25(OH)2D3 (21) (Figure 2). Macrophages within the granuloma serve as 
an extra-renal source of CYP27B1, which is up-regulated by interferon (ΙΡΝ)γ and 
lipopolysaccharide (23). Subsequent studies also revealed that 1,25(OH)2D3 synthesis by 
macrophages is common to granulomatous diseases in general, as well as tumors which 
involve significant macrophage infiltration (24). Other tissues known to possess the ability to 
synthesize 1,25(OH)2D3 include pancreatic islets, cerebellum, colonic epithelial cells, breast 
epithelial cells and keratinocytes. The ability to produce 1,25(OH)2D3 for local regulation of 
cellular activity is referred to as paracrine effects. This explains why vitamin D3 is related to a 
variety of cellular functions and can influence many aspects of human health, as exemplified 
in Figure 2. 
The pioneering work leading to the discovery of vitamin D3 involvement in the adaptive 
immune system showed the expression of vitamin D receptor (VDR) by human Τ 
lymphocytes (25;26). The VDR is a steroid hormone nuclear receptor pivotal in mediating the 
cellular effects of vitamin D3. Activation of the VDR by the active form of vitamin D, 
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1,25(OH)2D3 leads to modified gene expression. VDR signaling can influence the expression 
of more than 200 genes (27). Vitamin D receptor in Τ cells influence Τ cell receptor (TCR) 
signaling, leading to Τ cell activation (28). VDR polymorphisms have been associated with 
the clinical course of tuberculosis (29), human immunodeficiency virus (HIV) (30), and viral 
respiratory tract infections (31). 
Over the years, we learn about the interplay between 1,25(OH)2D3 and the immune 
response through in vitro and animal models. We discuss in depth the various 
immunomodulatory roles of vitamin D3 in Chapter 2 of this thesis. In brief, 1,25(OH)2D3 
modulates the antigen presenting ability and the differentiation of monocytes/macrophages 
and dendritic cells. It can also shape the phenotype and function of Τ helper cells and inhibit 
Τ cell proliferation (32). Progressively, we begin to understand the extent of which vitamin D3 
can influence human health and its effect on various diseases such as multiple sclerosis, 
type I diabetes mellitus and more recently, cardiovascular diseases (Figure 2). Based on the 
knowledge harnessed from studies on the role of vitamin D3 on the innate and adaptive 
immune system, observational studies in selected diseases and epidemiology findings, 
research on its potential clinical applications has gathered tremendous enthusiasm and has 
progressed towards randomized placebo-controlled trials in recent years (33;34). Having 
said that, there are new challenges presented to vitamin D immunity research and much still 
needs to be learned on its specific mechanism of immunomodulation in disease states and 
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THESIS OBJECTIVES 
The aims of this thesis are to explore in greater details the role of vitamin D3 in both the 
innate and adaptive immune system, and to contribute towards knowledge on its 
mechanisms and potential clinical applications in infectious diseases. We first examined its 
effects on the immune system in the presence of an infection, in order to understand better 
its clinical role. We also investigated its immunological function on a physiological basis in 
healthy individuals, and on a cellular basis by focusing on regulatory Τ cells (Tregs). 
The immunomodulatory properties of vitamin D3 have generated tremendous interest in the 
field of autoimmune and immune-mediated diseases (32). In Chapter 2 of this thesis, we 
reviewed the in vitro and clinically relevant data on the role of vitamin D3 in various infectious 
diseases, with the intent to identify its therapeutic potential and to identify novel areas for 
further research. 
Vitamin D3 has been known for a long time to influence Mycobacterium tuberculosis (MTB) 
infection (35-38). In order to improve our understanding on its role in the immune response 
to MTB, in Chapter 3 we investigated the effect of 1,25(OH)2D3 on the proinflammatory 
cytokine production induced by M. tuberculosis. We also studied the underlying mechanisms 
responsible for its effect on cytokine production, as well as its effect on the protective 
antimycobacterial peptide cathelicidin. 
The clinical outcome of other infectious diseases such as influenza (16;39), tuberculosis 
(15;17) and HIV infection (40;41) has also been associated with vitamin D3 status. Vitamin 
Ds has also been examined as a preventive and therapeutic agent in viral influenza 
(34;42;43) and tuberculosis (44-47). However, the potential impact of vitamin D3 on fungal 
infections in general, and on Candida albicans infection in particular, is not known. To 
explore the role of vitamin D3 on antifungal immunity, we assessed how in vitro 1,25(OH)2D3 
modulate the innate immune response of human leukocytes challenged by C. albicans in 
Chapter 4. 
Having established that 1,25(OH)2D3 has the capacity to modulate proinflammatory cytokine 
production in vitro and that this effect is attributable to the reduced surface expression of 
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pattern recognition receptors, we investigated its effect in vivo. It is not known whether 
seasonal variation in sun exposure and the resultant physiological vitamin D3 status (48) can 
modulate the immune response. In Chapter 5, we showed that elevated serum vitamin D3 
concentrations during summer act on the innate immune system resulting in attenuation of 
proinflammatory cytokine response in healthy individuals. Next, we examined the seasonal 
impact of vitamin D3 concentrations on the adaptive immune response in Chapter 6. We 
found seasonal changes in the composition of peripheral Τ cell and circulating Treg. This 
knowledge can facilitate our understanding on the amelioration of autoimmune diseases in 
summer, as well as the proposition if vaccine response may perhaps vary when 
administered during different seasons. 
One of the earliest known effect of vitamin D3 has been its capacity to inhibit Τ cell 
proliferation (49;50). Vitamin D3 is also known to induce Tregs by rendering antigen 
presenting cells (APC) tolerogenic (51;52) but its immediate effect on human naturally-
occurring Tregs is less clear. In Chapter 7, we investigated how 1,25(OH)2D3 can directly 
affect the proliferation, suppressive function and cytokine production of human naturally-
occurring Tregs in vitro. 
Human immunodeficiency virus infection is characterized by progressive CD4* Τ cell 
depletion and immune dysfunction. Vitamin D3 deficiency is common among HIV-infected 
patients as compared to healthy controls (18). The high prevalence of vitamin D3 deficiency 
in HIV-infected individuals is probably an unwanted result of highly active anti-retroviral 
therapy (HAART) (53-56). The enzymes involved in the conversion of 1,25(OH)2D3 are part 
of the cytochrome (CYP)450 superfamily and anti-retroviral agents are known to inhibit or 
induce these enzymes. In Chapter 8, we investigated whether cholecalciferol (vitamin D3) 
supplementation can impact Treg trafficking potential in HIV-infected individuals. 
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Chapter 2 
Translating the Role of Vitamin D3 in Infectious Diseases 
Ai Leng Khoo, Louis Y.A. Chai, Hans J.P.M. Koenen, Irma Joosten, 
Mihai C. Netea and André J.A.M. van der Ven 
O υ 
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ABSTRACT 
Vitamin D3 affects both the innate as well as adaptive immune responses. Epidemiological 
studies have established that vitamin D3 deficiency plays an important role in tuberculosis 
(TB) and viral influenza prevalence as well as susceptibility to active disease in TB. Vitamin 
D3 status has been associated with the clinical course of human immunodeficiency virus 
(HIV) infection and drug interaction with anti-retroviral therapy. This article reviews the 
immunomodulatory capacity of vitamin D3 and examines the impact of vitamin D3 
supplementation as a preventive or therapeutic intervention with the intent to uncover its 
potential therapeutic application in infectious diseases and to identify novel areas for future 
research. We present a review of randomized, placebo-controlled clinical studies conducted 
in humans which included assessment of the immune function or clinical outcome as study 
end points. Current data support vitamin D3 supplementation as risk-modifying intervention 
in tuberculosis and viral respiratory tract infection, but the optimal dosage regimen remains 
to be determined. However, to date the knowledge on its role in fungal infection and sepsis 
is limited although a potential benefit could be harnessed from its ability to curtail the 





Vitamin D3 has been conventionally associated with calcium and bone metabolism. It is only 
in recent years that vitamin D3 has been recognized as a potent modulator of the immune 
response. Sources of vitamin D3 include dietary uptake (primarily fatty fish and cod liver oil) 
as well as cutaneous previtamin D3 synthesis from 7-dehydrocholestrol upon ultraviolet 
(UV)-B (290-315 nm) exposure (1). Subsequently, previtamin D3 undergoes a spontaneous 
thermal isomerisation into vitamin D3 which upon entering the circulation, is first hydroxylated 
into 25-hydroxyvitamin D3 (25(OH)D3) by 25-hydroxylase (CYP27A1) in the liver (Figure 1). 
25(OH)D3 is further converted by 1 α-hydroxylase (CYP27B1) in the kidney into the 
biologically active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Metabolism of 
1,25(OH)2D3 is regulated by plasma parathyroid hormone levels as well as serum calcium 
and phosphorus levels. In turn, 24-hydroxylase converts 1,25(OH)2D3 into its inactive 
calcitrale acid, thereby limiting excessive vitamin D3 activity. 
>1< 












ney IW ' 
'Macrophages or DC 1 
1 Τ cells 1 
l1a-hydroxylase 1 ? ^ . _ ./ 
k i d n e y J W ( C Y P 2 7 B 1 ) h " ^"tiretrövTraTagents 
^ ^ e.g. ritonavir 
1,25-dihydroxyvitamin D, 
Figure 1. Vitamin D3 metabolism 
Exposure to UVB light (290-315 nm) results in the first step of vitamin D3 biosynthesis, causing 7-
dehydrocholestrol to form previtamin D3 in the skin. Previtamin D3 is subsequently converted into 
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vitamin D3 which enters the circulation and is first hydroxylated to 25(OH)D3 by 25-hydroxylase 
(CYP27A1) in the liver. 25(OH)D3 is further converted by 1 α-hydroxylase (CYP27B1) in the kidney 
into the biologically active form of vitamin D, 1,25(OH)2D3. Human Τ cells, DCs and macrophages 
express 1 α-hydroxylase and are able to increase cellular 1t25(OH)2D3 levels. 25-hydroxylase 
(CYP27A1) and 1 α-hydroxylase (CYP27B1) belongs to the cytochrome (CY)P450 enzyme 
superfamily and drugs which inhibit these enzymes can have an impact on vitamin D3 status. 
The vitamin D receptor (VDR) is a steroid hormone nuclear receptor pivotal in mediating the 
cellular effects of vitamin D3. Activation of the VDR by the active form of vitamin D, 
1,25(OH)2D3 leads to modified gene expression. VDR signaling can influence the expression 
of more than 200 genes (2). The discovery of VDR expression by human lymphocytes and 
monocytes was one of the first observations which put forward a role for vitamin D3 in the 
immune response (3;4). VDR is expressed by a diverse range of immune cells including 
macrophages, dendritic cells, neutrophils CD4+ and CD8+ Τ cells. The receptor is 
constitutively expressed in monocytes/macrophages (5) while naive CD4+ Τ cells display low 
VDR levels. However, the expression of VDR increases upon activation of Τ cells, 
suggesting an important role for vitamin D3 in influencing adaptive immunity (6;7). Τ cell 
antigen receptor (TCR)-mediated signaling via the protein kinase p38 pathway induces up-
regulation of VDR, and subsequently induction of phospholipase C (PLC)-gammal which is 
responsible for Τ cell activation (8). 
In this review, we present the in vitro immunomodulatory effects of vitamin D3 when 
challenged by pathogens; and focus our discussion on the clinical association between 
vitamin D3 and its therapeutic potential in various infections such as tuberculosis (TB), viral 
influenza, human immunodeficiency virus (HIV) and fungal infections. We aim to provide 
clinicians and researchers with an encompassing view on the prospects of translating 
knowledge on vitamin D3 from bench to bedside. 
ROLE OF VITAMIN D3 IN THE INNATE AND ADAPTIVE IMMUNE RESPONSE 
Increasing interest and research during the past decade has furthered our understanding on 
the influence of vitamin D3 on both the innate and acquired immune response. The host 
innate immune system mounts an instrumental frontline defence against pathogens. 
Macrophages and dendritic cells (DCs), which are the primary antigen presenting cells 
(ARC) bridging the innate with the adaptive immune system, represent an important platform 
through which 1,25(OH)2D3 acts upon. The recognition of microbial pathogen associated 
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molecular patterns (PAMPs) by pattern recognition receptors (PRRs) leads to APC activation 
and elicits adaptive immunity. The antigen presenting ability of monocytes/macrophages can 
be diminished by 1,25(OH)2D3 (Figure 2) as evident by a lower expression of co-stimulatory 
molecules CD80, CD86 and MHC class-ll antigens (9;10). The production of 
proinflammatory cytokines, such as tumor necrosis factor (TNF)a, interleukin (IL)-1ß, IL-6, 
IL-8 and IL-12 in monocytes, is therefore reduced by vitamin D3 (11). We and others have 
shown that this may also be attributable to vitamin D3's capacity to down-regulate 
transcription and hence surface expression of PRRs (12-14). Besides limiting the antigen 
presenting ability of macrophages (9;10), 1,25(OH)2D3 can suppress the maturation and 
differentiation of DCs and influence cytokine responses in these cells (15). This in turn 
dictates the type of Τ cell response. 1,25(OH)2D3 is capable of inducing the differentiation of 
DCs towards a more tolerogenic phenotype (Figure 2), characterized by a high IL-10 
secretion, at the same time with low IL-12 production and a reduced expression of MHC 
class-ll antigens, co-stimulatory molecules CD40, CD80, CD86 and the maturation-induced 
surface marker, CD83 (16-18). Overall, vitamin D3 inhibits DC and macrophage functions 
through attenuation of IL-12 while heightening IL-10-mediated responses. This leads to 
attenuation of Τ helper (Th)1 response while maintaining the ability to induce regulatory Τ 
cell (Treg) function. 
A well-established effect of vitamin D3 has been its capacity to inhibit Τ cell proliferation 
mediated in part through suppression of IL-2 production (19;20), resulting from the direct 
inhibition of NFATp/AP-1 complex formation (21). Vitamin D3 can suppress proinflammatory 
Th1 and Th17 cytokine responses (21-26). While vitamin D3 down-regulates the Th1 
response, at the same time it can enhance IL-4, IL-5 and IL-10 production and promote a 
Th2 response thereby control the proinflammatory cytokine response. (27-30). Furthermore, 
1,25(OH)2D3 either alone or in combination with dexamethasone, can potentiate the 
differentiation of IL-10-producing CD4+CD25+ Tregs (31;32). Tregs are responsible for 
suppressing immune responses and thus limiting excessive inflammation and collateral 
tissue damage. Previously, this effect of vitamin D3 has been thought to be mediated through 
modulation of the APC function exclusively, but recently, Jeffery et al reported that 
1,25(OH)2D3 can act directly on CD4+CD25" Τ cells to suppress the production of 
inflammatory cytokines and generate Foxp3* Tregs expressing high levels of CTLA-4 which 
are capable of immune suppression (23). The net result of 1,25(OH)2D3 action on Τ cell is 
skewing towards Th2 and Treg differentiation and away from Th1 and Th17 polarization 
(Figure 2). Thus, these effects underlined a potential role for 1,25(OH)2D3 in the control of 
autoimmunity. 
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Effects on Τ lymphocytes can be director via the APCs 
Figure 2. An overview of the anti-microbial and anti-inflammatory effects of vitamin D, 
Vitamin D3 can influence the differentiation of naive CD4* lymphocytes directly and indirectly via the antigen presenting cells (APC). Overall, it 
favors a Τ helper (Th)2 and regulatory Τ cell (Treg) cytokine profile over an anti-inflammatory Th1 and Th17 phenotype. Down-regulation of 
Toll-like receptor (TLR) 2, TLR4 and TLR9 on human monocytes/macrophages by vitamin D3 also leads to repression of anti-inflammatory 
cytokines. The antimicrobial effect of vitamin D3 upon TB stimulation is triggered when activation of TLR2/1 causes an up-regulation of both 
vitamin D receptor (VDR) and 1 α-hydroxylase genes. The consequential increased in local production of 1,25(ΟΗ^3 interact with the up-
regulated VDR and in turn activated cathelicidin gene and an increased synthesis of cathelicidin, an antimicrobial peptide. 
Based on what is known about the effect of vitamin D3 on the immune system, with an 
emphasis on proinflammatory Th1 and Th17 responses, this raises the question regarding 
its modulation of host defence in infections. This is highly relevant as it is thought that an 
adverse outcome from sepsis may be accentuated by an over-zealous and unchecked 
proinflammatory host response (33). Hence, we review in vitro and clinically relevant data on 
the role of vitamin D3 on the immune response when challenged by tuberculosis, sepsis, 
influenza, HIV and fungal infections, with the intent to identify potential areas of therapeutic 
application and to uncover novel areas for future work. 
EPIDEMIOLOGY OF VITAMIN D3 DEFICIENCY 
25-hydroxyvitamin D3 is a stable metabolite of vitamin D in the body. The concentration of 
25(OH)D3 is close to around 1000-fold higher than that of 1,25(OH)2D3. 25-hydroxyvitamin 
D3 has a half life of 1-2 months in contrast to that of 1,25(OH)2D3 which is several hours 
(34;35). As such, 25(OH)D3 concentration in the serum is thought to be the best indicator of 
vitamin D3 status (34;36). There is still an ongoing debate on what should be the optimal 
concentration of vitamin D3. A serum 25(OH)D3 concentration of less than 25 nmol/L is 
considered as deficient, while concentrations between 50 and 75 nmol/L are defined as 
vitamin D3 insufficiency (37). Opinions vary when it comes to the optimal vitamin D3 
circulating concentration, though a recent consensus panel recommends that a serum 
25(OH)D3 concentration greater than 75 nmol/L should be targeted (38), while others 
suggest that this target concentration should be higher (39). This recommendation is based 
on the mean serum 25(OH)D3 concentration associated with reduction in fracture risk in 
studies using vitamin D and calcium supplementation. This target 25(OH)D3 concentration is 
also a close estimate for maximal parathyroid hormone suppression and decreasing the 
likelihood of vitamin D3 deficiency-induced secondary hyperparathyroidism (40). 
Vitamin D3 deficiency is endemic and thought to affect an estimated 1 billion people 
worldwide (37). Across the world, individuals at risk of vitamin deficiency include those with 
dark-skin colour, young children, pregnant women and the elderly (41). Vitamin D 
supplementation is available in two forms, vitamin D2 (ergocalciferol) and vitamin D3 
(cholecalciferol). Vitamin D3 has been found to be more effective in elevating the serum 
25(OH)D3 concentrations (42). Vitamin D3 can be administered as low daily doses or in high 
doses as pulse therapy. The dose response of vitamin D3 depends on several factors such 
as baseline serum 25(OH)D3 concentration and body mass index (BMI) (43). For a low 
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baseline 25(OH)D3 concentration, a daily dose of 100 ID (2.5 meg) results in a mean 
increment of 2.75 nmol/L, while this leads to an increment of 1.75 nmol/L for those with high 
baseline concentrations (44). The recommended dose for vitamin D3 supplementation 
ranges from 800 to 2000 ID daily, though higher dosages are believed to be required for 
maintaining the target 25(OH)D3 concentration of 75 nmol/L (35). At 1000 IU and 4000 ID 
per day, serum 25(OH)D3 concentration > 75 nmol/L was attained in 35% (8/23) and 88% 
(22/25) of the subjects respectively (45). An increased risk of hypercalcemia may result from 
excessive vitamin D intake especially during concomitant increased calcium intake or 
dehydration (35). One important note is that current target serum 25(OH)D3 concentrations 
and dosage recommendations for vitamin D3 revolves around its application in bone health, 
while the effective dose required to elicit an effect on the immune system in vivo remains to 
be determined. 
VITAMIN D3 AND TUBERCULOSIS 
Tuberculosis remains as one of the most widely spread diseases worldwide. According to 
the World Health Organization, there were 9.2 million new cases of tuberculosis and 1.7 
million deaths in 2007 (46). The earliest clinical application of vitamin D for the management 
of tuberculosis was documented in 1849 when cod liver oil (rich in vitamin D) was used to 
treat the disease (47). Subsequently, purified vitamin D3 in high doses was used to treat skin 
and pulmonary TB in the pre-antibiotic era before the discovery of effective anti-
mycobacterial agents (48-51). Of note, these studies were anecdotal case series and since 
the mid-1950s, this practice was superseded by the availability of effective anti-tuberculous 
agents. 
Anti-mycobactehal activity is dependent on cell-mediated immune response involving 
macrophages, Τ cells and proinflammatory cytokines. Alveolar macrophages are the first line 
of defence in Mycobacterium tuberculosis (MTB) infection. Vitamin D3 has no direct anti-
mycobacterial action and several modes of action have been put forward. Earlier works 
revealed that 1,25(OH)2D3 induces cellular protection against M. tuberculosis in both 
monocytes (52) and macrophages (53) by limiting the growth of the bacilli. Others have 
shown that 1,25(OH)2D3 generates a superoxide burst (54) in M. tuberculosis-inlecteü cells 
as an anti-tuberculous defence mechanism. The success of the pathogen lies in its ability to 
survive and replicate within macrophages to evade detection by the host immune system, in 
which the avoidance of phagosome-lysosome fusion is vital for M. tuberculosis survival. 
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1,25(OH)2D3 has been shown to augment phagosome-lysosome fusion via a 
phosphoinositide 3-kinase signaling pathway in infected macrophages (55). 
Recently, Liu et al found that the activation of Toll-like receptor (TLR)2/1 on human 
monocytes/macrophages by M. tuberculosis led to an up-regulation of both 1 α-hydroxylase 
and VDR genes (56). Consequently, this led to increased production of 1,25(OH)2D3, which 
in turn interacts with the up-regulated VDR and turn on the cathelicidin gene (Figure 2). 
Cathelicidin is an antimicrobial peptide and the resultant increased cathelicidin production 
leads to killing of intracellular M. tuberculosis. Furthermore, the study showed that when 
serum concentrations of 25(OH)D3 fell below 50 nmol/L, the monocytes/macrophages were 
not able to initiate this innate immune response. This may provide the basis as to why dark-
skinned individuals, who are more prone to being vitamin D3 deficient, are at higher risks of 
contracting tuberculosis and tend to have a more aggressive form of the disease (57). 
The PAMP-PRR interaction between pathogen and host immune cells is critical for the 
activation of immune response against bacterial and fungal infections. TLRs 2, 4, 9 and C-
type lectin receptor Dectin-1 are involved in recognition of M. tuberculosis (58). 1,25(OH)2D3 
suppresses expression of TLRs 2, 4 and Dectin-1 on monocytes (13;14). Subsequently, 
production of the proinflammatory cytokines IL-6, TNFa and interferon (IFN)Y was attenuated 
while IL-10 was increased. We found that this down-regulation of proinflammatory cytokines 
resulted from upstream inhibition of TLRs 2, 4 and Dectin-1 transcription and membrane 
expression, which was reversed by VDR inhibition (59). Furthermore, this observed down-
modulation of PRRs was accompanied by increased cathelicidin production. Focusing on the 
effects of vitamin D3 on intracellular TLRs, Dickie et al reported that TLR9 expression on 
monocytes was down-regulated by 1,25(OH)2D3 while TLR3 was unaffected (12). The 
implication of such down-regulation of proinflammatory cytokine response in the 
pathogenesis of TB needs to be further studied in lieu of other interactions between 
1,25(OH)2D3 and cathelicidin (Figure 2). These two effects may have beneficial 
consequences, by reducing the collateral tissue damage induced by proinflammatory 
cytokines, while the antibacterial effects of cathelicidin are enhanced. 
Epidemiological data have established that vitamin D3 deficiency plays a role in TB 
prevalence and susceptibility to active disease (60-65). Patients with active TB have lower 
serum vitamin D3 concentrations as compared to healthy controls according to a meta-
24 
Vildf· , . ! D.rinr. in i 'H'OPj 
analysis (63). Likewise vitamin D3 deficiency seems to be associated with a 5-fold higher risk 
of progression to active TB in household contacts (64). Amongst African immigrants, there 
was a strong association between vitamin D3 deficiency and TB infection (60). Serum 
25(OH)D3 concentration below 25 nmol/L was reported in 78% of the patients with TB or 
history of TB and 33% of those with latent TB infections. 
Parallel to the uncovering of new evidence pertaining to the immune-modifying effect of 
vitamin D3, there has been a rekindled interest on the possible therapeutic role of vitamin D3 
in TB. Several prospective randomized studies evaluating its application in conjunction with 
standard TB treatment have been performed (Table 1 ). An earlier study was carried out in 24 
newly diagnosed tuberculous children (age 1.5-13 years old) from Egypt, treated with 
rifampicin, isoniazid and streptomycin either alone or with 1000 IU (25 meg) vitamin D for 8 
weeks. There were no statistically significant clinical benefits of vitamin D3 in terms of clinical 
and radiological responses (66). In another study cohort of 67 adults with pulmonary TB from 
Indonesia, a daily dose of vitamin D 10,000 IU (250 meg) was administered for 6 weeks as 
adjunctive therapy (67). Consequently sputum conversion to negative for acid fast bacteria 
was 100% in the vitamin D-supplemented group and 77% in the placebo arm. In addition 
radiological improvement was reported as 88% and 65% in the treatment and placebo group 
respectively, though this was not statistically significant. Of note, the actual vitamin D3 
concentrations were not measured and hence efficacy of this dose in correcting any 
underlying deficiency was unknown. On the other hand, a clinical study involving 356 adults 
from West Africa showed that vitamin D3 convey neither benefit in clinical outcome 
(measured by TBscore) nor reduction in mortality at 12 month (secondary endpoint) in both 
HIV-1 seropositive and seronegative patients (68). The authors employed a high dose 
pulsed therapy consisting of 100,000 IU (2.5 mg) cholecalciferol given at 0, 5 and 8 months 
and attributed the lack of therapeutic response to a suboptimal dosing regimen. When 
pulsed therapy of 100,000 IU cholecalciferol was administered as adjunctive therapy at 0, 
14, 28 and 42 days upon initiation of anti-mycobacterial therapy, the mean serum 25(OH)D3 
concentration was significantly increased from 21 nmol/L to 101 nmol/L at day 56 in the 
intervention group (69). However the time to sputum culture conversion was not affected in 
the entire treatment cohort though it did significantly enhance sputum culture conversion in 
individuals with the tt genotype of the Tagl VDR polymorphism. 
To assess the value of vitamin D3 in preventing reactivation of latent TB, Martineau et al 




Vitamin D dosage Antimicrobial therapy Therapeutic response Vitamin D status 
Adj> unctive therapy 
Morcos et al, 
1998; RCT, Egypt 
Nursyam et al, 
2006, RCT, 
Indonesia 
Wejse et al, 2009, 
RCT, Africa 
24 children (1 5-13 yo) PO 1000 IU daily for Rifampicin, isoniazid 
with pulmonary and 
extrapulmonary TB 
67 adults (15-59 yo) 
with pulmonary TB 
8 weeks 
PO 10,000 IU daily 
for 6 weeks 
365 adults (mean 13 yo) PO 100,000 IU 
with pulmonary and vitamin DjatO, 2 








No statistically significant 
response 
No significant difference 
between treatment and 
placebo arm 
Higher sputum conversion rates (p Not reported 
< 0 05) and radiological 
improvement (p > 0 05) 
No benefit in TBscore or reduction No significant difference 
in 12-months mortality rate between treatment and 
placebo arm at 2 months 
Martmeau et al, 
2011, RCT, UK 
146 adults (25-42 yo) 
with pulmonary TB 
PO 100, 000 IU 
vitamin D3 at 0, 14, 
28 and 42 days after 





No difference m time to sputum 
culture conversion except m 
patients with tt genotype of the 
Taq\ VDR polymorphism 
Mean serum 25(OH)D3 at day 
56 was significantly increased 
from 21 nmol/Lto 101 
nmol/L 
Preventive therapy 
Martmeau et al, 192 healthy adults TB PO 100,000 IU 
2007, RCT, UK contacts (median 30 yo) vitamin D2 stat 
None Enhanced cellular immunity 
against TB m-vitro 
Induced 91%increase in 
serum 25(OH)D3 and 
corrected deficiency for 6 
weeks 
Table 1. Clinical studies on vitamin D3 supplementation in Mycobacterium infections 
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that a single dose of 100,000 IU (2.5 mg) ergocalciferol (vitamin D2) corrected the deficiency 
and resulted in enhanced immunity to mycobacterial infection in vitro (70). Vitamin D3 
enhanced the ability of the whole blood to restrict BCG-lux luminescence in vitro, which 
corresponded to a beneficial effect of vitamin D3 on restricting the growth of bacillus 
Calmette-Guehn. Overall, vitamin 03 supplementation showed promises as a risk-modifying 
agent in TB contacts (70). There are also in vitro evidence that vitamin D3 enhance cellular 
immunity against M. tuberculosis (56). Even though chemotherapy has replaced the use of 
pharmacological doses of vitamin D3 for the treatment of TB, there is indicative evidence for 
use of vitamin D3 in the management of this disease. This is especially true for certain TB 
endemic regions where populations may have a high prevalence of vitamin D3 deficiency 
due to their skin pigmentation (60;64;65). Moreover, some of these areas are also poor in 
resources and vitamin D3 supplementation is an attractive approach to improve their vitamin 
D3 status due to its relatively low cost. However, the therapeutic dosage and clinical benefits 
of adjunctive vitamin Ds in TB treatment remains to be determined. 
VITAMIN D3 AND SEPSIS 
A role for vitamin D3 in the realm of sepsis pathogenesis and sepsis-induced disseminated 
intravascular coagulation (DIVC) may be proposed due to its ability to modulate cytokine 
responses. In the setting of sepsis, it is thought that whilst a 'proinflammatory-type' immune 
response is desirable initially, an unnecessarily prolonged 'hypehnflammatory phenotype' 
may be adverse for the outcome. When unchecked, an overzealous host inflammation 
response results in cellular and organ damage (33). The capacity of 1,25(OH)2D3 to 
modulate cytokine response and induce antimicrobial cathelicidin production makes it a 
promising adjuvant to treatment of sepsis. 
There have been several studies which examined the role of vitamin D3 in experimental 
sepsis models. Sadeghi et al demonstrated in vitro that 1,25(OH)2D3 down-regulates TLR2 
and TLR4 expression on monocytes, resulting in impaired TNFa production (13). During 
sepsis, lipopolysaccharide (LPS), a TLR4 ligand from Gram-negative pathogens induces 
TNFa and triggers release of tissue factor (TF). This results in thrombosis and consequently, 
DIVC. The modulatory role of 1,25(OH)2D3 on TLR4-mediated effects limits the release of TF 
and this function is conceivably beneficial. In animal models, 1,25(OH)2D3 treatment was 
associated with improved blood coagulation parameters in relation to DIVC during LPS-
induced sepsis (71-73). Asakura et al pointed out that this protective effect of vitamin D3 in 
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modulating coagulation disorders is specific to LPS-induced DIVC but not TF-induced DIVC 
(71). As seen in other settings, proinflammatory cytokines such as IL-12 and IFNy were 
markedly reduced by vitamin D3 treatment in LPS-induced sepsis while IL-10 production was 
up-regulated; a higher survival rate was seen in the vitamin Da-treated rats (74). It is also 
interesting to note that treatment with 1,25(OH)2D3 can inhibit LPS-induced activation and 
vasodilatation of the vascular endothelium in rats (75). 
Besides these in vitro and animals studies, one recent study reported a relationship between 
serum 25(OH)D3 concentrations and cathelicidin levels. Jeng et al reported that lower serum 
25(OI-l)D3 and vitamin D binding protein concentrations were seen in critically ill patients as 
compared to healthy controls. More than 95% of the critically ill subjects with and without 
sepsis were found to be vitamin D3 deficient (defined as 25(OH)D3 < 30 ng/ml or 75 nmol/L), 
while that number was 60% for the healthy controls. A lower systemic level of cathelicidin 
was found to be associated with lower serum 25(OH)D3 concentrations (76). 
VITAMIN D] AND VIRAL RESPIRATORY TRACT INFECTIONS 
It has been estimated that in a year, at least one upper respiratory tract infection (URTI) 
afflicts 72% of adults, of which viruses represent the most common pathogens. The main 
endogenous source of vitamin D3 in the body derives from biosynthesis in the skin upon 
ultraviolet exposure (77). A seasonal variation in vitamin D3 status in the temperate climates 
has been recorded. There has been a concern regarding the risk of vitamin D3 insufficiency 
among populations residing at elevated latitudes where solar radiation during a significant 
part of the year is inadequate for endogenous vitamin D3 synthesis (41). Seasonality in 
influenza and URTI occurrence has been attributed to low wintertime vitamin D3 levels (78-
80). Recently an inverse association between serum 25(OH)D3 concentrations and 
incidence of URTI has also been demonstrated. A significant reduction in the risk of 
developing viral URTI was attributed to serum 25(OH)D3 concentrations exceeding 75 
nmol/L (81). In other studies, this benefit was conferred by a higher 25(OH)D3 concentration 
of 100 nmol/L (79;82). 
Currently, clinical studies evaluating the potential benefits of vitamin D3 supplementation in 
reducing the occurrence of seasonal influenza in adults have not been conclusive (83;84), 
although it seems to be associated with protective benefits in children (85) (Table 2). In a 
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double-blind randomized controlled trial (RCT) involving 167 school children (age 6-15 years 
old), supplementation with 1200 IU cholecalciferol daily during winter significantly reduced 
the incidence of influenza A infections On the other hand, supplementation with 
cholecalciferol in 164 adult males at a daily dose of 400 IU for 6 months (October to March) 
did not reduce the incidence of URTI as determined by the number of days absent from 
work. This could be explained by an inadequacy in the dosage used leading to a lack of 
effect on the serum 25(OH)D3 concentration with only 29% individuals in the intervention 
group attaining concentrations beyond 80 nmol/L (mean 72 nmol/L) (84). In a post hoc 
analysis, Aloia et al found a decline in the rates of self-reported influenza and cold symptoms 
in patients supplemented with vitamin D3 (86). The same group later attempted to validate 
this effect in a randomized study and found that while daily supplementation of 2000 IU 
cholecalciferol significantly increased the mean serum 25(OH)D3 concentrations to 88.5 
nmol/L after 12 weeks, there was no benefit in reducing the severity and incidence of URTI 
during winter (83). Not unexpectedly, GM-CSF, IFNy, \L-4, IL-8 and IL-10 levels were lower 
in the intervention group as compared to those in the placebo group (87). 
It would be worthwhile to consider conducting randomized placebo-controlled trials in larger 
populations and with higher doses of vitamin D3 to explore the preventive role of vitamin D 
supplementation in seasonal influenza and acute URTI. Even though the plausible benefit of 
vitamin D3 on influenza and URTI is largely based upon epidemiological data, this 
hypothesis is also built on a reasonably sound scientific basis. Our group has recently found 
a seasonal variability in host cytokine responses, most likely due to differences in vitamin D3 
concentrations, which further supports this hypothesis in vivo (88). Serum 25(OH)D3 
concentrations were higher during summer relative to winter, which correlated with a down-
regulation of proinflammatory cytokine production. Putting forward this notion, it is 
conceivable that vaccination program may confer differential efficacy depending on vitamin 
D3 status and (seasonal) environmental UV exposure. Chadha et al conducted a clinical 
study on prostate cancer patients and found that higher serum 25(OH)D3 concentrations 
were associated with better serological response to influenza vaccine (89). Unfortunately, 
the 25(OH)D3 concentration defining such a response is not known. Conversely, a clinical 
trial in 175 healthy volunteers showed that co-administration of 40 IU vitamin D3 with 
influenza vaccine did not affect serological response (90). Further research is certainly 
needed to validate this postulation as it will have far-reaching implications for implementation 




Vitamin D dosage Antimicrobial therapy Therapeutic response Vitamin D status 
Adjunctive therapy in human immunodeficiency virus infections 




children (6-16 yo) 
PO 100,000 IU vitamin D3 
bi-monthly for 12 months 
Antiretroviral therapy No effect on CD4 counts and viral 44% achieve serum (trough) 
load 25(OH)D3 level > 75 nmol/L 
Preventive therapy in viral URTI and influenza 
Urashima et al, 
2010, RCT, Japan 
Laaksietal, 2010, 
RCT, Finland 
167 children (6- PO 1200 IU vitamin D3 None 
16 yo) daily for 4 months (in 
winter) 
164 adult males PO 400 IU vitamin D3 None 
(18-28 yo) daily for 6 months 
Li-Ngetal, 2009, 162 adults (mean PO 2000 IU vitamin D3 None 
RCT, USA 58 yo) daily for 12 weeks 
Significant reduction influenza A Not reported 
infections (relative risk 0 58,95% 
C I 0 3 4 , 0 9 9 ) 
No benefit in reducing occurrence Inadequate effect with only 
of URTI 29%achieve serum 25(OH)D3 
level > 80 nmol/L 
No benefit in reducing occurrence 73% achieve serum 25(OH)D3 
of URTI in winter level > 75 nmol/L 
Table 2. Clinical studies on vitamin 03 supplementation in viral infections 
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VITAMIN D3 AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION 
Human immunodeficiency virus infection is characterized by progressive CD4+ Τ cell 
depletion and immune dysfunction. The capacity of 1,25(OH)2D3 to modulate HIV infection 
has been examined in human monocytes/macrophages and yielded controversial results. 
Viral replication was reportedly either inhibited or enhanced following pre-treatment with 
1,25(OH)2D3 in vitro (91-93). Conflicting data also arises as to whether addition of 
1,25(OH)2D3 subsequent to HIV infections would result in inhibition (94) or enhancement 
(95) of viral replication. To date, this issue remains largely unresolved. However, it has been 
suggested that CD4 surface expression on monocytes could be reduced by 1,25(OH)2D3 
(91;92) and this may constitute a mechanism to control viral entry and slow disease 
progression. 
In addition, it is known that chemokine receptors CCR5 and CXCR4 act together with CD4 
as co-receptors for viral entry (96). 1,25(OH)2D3 is able to influence lymphocytic homing and 
chemokine receptors expression on 004* lymphocytes. In one study involving human 
leukemic cell line, the surface expression of CXCR4 was enhanced by 1,25(OH)2D3 (97). 
This effect was specific to the cell clone which sustains poor HIV replication. It remains to be 
tested whether 1,25(OH)2D3 can also modulate CCR5 and CXCR4 expression on HIV target 
cells thereby altering the course of viral replication. 
Serum 25(OH)D3 and 1,25(OH)2D3 concentrations are often decreased among HIV-infected 
patients as compared to healthy controls (98). Low levels of 1,25(OH)2D3 and VDR 
polymorphism have been associated with low CD4 counts, immunological hyperactivity, 
AIDS progression and HIV-related mortality (99-102). In a Norwegian (n=53) and a Tanzania 
(n=884) cohort of HIV-infected patients, higher vitamin D3 status offered protection against 
disease progression and mortality (101;102). The high prevalence of vitamin D3 deficiency in 
HIV-infected individuals (98) is probably an unwanted result of highly active anti-retroviral 
therapy (HAART) (103-106). The enzymes involved in the conversion of 1,25(OH)2D3 are 
part of the cytochrome (CY)P450 superfamily and anti-retroviral agents are known to inhibit 
or induce these enzymes. Thus, the interaction between HAART and vitamin D3 metabolism 
enzymes of CYP450 superfamily offers a likely explanation to this observation. In a study 
involving HIV-infected subjects, serum 1,25(OH)2D3 concentrations was found to be the 
lowest in patients receiving protease inhibitors (PI) as part of their HAART (105). The 
postulation that PI suppresses the activity of 1 α-hydroxylase was validated in an in vitro 
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study: in human hepatocyte and monocyte cell lines which express 25-hydroxylase and 1a-
hydroxylase respectively, the Pl-treated cells showed a markedly reduced vitamin D3 
metabolic capacity (107). Recently, other antiretroviral agents such as zidovudine 
(nucleoside reverse transcriptase inhibitor), efavirenz and nevirapine (non-nucleoside 
reverse transcriptase inhibitor) have also been reported to reduce serum vitamin Da 
concentrations (103;104;108). Therefore, the complexity of disease and drug interference 
with vitamin D3 availability justifies careful monitoring and correction of vitamin D3 status in 
this group of patients. 
The clinical effects of vitamin D3 has not been widely documented in HIV- infected patients 
since there have been very few studies performed using vitamin D3 supplementation alone in 
this group of patients (Table 2). In a cohort of 56 children and adolescents (age 6 to 16) 
randomized to receiving a bi-monthly supplementation of 100,000 ID cholecalciferol (with 
daily doses of calcium) or placebo, no differences in CD4 count or viral load over a 12-month 
period were observed, although serum 25(OH)D3 concentrations were higher in the treated 
group (109). 
VITAMIN D3 AND FUNGAL INFECTIONS 
Half a century ago, vitamin D3 was used in the treatment of chromoblastomycosis (110) and 
this treatment was repeated recently (111). We have recently assessed the effect of 
1,25(OH)2D3 on the anti-fungal host defence against a C. albicans model (14). 1,25(OH)2D3 
down-modulated the proinflammatory Th1 and Th17 cytokine responses when human 
leukocytes are stimulated with C. albicans. This effect is mediated by suppression of TLR2, 
TLR4, Dectin-1 and mannose receptor transcription, leading to reduced receptor expression. 
The above observations were validated ex vivo in healthy volunteers followed through the 
four seasons of the year in concordance to the fluctuating vitamin D3 levels. Besides 
providing an insight on the role of vitamin D3 on the pathophysiology of Candida infections, 
these also present in vivo evidence of differential immunomodulatory effects mediated by the 
seasonal fluctuation of vitamin D3 levels. 
In a similar study performed on CD4+ Τ lymphocytes isolated from Aspergillus fumigatus-
colonized cystic fibrosis patients, low serum vitamin D3 concentrations were associated with 
a heightened Th2 activity in patients with allergic bronchopulmonary aspergillosis (112). In 
32 
Vitj'-ii i i Π,.'ΠΓ Infpcfinni 
vitro, vitamin D3 reduced OX40 ligand expression in DCs, while tissue growth factor (TGF)ß 
expression was enhanced, resulting in a preferential Treg induction over Th2 lymphocytes. 
This suggests a role for vitamin D3 in the induction of tolerance, and these effects could 
potentially prevent allergic bronchopulmonary aspergillosis which is caused by a dominant 
Th2 response. Both these studies suggest important immunomodulatory effects of vitamin 
D3 on antifungal immunity and more work needs to be performed to study in greater details 
how vitamin D3 might affect the host response in fungal diseases and its potential 
therapeutic usage. 
FUTURE DIRECTIONS 
In light of its diverse immunomodulatory functions, we propose several situations related to 
infections in which vitamin D3 could be a viable pharmacological adjunct and could modify 
the course of infections (Figure 3). By virtue of its ability to promote regulatory immune 
responses, it is reasonable to think of vitamin D3 as an option to retard the risk of 
reactivation of latent infections such as tuberculosis. Higher serum 25(OH)D3 concentrations 
have been associated with a lower risk of active infection in TB contacts (64). Moreover, 
tuberculosis is known to be endemic in mostly resource-poor areas such as South-East Asia 
and Africa, where the inhabitants are primarily of dark skin colour. Given its relative low cost, 
vitamin D3 supplementation is an attractive and simple intervention that can potentially 
reduce the risk of TB progression. 
Vitamin D3 has the ability to reduce inflammatory response in the respiratory tract epithelium 
(113), and thus provide an attractive pharmacological option to limit disease severity, 
thereby resulting in less symptoms during acute epidemic viral infections caused by 
respiratory syncytial virus and influenza virus. Notably, cutaneous biosynthesis of vitamin D3 
is subjected to seasonal variability and wintertime vitamin D3 deficiency may be one factor 
associated with the remarkable seasonality of epidemic influenza. With the widespread 
annual occurrence of seasonal influenza which translates into loss of working days and 
productivity, it is worthwhile investigating the value of vitamin D3 supplementation for 
influenza prophylaxis and for implementing preventive health policies. On a separate note, it 
is tempting to hypothesize whether response to vaccination efficacy would differ with 
adjunctive vitamin D3 therapy given that very little is known at the moment about this 
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important therapeutic aspect (89;90). Suggestively, vitamin D3 has a role in mucosal 
immunity (114), therefore the route of vitamin D3 administration should be taken into 
consideration together with that of the vaccine, as there may be distinct roles of vitamin D3 
for vaccines administered subcutaneously or orally. 
The counter-inflammatory Th2/Treg profiles induced by 1,25(OH)2D3 (23;26-28;30) may be 
beneficial as an adjunct immunomodulatory agent in specific circumstances in which 
dysregulated host immune responses driven by Th1 and Th17 are implicated in the 
pathogenesis, such as in autoimmune diseases (115; 116) and sepsis (33). Nonetheless, one 
needs to be mindful that in the context of sepsis, mounting an appropriate host 
proinflammatory response at the onset of infection is vital. It is mainly the subsequent 
inability to quench an overzealous inflammatory response which may be detrimental to the 
host. Hence, in lieu of the immune kinetics in sepsis, the use of vitamin D3 as an immune 
modulating agent will need to be carefully timed so as to appropriately alter the disease 
course and optimise the clinical outcome. On another perspective, we postulate that this 
counter-inflammatory effect of vitamin D3 would be desirable in chronic infections whereby 
prolonged inflammatory process contributes to the pathology, as in the case of chronic 
hepatitis Β and hepatitis C infections. Low serum 25(OH)D3 concentrations, resulting from 
reduced vitamin D3 metabolizing enzyme (CYP27A1 ) caused by hepatic necroinflammatory 
activity, in turn correlated with severity of fibrosis and reduced therapeutic efficacy after 
standard antiviral treatment (117). 
Another novel area of vitamin D3 research would be to explore a possible role in infection-
induced autoimmunity. There has been a strong link between vitamin D3 and multiple 
sclerosis (MS), while Epstein-Barr virus infection is a known risk factor for MS (118). 
Modulation of host response to Epstein-Barr virus infection by vitamin D3 could be 
extrapolated to a MS risk-modifying modality (119). In addition, vitamin D3 might also play a 
role in immune reconstitution inflammatory syndrome upon initiation of HAART, although this 
is an area largely unexplored (120). More research will be needed before the above-
mentioned therapeutic potentials of vitamin D3 can be harnessed. 
Having said that, the level of 1,25(OH)2D3 required to effectively elicit a immune modulating 
function remains also largely unknown. One of the pioneering works revealing vitamin D3 as 
an immunomodulatory agent found that macrophages are able to metabolize 25(OH)D3 into 
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1,25(OH)2D3Via the enzyme CYP27B1 (121) (Figure 1). Subsequently, DCs and Τ cells have 
been shown to possess such capability as well (122;123). Indeed vitamin D3 affects many 
systems and holds potential as adjunctive therapy in various disease processes, but the 
threshold needed to exert an immunomodulatory function in various tissues is not yet 
defined. As a matter of fact, it is difficult to assess local 1,25(OH)2D3 concentrations at the 
tissue level in vivo, which is further confounded by the inter-individual variability in CYP450 
enzymes polymorphism. Nonetheless, it is necessary to derive a surrogate estimate for the 
physiological 1,25(OI-l)2D3 concentrations at the tissue level and employ such concentrations 
in the in vitro settings, so that the value of these studies can be extrapolated to clinical 
application. 
Lastly, an interesting aspect for future work would be the interaction of vitamin D3 with drug 
metabolism via the CYP450 superfamily. Vitamin D3 metabolism hinges on 25-hydroxylase 
and 1 α-hydroxylase which are part of the CYP450 enzymes, and anti-retroviral drugs, for 
instance, are known to induce or inhibit this enzyme system (107). In view of the variable 
associations of HIV with metabolic diseases processes, it remains to be determined how the 
modulation of immune responses at the cellular and tissue level via the vitamin D3 pathway 
would be influenced by the administration of HAART. 
CONCLUSIONS 
Current data support the view that vitamin D3 supplementation holds promises as risk-
modifying intervention in tuberculosis and viral respiratory tract infections, but the optimal 
dosage regimen remains to be determined. Besides infectious diseases, vitamin D3 has 
been implicated in potential risk reduction of autoimmune disease processes and 
malignancy beyond the scope of this review (118;124;125). Even though results from bench 
and translational studies have been very promising, more clinical studies and larger 
population-based epidemiological analyses will need to be conducted in order to validate the 
therapeutic benefits of vitamin D3. 
We propose that randomized placebo-controlled trials taking into account variation in 
ethnicity, geographical location and seasonal variability in vitamin D3 status are needed to 
effectively elucidate its therapeutic value (Figure 3). Supplementation with at least 2000 ID 
daily for 8-12 weeks to achieve target serum 25(OH)2D3 levels of 75 nmol/L should be 
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employed in clinical studies. The underlying vitamin D3 insufficiency/deficiency associated 
with certain infections should be corrected in order to further examine the clinical and 
immunological outcomes. The assessment of immunological functions would be of value in 
correlating with clinical outcomes. Moving forward, the optimal therapeutic doses and serum 
25(OH)D3 concentrations required to achieve an optimal impact on these non-classical roles 
of vitamin D3 need to be determined. 
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Recommendations for effective clinical trials: 
1 ) Randomised controlled trials 
2) Stratification of subjects/results according to ethnicity/skin pigmentation, age, 
geographical location and seasonal variability 
3) High dose supplementation with > 2000 III daily for 8-12 weeks 
4) Consensusontargetsenjm25(OH)2D3levels>75nmol/L 
5) Correlation of immunological/dinical outcome with serum 25(OH)2D3 levels 
6) Inclusion of functional immunological studies such as cytokine production 
Figure 3. Potential role of vitamin D3in infectious diseases 
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Vitamin D3 Down-regulates Proinflammatory Cytokine 
Response to Mycobacterium tuberculosis Through Pattern 
Recognition Receptors while Inducing Protective Cathelicidin 
Production 
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ABSTRACT 
A well-known association between vitamin D3 and infection with Mycobacterium tuberculosis 
has previously been reported, but little is known regarding the underlying mechanisms. We 
have investigated how 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) affects the proinflammatory 
cytokine production induced by M. tuberculosis. Furthermore, we explored whether 
1,25(OH)2D3 influence the production of the protective anti-mycobactehal peptide 
cathelicidin. Upon in vitro stimulation with M. tuberculosis, 1,25(OH)2D3 induced a dose-
dependent down-regulation of IL-6, TNFa and IFNy, while increasing the production of IL-10 
in culture supernatant as well as cathelicidin mRNA expression. This effect on cytokine 
response was not due to modulation of Τ helper cell differentiation, as T-bet, GAT A3, Foxp3 
and ROR-yt mRNA expression remained unaffected. Similarly, 1t25(OH)2D3 did not affect 
suppressor of cytokine signaling (SOCS)1 and SOCS3 mRNA expression. The mechanism 
whereby 1,25(OH)2D3 inhibited the proinflammatory cytokine response was through reduced 
expression of the pattern recognition receptors (PRR) such as Toll-like receptor (TLR)2, 
TLR4, Dectin-1 and mannose receptor, whose mRNA and protein expression were both 
reduced. The suppression of PRRs could be restored by a VDR antagonist. Upon M. 
tuberculosis stimulation, 1,25(OH)2D3 modulates the balance in cytokine production towards 
an anti-inflammatory profile by repression of TLR2, TLR4, Dectin-1 and mannose receptor 
expression, while increasing cathelicidin production. These two effects may have beneficial 
consequences, by reducing the collateral tissue damage induced by proinflammatory 
cytokines, while the antibacterial effects of cathelicidin are enhanced. 
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INTRODUCTION 
Mycobacterium tuberculosis (MTB) remains one of the most widespread pathogens. 
According to the World Health Organisation, there were 9.2 million new cases of tuberculosis 
(TB) and 1.7 million deaths in 2007 (1). Cod liver oil (2) and subsequently purified vitamin D3 
in high doses were used to treat and prevent TB in the pre-antibiotic era, before the 
discovery of effective anti-mycobactehal agents in the 1950s (3;4). Vitamin D is either 
synthesized from previtamin D in the skin during exposure to ultraviolet light, or through 
dietary intake, such as oily fish (5). Previtamin D is metabolised into 25-hydroxyvitamin D3 
(25(OH)D3) in the liver which is then further metabolised by 1 α-hydroxylase in the kidney into 
its biologically active form, 1,25(OH)2D3. Several studies and meta analysis have established 
that vitamin D3 deficiency plays an important role in TB prevalence, and in susceptibility to 
active disease (6-10). 
Emerging evidence on the immunomodulatory properties of vitamin D3 has offered a better 
understanding on its effects in mycobacterial infection (11;12). Even though chemotherapy 
has replaced the use of pharmacological doses of vitamin D3 for the treatment of TB, vitamin 
D3 supplementation is a relatively simple intervention in resource-poor settings where TB is 
endemic (13). Several clinical studies addressing the efficacy of vitamin D3 supplementation 
in TB has been conducted in recent times (14). A trial carried out in TB contacts 
demonstrated that a single dose of vitamin D3 corrects deficiency and results in enhanced 
immunity to mycobacterial infection in vitro (15). However, a recent randomized placebo-
controlled trial suggested that high-dose pulsed cholecalciferol regimen given with standard 
TB treatment does not improve clinical outcome or mortality in both human 
immunodeficiency virus (HIV) seropositive and seronegative patients (16). Thus, identifying 
the therapeutic role of vitamin D3 and targeting the right patient cohorts could improve TB 
treatment outcome. 
Anti-mycobacterial activity is dependent on cell-mediated immune response involving 
macrophages, Τ cells and proinflammatory cytokines. Alveolar macrophages are the first line 
of defense in M. tuberculosis infection, and Τ helper (Th)1 responses are essential in 
mounting an effective immunity against M. tuberculosis. Τ cells, monocytes and 
macrophages are known to express vitamin D receptor (VDR) (17;18). Moreover, monocytes 
and macrophages can produce 1 α-hydroxylase which converts 25(OH)D3 into the 
biologically active 1,25(OH)2D3 (19;20). Thus, these cells are believed to be important 
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targets for vitamin D3 action in TB. The interaction of Τ cells with infected macrophages is 
crucial for eliciting protective immunity against the bacillus and depends on the interplay of 
cytokines released. The aim of this study is to investigate how vitamin D3 modulates the host 
cytokine response upon M. tuberculosis challenge in human leukocytes, and to assess the 
involvement of both the innate and acquired immunity. This would offer a better 
understanding on the role of vitamin D3 on the immunopathogenesis of TB and create 
opportunities to explore further its role as an adjunctive therapy in TB. 
MATERIALS AND METHODS 
Microorganisms 
Cultures of M. tuberculosis H37Rv were grown to mid-log phase in Middlebrook 7H9 liquid 
medium supplemented with oleic acid/albumin/dextrose/catalase (Difco, Becton-Dickinson, 
Palo Alto, California, United States), washed three times in sterile saline, and resuspended 
in RPMI 1640 medium at the various concentrations. Separate culture suspensions were 
sonicated for 10 min on ice, in order to obtain cell lysates. 
Reagents 
TLR2 ligand lipopeptide (S)-(2,3-bis(palmitoyloxy)-(2RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-
Ser(S)-Lys4-OH, trihydrochloride (Pam3Cys) was purchased from EMC Microcollections 
(Tübingen, Germany). TLR4 ligand lipopolysaccharide (LPS; Escherichia coli serotype 
055:B5) was purchased from Sigma Chemical Co. (St. Louis, MO, USA). An extra 
purification step of LPS was performed as previously described (21). 1,25(OH)2D3 was 
purchased from Fluka Biochemika, Sigma-Aldrich (Missouri, USA) and dissolved in absolute 
ethanol. The 25-carboxylic ester vitamin D analog ZK159222 (22) was synthesized at Bayer 
Schering Pharma AG (Berlin, Germany) and a stock solution of 10~2 M by dissolving in 
absolute ethanol. 
Stimulation assays 
Venous blood was drawn into EDTA tubes from healthy volunteers after informed consent. 
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation on 
Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Cells were washed twice in saline, 
counted and the number adjusted to 5 χ 106 cells/ml. A 100 μΙ volume of PBMC, suspended 
in culture medium (RPMI 1640 DM; ICN Biomedicals, Costa Mesa, CA) supplemented with 
10 pg/ml gentamicin, 10 mM l-glutamine, 10 mM pyruvate and 10% human pooled serum 
was added to flat-bottomed 96-well plates (Greiner, The Netherlands). 
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PBMC were pre-incubated with M. tuberculosis or RPMI (as unprimed control). Cell cultures 
were incubated in a 37°C, 95% humidity, 5% CO2 incubator. The culture supernatants were 
collected after 24, 48 h or 7 days of incubation as appropriate and stored at -20 °C until 
cytokine assay. 
Flow cytometry 
Cells were phenotypically analyzed by five-color flow cytometry (Coulter Cytomics FC 500, 
Beekman Coulter, Fullerton, USA) using Coulter Epics Expo 32 software. Cells were washed 
with PBS with 0.2% bovine serum albumin (BSA) before being labeled with fluorochrome-
conjugated antibodies (mAb). After incubation for 20 min at room temperature in the dark, 
cells were washed twice to remove unbound antibodies and analyzed. For cell surface 
staining, the following mAb were used: Dectin-1 -PE (259931, R&D Systems, Minneapolis, 
MN), TLR2-FITC (TL2.1) and TLR4-PE (HTA125); both from eBioscience, San Diego, CA 
and mannose receptor (MR)-FITC (19.2; BD Bioscience, New York, NY). 
Cytokine measurements 
Interleukin (IL)-6, IL-10 and interferon (IFN)Y concentrations were measured by use of 
commercial sandwich ELISA kits (Pelikine Compact, CLB, Amsterdam, The Netherlands) 
according to the manufacturer's instructions. Human tumor necrosis factor alpha (TNFa) was 
measured by the appropriate commercial ELISA kits (R&D Systems, Minneapolis, MN). 
Detection limits were 8 pg/ml (IL-6 and IL-10), 20 pg/ml (IL-1ß and IFNy) and 40 pg/ml 
(TNFa). 
Quantitative polymerase chain reaction (PCR) 
To determine mRNA expression, RNA was extracted from PBMC stimulated with M. 
tuberculosis in the presence and absence of 1,25(OH)2D3 for 24 h. RNA was extracted from 
107 PBMC by using 1 ml TRIzol reagent (Sigma, St Louis, MO). Subsequently, 200 μΙ 
chloroform and 500 μΙ 2-propanol (Merck, Darmstadt, Germany) were used to separate the 
RNA from DNA and proteins. Finally, after washing with 75% ethanol, the dry RNA was 
dissolved in 50 μΙ of diethylpyrocarbonate (DEPC) water. The amount and quality of mRNA 
were determined using a NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE). cDNA was synthesized from using Superscript Reverse 
Transcriptase (Invitrogen) 
Quantitative real-time PCR was performed using the Bio-Rad iCycler and SYBR green. The 
following primers were used (5-3'): TGCCCAGGTCCTCAGCTAC (forward) and 
GTGACTGCTGTGTCGTCCT (reverse) for cathelicidin; AACCTCAGACAAAGCGTCAAATC 
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(forward) and ACCAAGATCCAGAAGAGCCAAA (reverse) for TLR2; 
TTCCTTCAACCAAGAACATAGATC (forward) and TTGTTTCAATTTCACACCTGGATAA 
(reverse) for TLR4; ACAATGCTGGCAACTGGGCT (forward) and 
GCCGAGAAAGGCCTATCCAAAA (reverse) for Dectin-1 ; TCAAGACAATCCACCAGTTACT 
(forward) and TTCTCTTTGCTGAAATAATACTGGTAGTC (reverse) for MR; 
GCAGGCGACAATGCAGTCT (forward) and GAACGGAATGTGCGGAAGTG (reverse) for 
S0CS1; TGCGCCTCAAGACCTTCAG (forward) and GAGCTGTCGCGGATCAGAAA 
(reverse) for SOCS3 and ATGAGTATGCCTGCCGTGTG (forward) and 
CCAAATGCGGCATCTTCAAAC (reverse) for β2 microglobulin (B2M) (Biolegio, The 
Netherlands) as housekeeping gene. 
In another system, transcripts were quantified by real-time quantitative PCR on an 
ABIPRISM 7700 Sequence Detector using pre-designed TaqMan GeneExpression Assays 
and reagents according to the manufacturer's instructions (Applied Biosystems, Foster City, 
CA). Probes with the following Applied Biosystems assay identification numbers were used: 
TBX21 (Tbet), Hs00203436_m1; GATA3, Hs00231122_m1; FOXP3, Hs00203958_m1; 
RORC1-2, Hs00172858_m1; RORC10-11, Hs01076112_m1, using human HPRT1 
Endogenous Control (4333768T; Applied Biosystems) as housekeeping gene. 
All primers were validated according to the protocol. Mean relative mRNA expression was 
calculated using Pfaffl method. Values are expressed as ratio of fold increase to mRNA 
levels of vitamin Da-untreated cells. 
Statistical analysis 
Results from at least five sets of experiments were pooled and analyzed using SPSS 16.0 
statistical software. Data given as means ± SE and the Wilcoxon signed rank test was used 
to compare differences between 2 groups: without (control) and with vitamin D3, unless 
otherwise stated. The level of significance was set at Ρ < 0.05. 
RESULTS 
1,25(01-1)203 diminishes the proinflammatory cytokine response to M. tuberculosis 
Firstly, we investigated the effects of 1,25(OH)2D3 on immune response to M. tuberculosis by 
stimulating PBMC in the presence of 1, 10 and 100 nM 1,25(OH)2D3 and assessed the 
cytokine levels in the supernatant. Using a concentration of 10 and 100 nM 1,25(OH)2D3, 
tumor necrosis factor (TNF)a and IL-6 production was decreased by more than 50-85%, in a 
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dose-dependent manner (P < 0.05). Reduction in interferon (ΙΡΝ)γ secretion was apparent at 
even the lowest dose of 1 nM 1,25(OH)2D3 and it was significantly suppressed with a greater 
than 90% drop at 100 nM 1,25(OH)2D3. On the contrary, IL-10 production was increased by 
1.5-2.5 folds at 10 and 100 nM, respectively (Pigure 1). These results implied that 
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Figure 1. 1,25(OH)2D3 modulates cytokine response and antimicrobial peptide production to 
MTB 
PBMC were incubated with 1-100 nM 1,25(OH)2D3 and stimulated with IO5 HK MTB. Supernatants 
were collected and analyzed for: (A) TNFa, (B) IL-6, (C) IFNy and (D) IL-10 at 24 h. (E) 1,25(OH)2D3 
increases the expression of the cathelicidin at the transcription level at 24 h. PBMC were incubated 
with and without 100 nM 1,25(OH)2D3 and stimulated with IO5 HK MTB. Quantitative PCR for human 
cathelicidin gene was normalized to ß2M gene expression. Data show results from six independent 
experiments performed with cells obtained from different donors. *P < 0.05 as compared to respective 
cell culture without the addition of 1,25(OH)2D3. 
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1,25(OH)2D3 is able to modify the cytokine response to M. tuberculosis towards an anti­
inflammatory profile. 
1,25(OH)2D3 induces the production of cathelicidin 
We also examined the antimicrobial effect of vitamin D3 by measuring cathelicidin 
production, which is an important component of antl-mycobacterial host defense. Despite 
the attenuated proinflammatory cytokine profile, the transcription of the antimicrobial peptide 
cathelicidin was up-regulated 16-fold by adding 100 nM 1,25(OH)2D3 to the system (Figure 
1E). Henceforth, 1,25(OH)2D3 is able to induce antimicrobial defence in response to M. 
tuberculosis. 
1,25(OH)?D3 does not attenuate cytokine response to M. tuberculosis through 
induction of SOCS or modulation of Τ cell differentiation 
From the above observations, we postulated that 1,25(OH)2D3 could have modulated the 
proinflammatory cytokine response to M. tuberculosis via induction of the suppressor of 
cytokine signaling (SOCS) proteins or modulation of Τ cell differentiation pathways. We 
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Figure 2. Vitamin D3 does not modulate Τ helper differentiation or SOCS expression 
(A) 1,25(OH)2D3 does not affect Τ cell transcription factors. (B) There is no significant effect by 
1,25(OH)2D3 on SOCS1 and SOCS3. Quantitative PCR for human Tbet, GATA3, Foxp3, ROR-yt, 
SOCS1 and SOCS3 was conducted with PBMC and normalized to ß2M gene expression. Cells were 
stimulated with 105 HK MTB and incubated with 10 nM 1,25(OH)2D3 or solvent for 24 or 4 h (SOCS1 
and 3). Data show results from five independent experiments performed with cells obtained from 
different donors and are expressed as fold change relative to controls. 
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Τ cell (Treg) phenotype. Therefore, we performed quantitative polymerase chain reaction 
(PCR) to analyze the gene expression of the various Τ cell transcription factors upon M. 
tuberculosis stimulation on PBMC, in the presence of 1,25(OH)2D3. We found no significant 
changes in T-bet, GATA3, Foxp3 or ROR-yt mRNA expression (Figure 2A) 24 h after 
stimulation. We also assessed SOCS1 and SOCS3 mRNA expression under the same 
conditions and found no significant effects induced by 1,25(OH)2D3 (Figure 2B). 
TLR2 and TLR4 mRNA and protein expression were decreased by 1,25(OH)2D3 
TLR2, TLR4, Dectin-1 and mannose receptors (MR) are pattern recognition receptors (PRR) 
known to be involved in M. tuberculosis infection. Hence, we investigated whether 
1,25(OH)2D3 could have acted through the various PRRs. We stimulated PBMC with M. 
tuberculosis, with or without 100 nM 1,25(OH)2D3, or with 100 nM 1,25(OH)2D3 followed by 
1000 nM vitamin D receptor (VDR) antagonist. Flow cytometric analysis of the various 
receptors was performed at 24, 48 h and day 4, and quantitative PCR was carried out to 
analyze the gene expression of TLR2 and TLR4 at 24 h. The surface expression of both 
TLR2 and TLR4 was reduced by 1,25(OH)2D3 (Figure 3A and B) at 24, 48 h and day 4; data 
not shown for 24 h and day 4. Furthermore, TLR2 and TLR4 mRNA was decreased by 
1,25(OH)2D3 at 24 h and was restored by the addition of a VDR antagonist, ZK159222 
(Figure 3C). 
Reduced C-type lectin receptors expression mediated by 1,25(OH)2D3 could be 
reversed by a VDR antagonist 
With the same experimental set-up as above, we analyzed the effects of 1,25(OH)2D3 on C-
type lectin receptors (CLR), namely Dectin-1 and mannose receptors. The surface 
expression of Dectin-1 receptor and MR was also inhibited by 1,25(OH)2D3 (Figure 4A and 
B) at 48 h and day 4 of incubation with M. tuberculosis, respectively. The expression of 
Dectin-1 receptor on flow cytometry was also reduced at 24 h and day 4 (data not shown), 
but MR expression was not apparent until day 4. The mRNA levels of these two receptors 
were also reduced in the presence of 1,25(OH)2D3 at 24 h. This effect could be reversed by 
the VDR antagonist ZK159222 (Figure 4C). 
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Figure 3. 1,25{OH)2D3 inhibits 
TLR2 and TLR4 expression 
Representative histogram overlay 
plots show decreased: (A) TLR2 
and (B) TLR4 expression at 48 h 
with 1,25(OH)2D3 treatment as 
assessed by flow cytometry. (C) 
1,25(OH)2D3 down-modulates the 
expression of these PRRs at the 
transcription level at 24 h and 
VDR antagonist reverse this 
effect. PBMC were Incubated with 
and without 100 nM 1,25(OH)2D3 
or with 100 nM 1,25(OH)2D3 
followed by 1000 nM VDR 
antagonist, ZK159222; and 
stimulated with IO5 HK MTB. 
Quantitative PCR for human 
TLR2 and TLR4 were normalized 
to ß2M gene expression. Data 
show results from six 
independent experiments 
performed with cells obtained 
from different donors and are 
expressed as fold change relative 
to controls. 
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Figure 4. 1,25(OH)?D3 suppress 
Dectin-1 receptor and MR 
expression 
Representative histogram overlay 
plots show 1,25(OH)2D3 down-
regulate the expression of: (A) 
Dectin-1 receptor and (B) MR with 
1,25(OH)2D3 treatment as assessed 
by flow cytometry. (C) 1,25(ΟΗ^3 
suppresses the expression of 
Dectin-1 receptor and MR at the 
transcription level at 24 h. Treatment 
with VDR antagonist reverses this 
effect. PBMC were incubated with 
and without 100 nM 1,25(ΟΗ^3 or 
with 100 nM 1,25(OH)2D3 followed by 
1000 nM VDR antagonist, 
ZK159222; and stimulated with 105 
HK MTB. Quantitative PCR for 
human Dectin-1 and MR were 
normalized to ß2M gene expression. 
Data show results from six 
independent experiments performed 
with cells obtained from different 
donors and are expressed as fold 
change relative to controls. 
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DISCUSSION 
Although the use of pharmacological doses of vitamin D3 in the treatment of tuberculosis is 
no longer in practice due to the availability of anti-mycobacterial chemotherapy, the 
immunomodulatory role of vitamin D3 in TB has gained an increased research interest. This 
study demonstrates that 1,25(OH)2D3 down-modulate host proinflammatory cytokine 
response to M. tuberculosis, while inducing the antimicrobial peptide cathelicidin. This effect 
on cytokine profile is mediated by VDR-dependent modulation of the various key PRRs 
involved in M. tuberculosis, TLR2, TLR4 and the C-type lectin receptors-Dectin-1 and MR. 
The most important observation of the present study is that while vitamin D3 down-
modulates the proinflammatory cytokine profile, it induces an antimicrobial response. We 
demonstrated a 16-fold increase in the antimicrobial peptide cathelicidin production with 
vitamin D3 treatment upon M. tuberculosis challenge. As reported previously, induction of 
cathelicidin by vitamin D3 is largely accountable for its antimicrobial activity against 
intracellular M. tuberculosis (23). Here, we also showed that 1,25(OH)2D3 differentially 
influenced cytokine profile during M. tuberculosis challenge, with production of the 
proinflammatory cytokines IFNy, TNFa and IL-6 notably reduced, while production of the 
anti-inflammatory cytokine IL-10 was up-regulated. In an ex vivo study using slightly different 
stimulation with M. tuberculosis antigen and live M. tuberculosis, Vidyarani et al described 
decreased IL-6, IL-8, IL-10, IL-12p40 and IFNy and increased IL-4 production by 
1,25(OH)2D3 (24). Here, we went a step beyond to evaluate the mechanism of action 
through which 1,25(OH)2D3 modulates cytokine production. It has been previously shown 
that vitamin D3 can modify the balance between Th1 and Th2 response (25-27), and we 
hypothesized that the increased IL-10 seen in our TB model could be the result of skewing 
towards Th2 differentiation pathway or the expansion of Treg population (28;29). However, 
there were no notable shifts in the Τ helper cell or Treg transcription factors: T-bet, GATA3, 
Foxp3 or ROR-yt mRNA expression was not changed by 1,25(OH)2D3 treatment in our 
study. Since there was significant suppression of IL-6 and IFNy by 1,25(OH)2D3, we 
investigated whether the underlying mechanism was due to unknown 1,25(OH)2D3 effects on 
the SOCS3 and SOCS1 regulatory pathways (30). However, there was no pronounced 
stimulation of SOCS1 and SOCS3 mRNA by 1,25(OH)2D3 that could have been related with 
the down-regulation of proinflammatory cytokine production. 
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We next investigated whether alteration of PRR expression could account for the shift in the 
cytokine balance induced by 1,25(OH)2D3. Interestingly, 1,25(OH)2D3 reduced surface 
expression of TLR2 and TLR4 and when investigated further revealed that its action was 
attributable to upstream inhibition at the mRNA transcription level. Upon reversal of inhibition 
by a VDR antagonist, we validated that this effect was mediated by VDR signaling. The 
detection of pathogen-associated molecular patterns by PRRs is crucial for the initiation and 
coordination of the immune response against mycobacterial infections. TLR signaling is the 
main arm of innate immunity upon challenged by M. tuberculosis, with involvement of 
primarily TLR2, TLR4 and TLR9 (31;32). Previously, Liu et al reported that activation of 
TLR2/TLR1 on human macrophages increased 1,25(OH)2D3 synthesis by these cells. This 
consequently induced an up-regulation of the antimicrobial peptide cathelicidin, leading to 
killing of intracellular M. tuberculosis (20). Here, we showed a converse relationship with 
1,25(OH)2D3 acting via VDR to down-regulate TLR2 expression. This finding brings about a 
new perspective how VDR and TLR signaling pathways interact. Another interesting point is 
the observation of a down-modulation of Th1 cytokine response in parallel with TLR2 
expression. This may suggest that TLR2 signaling negatively modulates macrophage 
functions and curtails Th1 activation (33;34). 
Besides the TLRs, Dectin-1 and MR are also related to macrophages' activity against M. 
tuberculosis (35-37). Of note, we were able to demonstrate that 1,25(OH)2D3 can also down-
regulate Dectin-1 and MR surface and mRNA expression. To date, only the TLRs have been 
reported to be associated with the immunologic activities of vitamin D3 and VDR signaling 
pathway. This is the first study to report effects of vitamin D3 on the expression of C-type 
lectin receptors. In addition, our results also suggest that the immunomodulatory effects of 
1,25(OH)2D3 against M. tuberculosis arise from its influence on innate, rather than acquired 
immune response. This interpretation is in keeping with an in vitro study conducted to 
evaluate innate and acquired host response in TB contacts. While a single oral dose of 
2.5 mg ergocalciferol led to an increase in serum and supernatant 25(OH)D3 concentration, 
the effect seemed to be primarily enhanced innate immunity to mycobacterial infection (15). 
Vitamin D3 has no direct anti-mycobacterial action and several modes of action have been 
put forward. Earlier work in the 1980s revealed that 1,25(OH)2D3 improve the bactericidal 
activity against M. tuberculosis in vitro in both monocytes (38) and macrophages (39). 
Others have shown that 1,25(OH)2D3 generates a superoxide burst (40) and enhances 
phagosome-lysosome fusion in macrophages infected with M. tuberculosis (41). Our 
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findings on 1,25(OH)2D3 dampening the proinflammatory cytokine response through TLR2/4, 
Dectin-1 and MR signaling provided new insights on the immunologic capacity of vitamin D3 
towards M. tuberculosis. 
Contrary to the common belief that Th1 cytokines are beneficial in TB treatment outcome 
(42;43), our data showed that vitamin D3 skew the cytokine balance away from a Th1 
phenotype. The signature cytokine of Th1 responses, IFNy, contributes to protective 
immunity against M. tuberculosis (44), while TNFa plays an important role in activating 
macrophages and facilitating granuloma formation (45). However, excessive secretion and 
release of TNFa into the circulation generate systemic side effects such as fever and 
wasting as well as local deleterious effects in the tissues, which can account for clinical 
deterioration early in treatment (46). lnterleukin-6 has both pro- and anti-inflammatory 
properties and it is said to be harmful in mycobacterial infections due to its inhibitory effects 
on IFNy and TNFa (47), as well as its ability to promote in vitro growth of Mycobacterium 
avium (48). 
lnterleukin-10 is an anti-inflammatory cytokine and has been associated with depressed Τ 
cell IFNy response against M. tuberculosis (49;50). Given that Th1 cytokines are often found 
along with IL-10, we suppose it is the relative balance between these two cytokines that 
determines whether the protective immunity against M. tuberculosis is suppressed. One 
study noted significantly higher levels of TNFa, IFNy, IL-10 and IL-12p40 in active pulmonary 
TB cases as compared to inactive cases and healthy controls. With anti-mycobacterial 
therapy, TNFa, IFNy and IL-10 concentrations were decreased (51). In another study, TNFa 
production was elevated while IFNy secretion was reduced in active pulmonary TB patients 
as compared to healthy individuals. IFNy trends correlated inversely with disease severity 
and were reversed with increase in IFNy/IL-IO ratios during anti-mycobacterial therapy (43). 
In our study, we showed that vitamin Da is capable of inducing the production of 
antimicrobial peptide cathelicidin, while limiting the proinflammatory cytokine response. An 
unrestrained proinflammatory response may give rise to excessive tissue damage. On the 
other hand, anti-inflammatory cytokines limit tissue injury by inhibiting excessive 
inflammatory response. Therefore, regulating the pro- and anti-inflammatory cytokine 
response influences the outcome of tuberculosis treatment We speculate from our data that 
by manipulating vitamin D3 therapy to attain an anti-mycobacterial effect while limiting 
excessive proinflammatory response during TB, desirable treatment outcome could be 
achieved. Having said that, future studies are warranted to optimise this model and to 
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identify the vitamin D dosages that may exert beneficial effects during disease. In addition, 
future animal studies to strengthen and validate the above findings and the potential value of 
adjunctive vitamin D3 therapy in TB are warranted, as well as to find the optimal dosage 
regimen to attain the desired therapeutic effects. Further studies on the interplay between 
TNFa and IFNy with cathelicidin in an in vivo system may elucidate key information on 
achieving protective immunity, while limiting excessive collateral tissue damage implied by 
our in vitro model. 
In conclusion, we describe immunomodulatory effects of 1,25(OH)2D3 that dampens 
proinflammatory cytokine responses as a result of inhibition of TLR and CLR expression. On 
the other hand, 1,25(OH)2D3 induces antimicrobial effects by up-regulating the production of 
cathelicidin. Future studies are warranted to investigate the role of vitamin D3 in controlling 
cytokine dynamics in different tuberculosis patient cohorts, to gain greater knowledge on 
how we can best employ this therapy to augment the outcome and prognosis of TB. 
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ABSTRACT 
Our interest in the immunological effects produced by vitamin D3 (1,25(OH)2D3) and its 
therapeutic potential prompted us to examine the role of 1,25(OH)2D3 on cytokine production 
induced by Candida albicans. Peripheral blood mononuclear cells (PBMC) were stimulated 
with C. albicans and 1,25(OH)2D3, cytokine concentrations were measured in culture 
supernatant. Quantitative polymerase chain reaction (qPCR) was performed for Τ cell 
transcription factors, suppressor of cytokine signaling (SOCS)1 and 3. Toll-like receptor 
(TLR)2/4, Dectin-1, and mannose receptor (MR) expression was studied using flow 
cytometry and qPCR. An ex vivo stimulation study was carried out in healthy volunteers to 
investigate the seasonality of immune response to C. albicans. Upon in vitro C. albicans 
stimulation, 1,25(OH)2D3 induced a dose-dependent, down-regulation of IL-6, TNFa, IL-17, 
and IFNy. It also increased IL-10 production. The shift in cytokine profile was not due to 
1,25(OH)2D3 augmenting expression of either Τ helper differentiation factors or SOCS1 and 
SOCS3 mRNA. 1,25(OH)2D3 inhibited TLR2, TLR4, Dectin-1, and MR mRNA and protein 
expression. In our seasonality study, both IL-17 and IFNy levels were suppressed in summer 
when 25(OH)D3 levels were elevated. Vitamin D3 skews cytokine responses toward an anti­
inflammatory profile, mediated by suppression of TLR2, TLR4, Dectin-1, and MR 
transcription, leading to reduced surface expression. The biological relevance of these 
effects has been confirmed by the seasonality of cytokine responses. 
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INTRODUCTION 
Beyond its classical role on bone metabolism, vitamin D3 has now been widely accepted as 
a potent modulator of immune function affecting various cell types. This view is based on 
several fundamental observations (1). First, vitamin D receptor (VDR), through which 
biologically active 1,25(OH)2D3 acts, is expressed by most immune cells, including Τ 
lymphocytes, neutrophils, macrophages, and dendritic cells (1-4). Second, Τ lymphocytes, 
macrophages, and dendritic cells are equipped with enzymes to metabolize 25(OH)D3 into 
1,25(OH)2D3 (5-7). Third, 1,25(OH)2D3 can influence both innate and adaptive immune cell 
types. Vitamin D3 has been shown to increase the proliferation and maturation of monocytes 
to macrophages in vitro (8;9). It also suppresses Τ cell proliferation and differentiation (10). 
1,25(OH)2D3 is known to induce a more tolerogenic phenotype in dendritic cells (11). In 
addition, it can skew Τ cell response toward a Τ helper (Th) 2 profile (7;12). 
The above immunomodulatory properties of vitamin D3 have fueled much interest on vitamin 
D3 potential as a therapeutic agent in infectious diseases. Most notably, the clinical course of 
tuberculosis (TB) (13), as well as viral influenza and human immunodeficiency virus (HIV) 
infection, has been associated with vitamin D3 status (14;15). However, the capability of 
vitamin D3 to modulate the host immune response to fungal infections is still unknown. 
Invasive candidiasis remains a disease with significant mortality and morbidity in hospitalized 
patients (16). Both innate and adaptive immunity are essential for optimal defence against 
fungal infections. Despite the current range of available antifungal therapy, mortality rates 
from invasive candidiasis remains high. This is partly due to the host's inability to mount a 
successful immune response to the invading fungi. 
We know that vitamin D3 is a powerful immunomodulator. However we do not know its 
potential impact on Candida albicans infection. We hypothesize that 1,25(OH)2D3 can 
modulate the innate immune response of human leukocytes challenged with C. albicans. We 
therefore surmise that the knowledge gained in this study will increase our understanding of 
the potential of vitamin D3 as an adjunct immunotherapeutic agent against invasive fungal 
infections. In addition, due to the seasonal human variability of vitamin D3 stores, we hoped 
to further validate our in vitro findings in a non-interventional, ex vivo setting by measuring 
cytokine response to C. albicans stimulation in a small cohort of healthy volunteers over a 1-
year period. 
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MATERIALS AND METHODS 
Micro-organisms 
Heat-killed C. albicans blastoconidia, a strain of American Type Culture Collection MYA-
3573 (UC820), were used at a concentration of 105 micro-organisms/mL as previously 
described (17;18). 
Reagents 
Toll-like receptor (TLR)2 ligand lipopeptide (S)-(2,3-bis(palmitoyloxy)-(2RS)-propyl)-N-
palmitoyl-(R)-Cys-(S)-Ser(S)-Lys4-OH, trihydrochloride (Pam3Cys), was purchased from 
EMC Microcollections (Tübingen, Germany). TLR4 ligand lipopolysacchande (LPS; E. coli 
serotype 055:B5) was purchased from Sigma Chemical Co (St Louis, MO, USA). An extra 
purification step of LPS was performed as previously described (19). Particulate ß-glucan 
was a kind gift from Dr. David Williams (University of Tennessee) (20). 1,25(OH)2D3 was 
purchased from Fluka Biochemika, Sigma-Aldrich (Missouri, USA) and dissolved in absolute 
ethanol. 
Stimulation assays 
Venous blood was drawn into EDTA tubes from healthy volunteers after informed consent. 
The study protocol was approved by institutional ethics committee. PBMC were isolated by 
density centrifugation on Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Cells were 
washed twice in saline and counted. The cell counts were adjusted to 5x106 cells/mL. A 100 
μ ι volume of PBMC, suspended in culture medium (RPMI 1640 DM; ICN Biomedicals, 
Costa Mesa, CA) and supplemented with 10 pg/mL gentamicin, 10 mM L-glutamine, 10 mM 
pyruvate, and 10% human pooled serum was added to flat-bottomed, 96-well plates 
(Greiner, The Netherlands). 
PBMC were preincubated with 1,25(OH)2D3 (at the respective doses indicated) for 30 
minutes, followed by addition of C. albicans at 105 micro-organisms/mL or RPMI (as 
unprimed control). This concentration of C. albicans has been predetermined in pilot 
experiments to yield optimal cytokine response. In the stimulation experiments using specific 
ligands, PBMC were incubated with the various stimuli individually (or in combination): TLR2 
ligand (Pam3Cys 10 pg/mL), TLR4 ligand (LPS 1 ng/mL), Dectin-1 ligand (ß-glucan 20 
pg/mL), or combinations of ß-glucan/Pam3Cys and ß-glucan/LPS. Cell cultures were 
incubated in a 37°C, 95% humidity, 5% CO2 incubator. The culture supernatants were 
collected after 24 or 48 hours or 7 days of incubation, as appropriate, and stored at -20°C 
until cytokine assay. 
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Flow cytometry 
Cells were phenotypically analyzed by 5-color flow cytometry (Coulter Cytomics FC 500, 
Beekman Coulter, Fullerton, USA) using Coulter Epics Expo 32 software. Cells were washed 
with PBS with 0.2% bovine serum albumin (BSA) before being labeled with fluorochrome-
conjugated antibodies (mAb). After incubation for 20 minutes in the dark at room 
temperature, cells were washed twice to remove unbound antibodies and analyzed. For cell-
surface staining, the following mAb were used- Dectin-1 receptor-PE (259931, R&D 
Systems, Minneapolis, MN), along with TLR2-FITC (TL2.1) and TLR4-PE (HTA125) (both 
from eBioscience, San Diego, CA) and mannose receptor (MR)-FITC (19.2, BD Bioscience, 
New York, NY). 
Cytokine measurements 
Interleukins (IL)-6, IL-1ß, IL-10 and interferon (ΙΡΝ)γ concentrations were measured by 
commercial sandwich ELISA kits (Pelikine Compact, CLB, Amsterdam, The Netherlands) 
according to manufacturer instructions. Human tumor necrosis factor alpha (TNFa) and IL-
17 were measured by the appropriate commercial ELISA kits (R&D Systems, Minneapolis, 
MN). Detection limits were 8 pg/mL (IL-6 and IL-10), 20 pg/mL (IL-1ß and IFNy), and 40 
pg/mL(TNF-aandlL-17). 
Quantitative polymerase chain reaction (qPCR) 
To determine mRNA expression, we extracted RNA from PBMC stimulated with C. albicans 
in both the presence and absence of 1,25(OH)2D3 for 24 hours. We extracted that RNA from 
107 PBMC by using 1 mL TRIzol reagent (Sigma, St. Louis, MO). Subsequently, 200 μ ι 
chloroform and 500 pL 2-propanol (Merck, Darmstadt, Germany) were used to separate the 
RNA from DNA and proteins. Finally, after washing with 75% ethanol, we dissolved the dry 
RNA in 50 \iL of diethylpyrocarbonate (DEPC) water. The amount and quality of mRNA were 
determined using a NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE). Complementary DNA was synthesized with a Superscript 
Reverse Transcriptase (Invitrogen). 
Quantitative, real-time PCR was performed using the Bio-Rad iCycler and SYBR Green. The 
following primers were used (5'-3'): 
1 .AACCTCAGACAAAGCGTCAAATC (forward) and ACCAAGATCCAGAAGAGCCAAA 
(reverse) for TLR2, TTCCTTCAACCAAGAACATAGATC (forward) and 
TTGTTTCAATTTCACACCTGGATAA (reverse) 
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2.for TLR4, ACAATGCTGGCAACTGGGCT (forward) and CCGAGAAAGGCCTATCCAAAA 
(reverse) for Dectin-1 receptor, TCAAGACAATCCACCAGTTACT (forward) and 
TTCTCTTTGCTGAAATAATACTGGTAGTC (reverse) 
3.for MR, GCAGCCGACAATGCAGTCT (forward) and GAACGGAATGTGCGGAAGTG 
(reverse) for SOCS1, TGCGCCTCAAGACCTTCAG (forward) and 
GAGCTGTCGCGGATCAGAAA (reverse) for S0CS3 and 
4.ATGAGTATGCCTGCCGTGTG (forward) and CCAAATGCGGCATCTTCAAAC (reverse) 
for β2 microglobulin (B2M) (Biolegio, The Netherlands) as housekeeping gene. 
In another system, we quantified transcripts by real-time quantitative PCR on an ABIPRISM 
7700 Sequence Detector using predesigned TaqMan GeneExpression Assays and reagents 
according to manufacturer instructions (Applied Biosystems, Foster City, CA). Probes with 
the following Applied Biosystems assay identification numbers were used: TBX21 (Tbet), 
Hs00203436_mL; GATA3, Hs00231122_mL; FOXP3, Hs00203958_mL; RORC1-2, 
Hs00172858_mL; RORC10-11, Hs01076112_mL, using human HPRT1 Endogenous 
Control (4333768T; Applied Biosystems) acted as housekeeping gene. 
We validated all primers according to protocol. Mean relative mRNA expression was 
calculated using PfaffI method. Values are expressed as ratio of fold increase to mRNA 
levels of vitamin Ds-untreated cells. 
Ex vivo study 
We recruited 15 healthy male volunteers from Radboud University Nijmegen Medical Centre, 
The Netherlands. Venous blood was drawn from all subjects on 4 occasions—in winter, 
spring, summer, and autumn of 2009. PBMC were isolated and stimulation assay was 
performed with C. albicans as discussed. This study has been approved by the local ethics 
committee. Informed consent was obtained from all volunteers. 
Vitamin D3 measurement 
Serum 25(OH)D3 levels were determined using high-performance liquid chromatography 
(HPLC) with UV detection, after prior extraction on small SepPak columns. Tritiated 
25(OH)D3, collected from the HPLCsystem during passage of the UV peak, corrected for 
procedural losses. 
Statistical analysis 
Results from at least 5 experiments were pooled and analyzed using SPSS 16.0 statistical 
software. Data given as means + SEM and the Wilcoxon signed rank test compared 




1,25(OH)2D3 down-modulate proinflammatory cytokine response to C. albicans 
The influence of 1,25(OH)2D3 on immune response to C. albicans was assessed by 
stimulating PBMC in the presence of 1, 10, and 100 nmol/L of 1,25(OH)2D3. 1,25(OH)2D3 
down-regulated TNFa secretion (25% drop) as well as IL-6 and IL-17 production (by more 
than 70%, in a dose-dependent manner (P <0.05). IFNy secretion was also attenuated by 
1,25(OH)2D3. In contrast, IL-10 production is increased 1.5-fold (although this was 
statistically insignificant) (Figure 1). These observations suggested that 1,25(OH)2D3 has the 




































Figure 1.1,25(OH)?D3 attenuates the cytokine response to Candida albicans 
PBMC were incubated in the absence or presence of various 1,25(OH)2D3 concentrations ranging 
from 1 to 100 nmol/L and stimulated with 105 HK C. albicans. Supernatants were collected and 
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analyzed for A) TNFa, B) IL-6, C) IFNy, D) IL-10 and E) IL-1ß at 24 h and F) 1L-17 at day 7. Data 
show results from 6 Independent experiments performed with cells obtained from different donors. 
*P < 0.05 as compared to respective cell culture without the addition of 1,25(OH)2D3. 
Modulatory effects of 1,25(OH)2D3 are not mediated through SOCS or skewing of Τ cell 
differentiation 
Two possible mechanisms through which 1,25(OH)2D3 could have attenuated 
proinflammatory response to C. albicans was through disruption of the suppressors of 
cytokine signaling (SOCS) pathway or a shift in Τ cell differentiation away from Th1 and 
Th17 toward Th2 or regulatory Τ cell (Treg) profile. To assess the gene expression profiles 
of the various Τ cell transcription factors in response to 1,25(OH)2D3, we performed 
quantitative PCR after stimulating PBMC with C. albicans. There were no significant 
changes in Tbet, GATA3, Foxp3, or ROR-yt mRNA expression (Figure 2A) 24 hours after 
cells were stimulated with C. albicans in the presence of 1,25(OH)2D3. We examined the 
effect of 1,25(OH)2D3 on SOCS1 and SOCS3 mRNA expression under the same conditions 
and found a moderate drop in SOCS1 at 4 hours (Figure 2B), but this cannot explain a 
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Figure 2. 1,25(OH)2D3 does not act through modulation of Τ helper differentiation or SOCS 
pathway 
A) 1,25(OH)2D3 does not modulate of Τ cell transcription factors. B) Modulation of SOCS1 and 
SOCS3 mRNA expression by 1,25(ΟΗ^3. Quantitative PCR for human Tbet, GATA3, Foxp3, ROR-
yt, SOCS, and SOCS3 was conducted with PBMC and normalized to HPRT1 or ß2M (for SOCS1 and 
3) gene expression. Cells were incubated with 10 nmol/L 1,25(OH)2D3 or solvent for 24 h or 4 h 
(SOCS1 and 3). Data show results from 5 independent experiments and are expressed as fold 
change relative to solvent control. 
75 
Chapter 4 
Reduced TLR2 and TLR4 mRNA and protein expression by 1,25(OH)2D3 
TLR2, TLR4, Dectin-1 and MR are well-established pattern recognition receptors (PRR) for 
the detection of C. albicans. Therefore, we investigated whether 1,25(OH)2D3 could also 
modulate the expression of PRRs. In PBMC incubated with C. albicans, the expressions of 
both TLR2 and TLR4 were reduced by 1,25(OH)2D3 at 24 hours, 48 hours (Figure 3A-3D), 
and day 4 (not shown). In addition, TLR2 mRNA was decreased by 1,25(OH)2D3 after 24 
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Figure 3.1,25(OH)2D3 inhibits expression of TLR2, TLR4, Dectin-1 receptor and MR 
Representative histogram overlay plots show reduced A and B) TLR2 (at 24 h and 48 h), C and D) 
TLR4 (at 24 h and 48 h), E) Dectin-1 (at 48 h) and F) MR (day 4) with and without 1,25(OH)2D3 
treatment as assessed by flow cytometry. G) 1,25(ΟΗ^3 down-modulates TLR2, TLR4, Dectin-1 and 
MR mRNA expression. PBMC were incubated in the absence or presence of 100 nmol/L 1,25(ΟΗ^3 
and stimulated with 105 HK Candida albicans . Flow cytometry data shown was performed at 24 h and 
48 h for TLR2, TLR4; 48 h for Dectin-1; and day 4 for MR. Quantitative PCR for human TLR2, TLR4, 
Dectin-1, and MR (normalized to ß2M gene expression) was performed at 24 h. Data represent 5 
independent experiments performed with cells obtained from different donors. 
1,25(OH)2D;i diminished Dectin-1 and mannose receptors expression at the level of 
transcription 
The surface expression of Dectin-1 was inhibited by 1,25(OH)2D3 upon stimulation with C. 
albicans, and this was most evident at 48 hours (Figure 3E); data at 24 hours and day 4 is 
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not shown. Down-regulation of MR surface expression by 1,25(OH)2D3 is clearly seen by day 
4 (Figure 3F) even though MR protein expression on PBMC is usually only apparent after 72 
hours of incubation. Likewise, the mRNA levels of both receptors were also reduced in the 
vitamin Da-treated cells (Figure 3G). 
Functional consequence of 1,25(OH)2D3-induced suppression of TLRs and C-Type 
lectin receptor expression 
To validate our findings and to assess the functional consequences of vitamin D3 on TLRs 
and C-type lectin receptor (CLR) expression, we carried out stimulation using purified TLR2, 
TLR4, and Dectin-1 ligands in PBMC in the presence of 1,25(OH)2D3. A significant drop in 
IL-6 and TNFa secretion was observed in cells treated with 1,25(OH)2D3. In addition, we 
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Figure 4. 1,25(OH)2D3 inhibited proinflammatory cytokines induced by purified TLR/Dectin-1 
ligands 
PBMC were incubated in the presence or absence of 100 nmol/L 1,25(OH)2D3 and stimulated with 10 
pg/mL Pam3Cys, 2 ng/mL LPS, 20 Mg/mL ß-glucan, and ß-glucan in combination with Pam3Cys or 
LPS. Supernatants were collected and analyzed for A) IL-6 and B) TNFa at 24h. Data show results 
from five independent experiments performed with cells obtained from different donors. *P< 0.05 as 
compared to respective cell culture without the addition of 1,25(OH)2D3. 
between TLR2 or TLR4 and Dectin-1. Notably, we found reduced synergistic effects 
mediated by Dectin-1 when 1,25(OH)2D3 was added to the culture (Figure 4). 
Increased in vivo 1,25(OH)2D3 led to attenuated inflammatory response to C. albicans 
ex-vivo in human volunteers 
To validate our in vitro findings, we performed an ex vivo study on 15 healthy male 
volunteers (median age 36, range 28-60 years old). We examined how physiological 
seasonal variation in sun exposure (through winter, spring, summer, and autumn) could 
influence host innate immunity against C. albicans infections. PBMC from subjects isolated 
during each season of the year were stimulated with C. albicans. It was of great interest to 
us that we observed a significant drop in IFNy and IL-17 secretion in spring and summer 
months, while the IL-10 levels were higher in summer as compared to winter (Figure 5B-5D). 
These observations correlated with the serum 25(OH)D3 concentrations, which doubled in 
summer compared to winter (Figure 5A). Trends in IL-6 and TNFa production, however, 
displayed wider variation and were not statistically significant (data not shown). 
DISCUSSION 
Despite its well-known immunomodulatory effects, nothing to date has been discovered 
about the effects of vitamin D on the innate immune response to Candida. We demonstrate 
in this study that 1,25(OH)2D3 can significantly modulate host proinflammatory and Th17 
response to C. albicans, both in vitro and ex vivo. This biologically active component of 
vitamin D3 exerted its effect through modulation of the expression of PRR, recognizing 
fungi—both TLR2 and TLR4—and C-type lectin receptors, Dectin-1 and MR. Until now, the 
effect of 1,25(OH)2D3 on CLR has not been recognized. 
The constitutive expression of the VDR by human immune cells, including monocytes, 
macrophages, and lymphocytes, has been well-established (2-4). This is a prerequisite for 
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Figure 5. Seasonal variation of host immune response to ex-vivo Candida albicans stimulation 
A) Mean serum 25(OH)D3 concentrations of 15 healthy volunteers at different seasons of the year 
*P< 0.05 as compared to winter. PBMC were stimulated with 105 HK C. albicans and supernatants 
collected and analyzed for B) IFNy, C) IL-10, and D) IL-17 at day 7. Data show results from 15 
subjects at the different seasonal time points. 
vitamin D3 to exert any immunomodulatory effect. We have shown that 1,25(OH)2D3 has a 
distinct propensity to skew host response to C. albicans away from a "proinflammatory" 
profile through attenuation of TNFa, IL-6, ΙΡΝγ as well as production of IL-17. Other 
researchers have reported inhibition of Th1 cytokine production with 1,25(OH)2D3, although 
not in the setting of Candida infection and polarization toward a Th2-type response (21-23). 
In our system using human PBMC stimulated by C. albicans, we also observed an increase 
in IL-10 production in vitamin D presence. We initially hypothesized that this IL-10 might 
originate from skewing toward Th2 differentiation as seen elsewhere (24;25) or from the 
potentiation of regulatory Τ cell function (26;27). However, we were unable to demonstrate 
any significant shift in the Τ helper or Treg transcription factors (Tbet, GATA3, Foxp3 or 
ROR-yt) mRNA expression in our Cand/da-stimulation model under the influence of 
1,25(OH)2D3. Our observation that 1,25(OH)2D3 had the characteristic capability to suppress 
IL-6 production, and to some extent, IFNy also led us to investigate whether the underlying 
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mechanism was due to novel 1,25(OH)2D3 activity on the respective SOCS3 and SOCS1 
regulatory pathways (28). However, we found no evidence of direct or indirect 1,25(OH)2D3-
related interference on SOCS regulatory function. Stimulation of SOCS1 and SOCS3 mRNA 
would have been an anticipated response following the suppression of proinflammatory 
cytokine production by 1,25(OH)2D3. Slight drops in SOCS1 mRNA expression is a 
consequence of decreased TLR 2/4 and Dectin-1 signaling rather than the direct effect of 
1,25(OH)2D3. 
Another mechanism that could account for our observation is vitamin D3-mediated 
suppression of PRR expression, followed by modulation of response by host immune cells to 
Candida. 1,25(01-1)203 indeed diminished surface expression of TLR2 and TLR4, which on 
follow-up investigation was attributable to its effect on inhibition of upstream TLR2 and TLR4 
mRNA transcription. A similar observation had also been reported by Sadeghi et al (29) in 
the setting of bacterial cell wall components. In addition, 1,25(OH)2D3 had further influence 
on functioning of other PRRs not previously recognized. Besides TLR2 and TLR4, the C-
type lectin receptors Dectin-1 and MR are known to play pivotal roles in triggering the 
immune signaling cascade upon activation by C. albicans (30).We found that 1,25(OH)2D3 
activity also exerted inhibition of upstream Dectin-1 and MR protein synthesis. This latter 
finding was especially significant relative to that of the TLRs, because the extent of 
1,25(OH)2D3-induced inhibition of Dectin-1 and MR functioning was suggestively more 
pronounced than on TLR2 and TLR4. We have also recently reported that Candida 
recognition by CLRs such as Dectin-1 and MR is a more constant feature of antifungal 
innate immunity than recognition by TLRs (31). 
Furthermore, we ascertained the functional consequences of synergistic effects resulted 
from 1,25(OH)2D3-related suppression of TLR2, TLR4, and Dectin-1 in the setting of C. 
albicans infection. This is important because it has been well-described that "cross-talk" 
between the TLR2/4 and Dectin-1 is responsible for the synergy of proinflammatory 
response mounted by the host (32-34). Our use of pure TLR2, TLR4, and Dectin-1 ligands, 
as well as TLR2/Dectin-1 and TLR4/Dectin-1 ligand combination, illustrated the profound 
influence that 1,25(OH)2D3 exerted beyond its effect on the individual PRR. The results 
demonstrated how use of 1,25(OH)2D3 has also led to ablation of the TLR-Dectin-1 synergy, 
which in the setting of C. albicans infection especially, would be very significant. Resultant 
suppression of MR function most likely further contributes to attenuation of host IL-17 
response to Candida (35). Hence, the net effect of 1,25(OH)2D3 is a critical shift away from 
80 
V't jmin I), j nd C o'ò/i.o'1^ nfk'ctio" 
the proinflammatory response, which would have been anticipated upon C. albicans 
challenge. 
We know that production of the vitamin D3 precursor in the skin depends on UV radiation 
exposure. A seasonal variation in vitamin D3 status in temperate climates is widely accepted 
(36). To validate our in vitro findings, we carried out an ex vivo study in 15 healthy subjects 
to investigate the variation in cytokine response to C. albicans through the year's four 
seasons. Compared to winter, during spring and summer months IFNy and IL-17 response 
to Candida is significantly reduced. This correlates inversely with serum 25(OH)D3 levels. 
Conversely, IL-10 production is higher in summer, lnterleukin-6 and TNFa trends were found 
to be less consistent. This might be attributed to other factors inducing wider biological 
variation in the ex vivo study. Such factors might be UV radiation exposure and the levels of 
vitamin D3 necessary to effect a modulation in these cytokine responses. It has been 
suggested that a higher serum 25(OH)D3 level (>100 nmol/L) may be required to sustain 
immune function (37). Therefore, we ought to be mindful that while certain cytokine trends in 
the seasonality study correlate with our in vitro work, the physiological levels of vitamin D3 
required to comprehensively attenuate the immune responses to Candida infection remain to 
be determined. Nevertheless, our study is the first clear demonstration of seasonal variation 
in innate immune responses to an important human pathogen. 
Research has been ongoing to study the potential role of vitamin D as a therapeutic agent 
(38). It has been proposed that in invasive fungal infections such as candidiasis and 
aspergillosis, disease pathology may be attributable to an exaggerated or dysregulated host 
inflammatory response that results in undue tissue damage (39;40). While a 
proinflammatory-type immune response will be desirable at disease onset, an unnecessarily 
prolonged hyperinflammatory phenotype may be averse to outcome. Likewise, Th1 and 
especially Th17 responses are known to exacerbate and often cause autoimmune 
phenomena (41;42). Hence, given the immunomodulatory profile of 1,25(OH)2D3, it is 
tempting to speculate that in specific clinical settings, 1,25(OH)2D3 may have a role in 
modulating and regulating any unnecessary and prolonged inflammatory response 
generated by the host. Also, the significant effect of seasonal variation on Τ helper 
responses makes it tempting to speculate whether vaccination programs during winter 
months may be more efficient than those during the summer period. Although speculative at 
the moment, research on this subject is certainly needed. An encouraging answer would 
have far-reaching implications for health policy. 
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In conclusion, we have shown that 1,25(OH)2D3 plays a novel role for the modulation of 
innate host response to C. albicans, by modifying the proinflammatory cytokine responses 
both in vitro and ex vivo. By exerting its influence on almost all the major PRRs involved in 
Candida recognition and immune signaling, namely TLR2, TLR4, Dectin-1, and MR, its anti-
inflammatory effect is profound in Candida infection. Seasonal variation of cytokine 
responses seems notably important. This opens up a new area of clinical research. We 
expect that the epidemiological and clinical consequences of our findings could be 
significant. Future studies are warranted. 
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ABSTRACT 
The immune modulating capacity of vitamin D3 is well-recognized. Ultraviolet (UV) exposure 
determines production of vitamin D3 in vivo and varies through the course of the year, 
especially in temperate regions. However, it is not known whether the human innate immune 
response differs due to seasonality. To validate the seasonal effects of vitamin D3, the effect 
of 1,25(OH)2D3 on peripheral blood mononuclear cells (PBMC) cytokine response was first 
determined in vitro. 1,25(OH)2D3 decreased interleukin (IL)-6 and tumour necrosis factor 
(TNF)a release by PBMC stimulated with tripalmitoyl-S-glycerylcysteine (Pam3Cys) or 
lipopolysaccharide (LPS). Subsequently, ex vivo stimulation studies were performed in 15 
healthy volunteers through the course of the four seasons of the year. PBMC were isolated 
and stimulated with Toll-like receptor (TLR)2 and TLR4 ligands Pam3Cys and LPS, 
respectively. Circulating concentrations of 25(OH)D3 and 1,25(OH)2D3 were higher during 
summer (P < 005) and a down-regulation of TLR4-mediated IL-1ß, IL-6, TNFa, interferon 
(IFN)Y and IL-10 production in summer was observed compared to winter (P < 005). The 
variation in cytokine response upon TLR2 (Pam3Cys) stimulation was moderate throughout 
the four seasons. The repressed cytokine production during the summer months could be 
explained partly by the reduced cell membrane expression of TLRs. Physiological variation 
in vitamin D3 status through the four seasons of the year can lead to alteration in the innate 
immune responses. Elevated vitamin D3 level in vivo is associated with down-regulation of 
cytokine response through diminished surface expression of pattern recognition receptors. 
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INTRODUCTION 
The conventional role of vitamin D3 is that of bone homeostasis and calcium metabolism. 
Recently, vitamin D3 has been described to exhibit immunomodulatory effects with the 
uncovering of vitamin D receptors (VDR) expression on activated CD4+ and CD8+ Τ 
lymphocytes and antigen presenting cells (APC) such as monocytes, dendritic cells and 
macrophages (1-3). The biologically active form of vitamin D3, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3), has been shown to influence the differentiation and function of both the 
innate and adaptive immune cell types and to augment cytokine production differentially (4-
6). 1,25(OH)2D3 has been implicated in various immune-mediated diseases, and 
investigation into its therapeutic potential in autoimmune diseases and infections are 
ongoing (7,8). 
A major source of vitamin D3 in the body comes from sun exposure (9). Exposure to 
ultraviolet (UV)B light (290-315 nm) results in the first step of vitamin D3 biosynthesis, 
causing 7-dehydrocholestrol to form previtamin D3 in the skin (10). Previtamin D3 undergoes 
a spontaneous thermal isomerization into vitamin D3. Vitamin D3 is subsequently 
hydroxylated into 25-hydroxyvitamin D3 (25(OH)D3) by 25-hydroxylase in the liver. 25(OH)D3 
is further converted by 1 α-hydroxylase (CYP27B1) in the kidney into the biologically active 
metabolite, 1,25(OH)2D3. A seasonal variation in vitamin D3 status in temperate climates is 
well known (11;12). There has been concern regarding the risk of vitamin D insufficiency 
among populations residing at higher latitudes where solar radiation during certain periods of 
the year is inadequate for sufficient cutaneous vitamin D synthesis (13). Epidemiological 
studies have implicated seasonality and geographical variation in UV radiation as 
contributing factors to the prevalence of autoimmune disorders such as multiple sclerosis 
(MS), rheumatoid arthritis and type 1 diabetes (14). It has been reported that the prevalence 
of MS rises with increasing latitude (15). The season of birth has been implicated in MS 
occurrence and type 1 diabetes (16-18). Collectively, these data suggest that sun exposure 
and vitamin D3 levels are candidate risk-modifying factors in certain autoimmune diseases. 
On a similar note, it is widely perceived that there is seasonality for influenza as well as viral 
upper respiratory tract infections (URTI), and wintertime vitamin D insufficiency is said to be 
an important contributory factor (19-21). An inverse association between serum 25(OH)D3 
levels and incidence of URTI has been demonstrated (21;22). A significant reduction in the 
risk of developing viral URTI was attributed to serum 25(OH)D3 levels of more than 30 ng/ml 
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(75 nmol/l). In other studies, this benefit was conveyed by a higher 25(OH)D3 level of 40 
ng/ml (100 nmol/l) (20;23). Currently, clinical studies evaluating the potential benefits of 
vitamin D supplementation in reducing the occurrence of seasonal influenza in adults has 
not been conclusive (24;25), although it seems to be protective in children (26). In a double-
blind randomized placebo-controlled trial involving school children (aged 6-15 years), 
supplementation with 1200 IU cholecalciferol daily during winter reduced influenza A 
infections significantly. 
Despite this wealth of data supporting an immunomodulatory role of vitamin D, no 
information is available on whether the innate immune response of healthy individuals can 
vary due to physiological variation in vitamin D3 store during different seasons of the year. In 
this study, we investigated whether seasonal variation in vitamin D3 in the body is associated 
with differential Toll-like receptor (TLR)2 and TLR4-mediated immune response in healthy 
subjects living in a temperate region. Such a study would enhance our knowledge on the 
circumstances determining susceptibility to certain diseases as dictated by the immune-
modifying effects of vitamin D3 in vivo. 
MATERIALS AND METHODS 
Reagents 
TLR2 ligand lipopeptide (S)-(2RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser(S)-Lys4-OH, 
tripalmitoyl-S-glycerylcysteine (Pam3Cys) was purchased from EMC Microcollections 
(Tübingen, Germany). TLR4 ligand lipopolysaccharide (LPS; Esvherichia coli serotype 
055:B5) was purchased from Sigma Chemical Co (St Louis, MO, USA). An extra purification 
step of LPS was performed as described previously (27). 1,25(OH)2D3 was purchased from 
Fluka Biochemika, Sigma-Aldrich (Missouri, Ml, USA) and dissolved in absolute ethanol. The 
reagents were all prepared just before commencement of the seasonal study and stored as 
aliquots at -70oC for single use only. This was conducted to ensure uniformity of the 
respective stimuli used for the study. 
Stimulation assays 
The study was approved by the Ethical Committee on Human Experimentation of the 
Radboud University Nijmegen. Written consent was obtained from all participants to the 
study. Venous blood was drawn into ethylenediamine tetraacetic acid (EDTA) tubes from 
healthy subjects for in vitro experiments. For the ex vivo study, 15 healthy male volunteers 
91 
(median age 36 years, range 28-60; mean body mass index (BMI) 22-8 kg/m2, range 20-5-
26-2) were recruited and followed up for 1 year. Venous blood was drawn from the subjects 
during four consecutive seasons: winter (December-February), spring (March-May), summer 
(June-August) and autumn (September-November) of 2009. On the rare occasions that any 
of the participants reported being unwell, the experiment was postponed until 1 week post-
recovery. 
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation on Ficoll-
Hypaque (Pharmacia Biotech, Uppsala, Sweden). Cells were washed twice in saline, 
counted in a Coulter counter and the number adjusted to 5 « 106 cells/ml. A 100 μΙ volume of 
PBMC, suspended in culture medium (RPMI-1640 DM; ICN Biomedicals, Costa Mesa, CA, 
USA) supplemented with 10 pg/ml gentamicin, 10 mM l-glutamine, 10 mM pyruvate and 10% 
human pooled serum was added to flat-bottomed 96-well plates (Greiner, Alphen aid Rijn, 
the Netherlands). 
For the in vitro study to validate the effects of vitamin D3, PBMC were preincubated with 100 
nm 1,25(OH)2D3 for 30 min, followed by addition of TLR2 ligand (Pam3Cys 10 pg/ml), TLR4 
ligand (LPS 10 ng/ml) or RPMI-1640 (as unprimed control). As with the ex vivo study, PBMC 
were stimulated with similar concentrations of Pam3Cys and LPS. In addition, other 
concentrations tested ex vivo include Pam3Cys 1 pg/ml and LPS 1 and 100 ng/ml. Cell 
cultures were incubated in a 37°C, 95% humidity, 5% CO2 incubator. The culture 
supernatants were collected after 24 h (or 48 h for interferon (ΙΡΝ)-γ) of incubation as 
appropriate and stored at -20oC until cytokine assay. 
Flow cytometry 
Cells were analysed phenotypically by five-colour flow cytometry (Coulter Cytomics FC 500; 
Beekman Coulter, Fullerton, CA, USA) using Coulter Epics Expo 32 software. PBMC as well 
as whole blood (after cell lysis) was used for flow cytometry analysis after. Cells were 
washed with PBS with 0-2% bovine serum albumin (BSA) before being labelled with 
fluorochrome-conjugated antibodies (mAb). After incubation for 20 min at room temperature 
in the dark, cells were washed twice to remove unbound antibodies and analysed. For cell 
surface staining, the following mAbs were used: TLR2-fluorescein isothiocyanate (FITC) 
(TL2-1) and TLR4-phycoerythrin (ΡΕ) (HTA125), both from eBioscience (San Diego, CA, 
USA). 
92 
Sc>,)sorii)lity of Lylok.rio Ri spons. 
Cytokine measurements 
Interleukin (IL)-6, IL-1ß, IL-10 and IFNy concentrations were measured using commercial 
sandwich enzyme-linked immunosorbent assay (ELISA) kits (Pelikine Compact; CLB, 
Amsterdam, the Netherlands) according to the manufacturer's instructions. Human tumour 
necrosis factor (TNF)a was measured by a commercial ELISA kit (R&D Systems, 
Minneapolis, MN, USA). Detection limits were 8 pg/ml (IL-10 and IFNy), 16 pg/ml (IL-6), 20 
pg/ml (IL-Ιβ) and 40 pg/ml (TNFa). 
Vitamin D3 measurement 
Serum 25(OH)D3 was determined using high-performance liquid chromatography (HPLC) 
with ultraviolet detection, after prior extraction on small SepPak columns. Tritiated 25(OH)D3, 
collected from the HPLC system during the passage of the UV peak, was used to correct for 
procedural losses. Serum 1,25(OH)2D3 was measured using a radioreceptor assay (RRA) 
with prior extraction and chromatographic prepuhfication with correction for recovery as 
described previously (28). 
Statistical analysis 
Results were pooled and analysed using spss 160 statistical software. Data given as means 
+ standard error of the mean (S.E.M) and Wilcoxon's signed-rank test was used to compare 
differences between groups (unless otherwise stated). The level of significance was set at Ρ 
< 0 0 5 . 
RESULTS 
1,25(OH)2D3 resulted in suppression of proinflammatory cytokine response in vitro 
First, we carried out LPS and Pam3Cys stimulation on PBMC with the addition of 100 nM 
1,25(OH)2D3. After 24 h, IL-6 secretion was reduced by 53% and 29% upon Pam3Cys and 
LPS stimulation, respectively, in the cells treated with 1,25(OH)2D3 (Figure 1A). A significant 
drop in TNFa production by 17% (Pam3Cys stimulation) and 35% (LPS stimulation) was 
also observed with 1,25(OH)2D3 at 24 h (Figure 1B). Having demonstrated that 1,25(OH)2D3 
had the capacity to modulated IL-6 and TNFa response in vitro, and with the understanding 
that physiological vitamin D3 levels in the body may vary through the seasons, we validate 
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Figure 1. The effect of vitamin D;. on cytokine responses after in vitro stimulation 
Peripheral blood mononuclear cells (PBMC) were preincubated in the presence or absence (carrier) 
of 100 nM 1,25(OH)2D3 and thereafter stimulated with 10 pg/ml tripalmitoyl-S-glycerylcysteine 
(Pam3Cys) or 10 ng/ml lipopolysaccharide (LPS). After 24 h, A) interleukin (IL)-6 and B) tumour 
necrosis factor (TNF)a were measured in the supernatant. Data show results from five independent 
experiments performed with cells obtained from different donors. *P < 0 0 5 compared to respective 
untreated cell culture without the addition of 1,25(OH)2D3. 
Serum 25(01-1)0;, and 1,25(OH)^D3 was increased s ign i f icant ly in s u m m e r 
We determined the serum levels of 25(OH)D3 and 1,25(OH)2D3 levels in 15 healthy male 
volunteers through winter (December-February), spring (March-May), summer (June-
August) and autumn (September-November). The amount of sunlight in the study region 
varied with the seasons (Figure 2A). The total duration of sunlight in a month prior to vitamin 
D3 levels and cytokine measurement was 103 h and 240 h in winter and summer, 
respectively. The median 25(OH)D3 level increased steadily from 43 nmol/l in winter to 
spring and doubled to 89 nmol/l in summer, with a drop again in autumn (Figure 2B). The 
median serum 1,25(OH)2D3 levels raised significantly from 219 pmol/l in winter to 237 pmol/l 
in summer (Figure 2C). 
94 
Seasonality of Cytokine Response 
A) 
300 η 
I Total duration Average daily duration 
8 
τ Γ 
















Variation in serum 2. v
vitamin D3 levels throughout the 
Figure 
 1̂ 3 •cvci unw  
four seasons of the year 
A) Total duration of sunlight in the 
study region 4 weeks prior to serum 
vitamin D3 concentration assay 
(source: the Royal Netherlands 
Meteorological Institute). Median 
serum B) 25(OH)D3 and C) 
1,25(OH)2D3 concentrations of 15 
healthy volunteers at different 
seasons of the year. *P < 0 05 
compared to winter. 
Spring 
TLR4 (LPS)-mediated cytokine response with variation in vitamin D3 levels 
Increased serum vitamin D3 level in summer was associated with a significant drop in TNFa 
(64%), IL-6 (33%), IL-1ß (59%) and ΙΡΝγ (46%) production when compared against winter 
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(Figure 3A-D). IL-10 production was also reduced by 55% (P < 005) during summer 
compared to winter (Figure 3E). These observations show that elevated serum vitamin D3 
levels are associated with attenuation of the host inflammatory response after engagement 
of TLR4. 
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Figure 3. Variation in cytokine responses to lipopolysaccharide (LPS) stimulation during the 
four seasons of the year 
Peripheral blood mononuclear cells (PBMC) were isolated from 15 healthy volunteers during each of 
the four seasons and stimulated with 10 ng/ml LPS. A) Interleukin (IL)-Iß, Β) IL-6, C) tumour necrosis 
factor (TNF)a, D) interferon (ΙΡΝ)γ and E) IL-10 were measured. Data show results from 15 healthy 
donors. 'P < 005 compared among the respective seasons. 
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TLR2 (Pam3Cys)-mediated cytokine response with variation in vitamin D3 levels 
We also determined the regulation of cytokine production upon Pam3Cys stimulation of 
PBMC. After 24 h of stimulation, a modest drop in TNFa and IL-1ß production by 27% (P < 
005) and 22% (P > 005), respectively, was seen during summer compared to winter 
(Figure 4A and C). The variation in IL-6 and IL-10 (Figure 4B and D) production was limited 
throughout the course of the four seasons. The seasonal variation of TLR2-mediated host 
cytokine response was more limited compared to TLR4-mediated responses. 
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Figure 4. Variation In cytokine responses to trlpalmltoyl-S-glycerylcystelne (Pam3Cys) 
stimulation during the four seasons of the year 
Peripheral blood mononuclear cells (PBMC) were isolated from 15 healthy volunteers during each 
season and stimulated with 10 pg/mi Pam3Cys. A) Interleukin (IL)-Iß, Β) IL-6 and C) tumour necrosis 
factor (TNF)a and D) IL-10 were measured. Data show results from 15 healthy donors. *P < 005 
compared among the respective seasons. 
Reduced TLR2 and TLR4 expression could explain the suppression of cytokine 
responses in summer 
We have found recently that 1,25(OH)2D3 had the capacity to modulate TLR2 and TLR4 
expression in vitro (6). Therefore, we investigated whether the attenuated proinflammatory 
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cytokine responses observed in our ex vivo experiments was indeed the result of an altered 
pattern recognition receptors (PRR) expression. Using flow cytometric analysis, we found 
that the expression of both TLR2 and TLR4 on monocytes was reduced during summer 










Figure 5. Expression of A) Toll-like receptor (TLR)2 and B) TLR4 on the cell membrane of 
monocytes 
Peripheral blood mononuclear cells (PBMC) were isolated from 15 healthy volunteers during each 
season and analysed for the respective markers using flow cytometry as gated on monocytes. Data 
show results from 15 healthy donors. *P < 005 compared to winter. 
DISCUSSION 
Much interest has been shown recently in the immunomodulatory capacity of vitamin D3 and 
the role it plays in health and diseases. While biosynthesis upon UVB exposure serves as 
the main source of vitamin D3 in the body (9), it is not known if seasonal variation in vitamin 
D3 store arising from a fluctuating solar exposure can impact the innate immune response. 
We show for the first time that, relative to winter levels, there was a physiological elevation in 
vitamin D3 store during summer and this led to down-regulation in proinflammatory cytokine 
production, particularly when stimulated via the TLR4-mediated signalling pathway. 
25(OH)D3 is the major circulating form of vitamin D3 and its concentration is used commonly 
as an indicator of vitamin D3 status (29), whereas 1,25(OH)2D3 is the biologically active form 
of vitamin D3. BMI has been shown to be related inversely to vitamin D3 levels (30). This 
confounder has been excluded due to the fact that none of the volunteers in the study was 
obese (BMI > 30 kg/m2). Here, we found that the difference between winter (December-
February) and summer (June-August) 25(OH)D3 levels to be 46 nmol/l. As expected, serum 





mg Summer Autumn Spring Summer Aulumn 
S M s o ' i d i i t y of ( νΐη«.'Ί " Λ» Ν Ο Ο · ^ Ι 
vitamin D3 levels correlated with the amount of sunlight in the study region. In our cohort of 
15 subjects residing at 520N from the Equator, we were hence able to demonstrate an 
evident variation of vitamin D3 status throughout the four seasons. Other studies have also 
demonstrated such a difference in young adults residing along similar latitudes at 40-50oN 
(11;12;31). Epidemiological studies have suggested that wintertime vitamin D insufficiency 
may account for the seasonal variation in incidence of viral respiratory tract infections 
(19;20;22). As such, it is most appropriate to look further into how the host immune 
responses vary during the different seasons. 
Looking specifically at TLR2 and TLR4-mediated response, as main pattern recognition 
receptors are involved, we first demonstrated that in vitro 1,25(OH)2D3-treated cells 
produced less IL-6 and TNFa. In line with the modulatory effects of vitamin D3, a general 
down-regulation of cytokine production was found during the summer months when the 
serum vitamin D3 levels were elevated, especially when PBMC from the volunteers were 
challenged with LPS. A fundamental aspect to be taken into account is that the physiological 
up-regulation of vitamin D3 levels by solar radiation in our study differs from the vitamin D3 
doses employed in the in vivo and in vitro studies. This could explain why the effect on IL-6 
production was less evident with Pam3Cys in our ex vivo experiment, although there was a 
50% reduction in the in vitro set-up. Conversely, we saw a similar reduction in TNFa 
production both in vitro and ex vivo following ligation of TLR2. 
One of the key targets of 1,25(OH)2D3 is the CD4
+ Τ lymphocytes. 1,25(OH)2D3 is known to 
suppress the secretion of IFNy and IL-2, while enhancing IL-4, IL-5 and IL-10 production 
(32;33). By inhibiting the secretion of IFNy, 1,25(OH)2D3 limits antigen presentation and 
recruitment of other Τ cells, thereby down-regulating the proinflammatory response. 
Conversely, 1,25(OH)2D3 promotes the production of the anti-inflammatory cytokines IL-4 
and IL-10, thus shifting the balance towards a Τ helper type 2 (Th2) or regulatory Τ cells 
(Treg) phenotype (34;35). Of note, a major difference from some of these previous in vitro 
and mice studies is that our ex vivo data show both the proinflammatory and anti­
inflammatory cytokines being down-regulated in summer. Again, the concentrations of 
1,25(OH)2D3 used in vitro and the actual physiological levels in the body may account for this 
apparent discordance. In contrast, there have also been recent reports of 1,25(OH)2D3 
suppressing both IFNy and IL-10 in CD4+ Τ lymphocytes (36). In a similar experimental set­
up using LPS stimulation, Matilainen et al pointed out that the impaired IL-10 production 
induced by 1,25(OH)2D3 was time-dependent and not sustainable. They reported that while 
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IL-10 secretion from monocytes was suppressed by 1,25(OH)2D3 during the initial 8 h, there 
was a rebound up-regulation at 48 h (37). 
We attempted to study the mechanisms responsible for the down-regulation of the 
proinflammatory cytokine response during summer. An explanation could be that 
1,25(OH)2D3 induces down-regulation of TLR expression, and this may account for the 
attenuated response after stimulation with TLR2 and TLR4 ligands (6;38). Indeed, we found 
a reduced surface expression of TLR2 and TLR4 associated with elevated vitamin D3 stores 
during summer which persisted throughout autumn. Through modification of TLR2 and TLR4 
expression, 1,25(OH)2D3 had the propensity to limit cytokine response following ligation of 
the receptors. Similarly, Sadeghi et al has demonstrated in vitro that 1,25(OH)2D3 down-
regulates TLR2 and TLR4 mRNA and protein expressions on monocytes, and this resulted 
in an impaired TNFa production upon LPS challenge (38). Furthermore, they concluded that 
this effect was VDR-dependent by showing that the down-regulation of TLR expression was 
reversed by a vitamin D receptor antagonist. However, we note from our ex vivo experiments 
that the reduction of TLR2 expression during summer was accompanied by a corresponding 
drop in TNFa production following stimulation with Pam3Cys, but this trend was less evident 
for IL-6. 
A still unresolved question arising from ongoing bench and clinical research has been the 
serum vitamin D3 concentrations needed to elicit an optimal immune response (39). The 
present results also suggest that there may be differences in the intracellular pathways 
leading to TNFa and IL-6 production (40), and these pathways may be modulated 
differentially by vitamin D3 concentration in vivo. Nevertheless, overall it seems remarkable 
here that our observations streaming from the physiological changes in vitamin D3 levels 
show similar trends correlating TLR expression and cytokine production compared to those 
from an in vitro setting. 
In the present study, we assessed a homogeneous study population (healthy, adult males 
with normal BMI) to establish if and how host cytokine response vary with seasons. Unique 
to previous in vitro and in vivo studies examining the role of vitamin D3, our data showed 
how innate immune responses can be influenced by the physiological variation of serum 
vitamin D3 levels during the four seasons of the year. It would be prudent to validate these 
observations in a larger and more diverse population cohort to identify any possible 
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differences in cytokine responses among the extreme of ages and different genders. 
Nevertheless, with these results in mind, it is tempting to hypothesize whether response to 
vaccination programmes could be different when carried out during winter or summer. A 
recent study conducted in a small cohort of prostate cancer patients suggested that there 
was a trend towards a better serological response rate against among patients with higher 
serum 25(OH)D3 levels (41). However, the 25(OH)D3 level delineating such a difference was 
not reported. Conversely, a clinical trial in healthy volunteers showed that co-administration 
of 1,25(OH)2D3 with influenza vaccine did not affect serological response against H1N1, 
H3N2 or influenza Β antigens (42). Further research is needed to validate this hypothesis, as 
this would have far-reaching implications for implementation of preventive health policies. 
These data may also provide better insight into previous epidemiological findings regarding 
the prevalence of autoimmune diseases and infections, which have been attributed to 
seasonal variation in vitamin Da status. In a step further, the season of birth has been 
implicated with the occurrence of MS and insulin-dependent diabetes mellitus (16-18). In 
addition to that, higher serum 25(OH)D3 levels have been associated with lower relapse risk 
in MS, occurring in a dose-dependent linear fashion (43). Hypothetically, a heightened 
proinflammatory response in utero during wintertime may have important connotation on 
eventual development of MS and insulin-dependent diabetes mellitus. Further studies are 
warranted to validate this by looking at cytokine responses during pregnancy across the four 
seasons and assessing the therapeutic benefits of vitamin D supplementation during 
pregnancy. 
In conclusion, we have demonstrated for the first time that variations in innate immune 
response exist throughout the four seasons of the year. In summer, elevated serum vitamin 
D3 levels are associated with an attenuated cytokine-producing capacity attributable to a 
suppressed expression of TLR2 and TLR4. This harbours potentially important implications 
for our understanding of disease epidemiology and implementation of vitamin D3 
supplementation in temperate regions during winter. 
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ABSTRACT 
It is well-recognized that vitamin Da has immune-modulatory properties and that the variation 
in ultraviolet (UV) exposure affects vitamin Da status. Here, we investigated if and to what 
extent seasonality of vitamin D3 levels are associated with changes in Τ cell numbers and 
phenotypes. Every three months during the course of the entire year, human PBMC and 
whole blood from 15 healthy subjects were sampled and analyzed using flow cytometry. We 
observed that elevated serum 25(OH)D3 and 1,25(OH)2D3 levels in summer were associated 
with a higher number of peripheral CD4+ and CD8+ Τ cells. In addition, an increase in naive 
CD4+CD45RA+ Τ cells with a reciprocal drop in memory CD4+CD45RO+ Τ cells was 
observed. The increase in CD4+CD45RA+ Τ cell count was a result of heightened 
proliferative capacity rather than recent thymic emigration of Τ cells. The percentage of 
regulatory Τ cell (Treg) dropped in summer, but not the absolute Treg numbers. Notably, in 
the Treg population, the level of forkhead box protein 3 (Foxp3) expression was increased in 
summer. Skin, gut and lymphoid tissue homing potential was increased during summer as 
well, exemplified by increased CCR4, CCR6, CLA, CCR9 and CCR7 levels. Also, in 
summer, 004* and CD8+ Τ cells revealed a reduced capacity to produce proinflammatory 
cytokines. In conclusion, seasonal variation in vitamin D3 status in vivo throughout the year 
is associated with changes in the human peripheral Τ cell compartment and may as such 
explain some of the seasonal changes in immune status which has been observed 
previously. Given that the current observations are limited to healthy adult males, larger 
population-based studies would be useful to validate these findings. 
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INTRODUCTION 
Vitamin D3 is traditionally associated with bone homeostasis and calcium metabolism. The 
extra-renal synthesis of 1,25-dihydroxyvitamin Ds (1,25(OH)2D3) by macrophages and other 
immune cells has re-invented the role of vitamin D3. In recent years, research efforts were 
also focused on understanding the immune-modulatory properties of vitamin D3. 1,25-
dihydroxyvitamin D3 has been shown to influence the growth and differentiation of both the 
innate and adaptive immune cells, as well as their functions such as cytokine production (1-
3). As such, there has been much interest to identify its therapeutic potential in autoimmune 
or inflammatory diseases. 
Sources of vitamin D3 include dietary uptake (primarily fatty fish and cod liver oil) as well as 
cutaneous biosynthesis from ultraviolet (UV)B exposure causing 7-dehydrocholestrol to form 
previtamin D3 in the skin. Vitamin D3 is subsequently hydroxylated into 25-hydroxyvitamin D3 
(25(OH)D3) by 25-hydroxylase in the liver. 25-hydroxyvitamin D3 is further hydroxylated by 
1 α-hydroxylase in the kidney into the biologically active metabolite, 1,25(OH)2D3 (4). The 
main source of vitamin D3 derives from UVB-induced vitamin D3 production, accounting for 
80 to 90% of circulating vitamin D3 (5). The seasonal fluctuation in vitamin D3 status in 
temperate and cold climates with reduced sunlight exposure during certain periods of the 
year is thought to be responsible for the high prevalence of vitamin D3 insufficiency among 
populations residing at higher latitudes (6). Low wintertime vitamin D3 levels have been 
found partly accountable for the seasonal peak in influenza and URTI occurrence (7-9). 
Moreover, reduced sun exposure and vitamin D3 status have been identified as risk factors 
for the development of autoimmune diseases. Epidemiological studies have implicated 
seasonality of birth as well as geographical variation in UV radiation and serum vitamin D3 
levels as contributing factors to the prevalence of multiple sclerosis and insulin-dependent 
diabetes mellitus (10-15). 
Τ cells are known targets for 1,25(OH)2D3 since they express vitamin D receptor (16;17). 
Upon Τ cell activation, the expression of vitamin D receptor (VDR) is up-regulated, 
suggesting an important functional role for vitamin D3 in adaptive immunity. Both human in 
vitro and animal models revealed that vitamin D3 can suppress proinflammatory Τ helper 
(Th)1 and Th17 cytokine responses (18;19), while enhancing the production of interleukin 
(IL)-4, IL-5 and IL-10, thereby promoting a Th2 and regulatory Τ cell (Treg) phenotype 
(20;21). Indeed, accumulating evidence supports the notion that vitamin D3 could favourably 
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influence the course of certain autoimmune pathology by increasing the number of Treg 
(13;15). In addition, chemokine receptors expression is a determining factor in migration and 
localization of Τ lymphocytes during physiological and inflammatory responses (22;23); 
1,25(OH)2D3 has been demonstrated to affect the homing capacity of the peripheral CD4+ Τ 
cell population in vitro and in an animal model (24;25). 
Taken together, the involvement of 1,25(OH)2D3 in the dynamics of Τ cell compartment 
warrants further investigation. Previously, we have found a down-regulation of Toll-like 
receptor (TLR)4-mediated proinflammatory cytokines production in association with an 
elevated vitamin D3 status in summer (26). However, our current knowledge on the 
immunomodulatory role of vitamin D3 conveys limited information on how the adaptive 
immune response of healthy individuals varies in response to physiological changes in 
vitamin Ds status in vivo during the different seasons of the year. Intrigued by the strong 
epidemiological association between vitamin D3 deficiency and autoimmunity, and the 
proposed effects of 1,25(01-1)203 on Treg, we investigated whether there is a seasonal 
variation in the composition of the peripheral Τ cell pool and the circulating Treg. A potential 
modification in these parameters may provide a better understanding on how sun exposure 
and vitamin D3 can act as candidate risk-modifying factors in certain autoimmune disorders. 
MATERIALS AND METHODS 
Study subjects 
Fifteen healthy male volunteers (median 36 years old, range 28-60; mean BMI 22.8 kg/m2, 
range 20.5 - 26.2) were recruited and followed up for one year. Body mass index (BMI) has 
been shown to be inversely related to vitamin D3 levels (27). We have eliminated this 
confounder from our study since none of the 15 volunteers was obese (BMI > 30 kg/m2). 
Venous blood was drawn from the subjects every three months, at the end of four 
consecutive seasons in 2009; February in winter, May in spring, August in summer and 
November in autumn. On the rare occasions that a participant reported on being unwell, the 
experiment would be postponed until one week post-recovery. 
Ethics statement 
The study was approved by the Ethical Committee on Human Experimentation of the 
Radboud University Nijmegen. A written consent was obtained from all participants in the 
study. 
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Flow cytometry 
Cells were phenotypically analyzed by five-color flow cytometry (Coulter Cytomics FC 500, 
Beekman Coulter, Fullerton, USA) using Coulter Epics Expo 32 software. PBMC as well as 
whole blood (after red cell lysis) were used for flow cytometric analysis. Peripheral blood 
mononuclear cells (PBMC) were isolated by density centrifugation on Ficoll-Hypaque 
(Pharmacia Biotech, Uppsala, Sweden). Cells were washed with PBS with 0.2% bovine 
serum albumin (BSA) before being labeled with fluorochrome-conjugated antibodies (mAb). 
After incubation for 20 minutes at room temperature, in the dark, cells were washed twice to 
remove unbound antibodies and analyzed. For cell surface staining, the following mAb were 
used: CD127 PC5- or PC7-labeled (RDR5; eBioscience, Uithoorn, The Netherlands), CD25-
PE (M-A251), CD25-APC (2A3) CD45RA-FITC (HI100), CCR4-PC7 (1G1), CCR6-PE 
(11A9), CLA-FITC (HECA-452) (all from BD Biosciences, Breda, The Netherlands), CD3-
ECD (UCHT1), CD4 ECD- or PC7-labeled (SFCI12T4D11), CD4-PC5 (13B8.2), CD8-ECD 
(SFCI21Thy2D3), CD8-PC5 (B9.11), CD27-PC5 (1A4CD27), CD45RA-ECD 
(2H4LDH11LDB9) CD45RO-ECD (UCHL1) (all from Beekman Coulter, Mijdrecht The 
Netherlands), CCR7-FITC (150503), CCR9-PE (112509) (both from R&D Systems, 
Minneapolis, USA), CD27-FITC (M-T271), CD45-PE (T29/33), CD45RA-PE (4KB5) (both 
from Dako, Glostrup, Denmark) and CD31 Alexa Fluor® 488 (WM59) (BioLegend, San 
Diego, USA). Appropriate isotype control mAbs were used for gate settings. The live gate 
was set based on the fon/vard angle light scatter (FSCs) and the side angle light scatter 
(SSCs), and Annexin-V/PI staining. 
For intracellular staining of FoxP3 and Ki-67, cells were fixed and permeabilized using Fix 
and Perm reagent (eBioscience) according to the manufacturer's recommendations. The 
following mAb were used for staining: anti-FoxP3 FITC- or PE- labeled (FCH101; 
eBioscience), anti-Ki-67-FITC (B56, BD Biosciences). 
Intracellular staining of cytokines was performed after 4 hours stimulation with PMA (12.5 
ng/ml) and ionomycin (500 ng/ml) in the presence of Brefeldin A (5 pg/ml; Sigma, 
Zwijndrecht, The Netherlands). Cells were fixed and permeabilized using Fix and Perm 
reagent (eBioscience) according to the manufacturer's recommendations. The following mAb 
were used for staining: anti-IFNY-PC7 (4S.B3), anti-IL-17-Alexa Fluor® 647 (eBI064DEC17) 
(both from eBioscience), and anti-IL-2-PE (MQ1-17H12) (BD Bioscience). 
Vitamin Ds measurement 
Serum 25(OH)D3 was determined using high-performance liquid chromatography (HPLC) 
with ultraviolet (UV) detection, after prior extraction on small SepPak columns as previously 
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described (28). Tritiated 25(OH)D3, collected from the HPLC system during passage of the 
UV peak, was used to correct for procedural losses. Serum 1,25(OH)2D3 was measured 
using a radioreceptor assay (RRA) with prior extraction and chromatographic pre-puhfication 
with correction for recovery as previously described (29). For 25(OH)D3, the within run 
precision was 2.6% at 69 nmol/L and between run precision was 6.2% at 69 nmol/L. For 
1,25(OH)2D3, the within run precision was 10.6% at 115 pmol/L and between run 
precision was 17.2% at 69 nmol/L. 
Statistical analysis 
Results were pooled and analyzed using SPSS 16.0 statistical software. Data given as 
means + SEM and the Analysis of Variance (ANOVA) was performed to assess overall 
variation. Where the ANOVA indicated a significant difference (P < 0.05), the Friedman test 
using Graphpad PRISM software (Graphpad Prism Inc., version 4, CA, USA) was used to 
compare differences between groups (unless otherwise stated). The level of significance 
was set at Ρ < 0.05. 
RESULTS 
Serum 25(OH)D3 and 1,25(OH)2D3 levels are increased during summer 
First, we determined serum concentrations of both 25(OH)D3 and 1,25(OH)2D3 in 15 healthy 
volunteers (median 36 years old, range 28-60) through winter (December to February), 
spring (March to May), summer (June to August) and autumn (September to November). 
The median concentration of 25(OH)D3 varied between the four seasons and was doubled 
from 43 nmol/L in winter to 89 nmol/L in summer (Figure 1A). Also, the median serum 
concentration of 1,25(OH)2D3 raised significantly from 219 pmol/L in winter to 237 pmol/L in 
summer (Figure 1B). These observed trends paralleled the amount of sunlight in the study 
region. Likewise, there is considerable seasonal difference in ultraviolet Β (UVB) radiation in 
the study region (30). The total duration of daylight in a month prior to vitamin D3 
measurement were 103 hours and 240 hours in winter and summer respectively, which 
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Figure 1. Seasonal variation in serum vitamin 
O3 levels and the amount of daylight 
Median serum A) 25(OH)D3 and B) 1,25(OH)2D3 
concentrations of 15 healthy volunteers during 
each of the four seasons. C) Duration of daylight 
in the study region in a month prior to serum 
vitamin D3 concentration assay (source: the 
Royal Netherlands Meteorological Institute). *P < 
0.05 as compared to winter. 
Seasonal variation in peripheral blood Τ cell subset numbers associated with vitamin 
D3 levels 
Next, we investigated whether seasonal variation in vitamin D3 status was associated with 
changes in the peripheral Τ cell pool, by performing flowcytometric analysis on blood 
samples obtained during the different seasons of the year (Figure S1). In spring and summer 
months when serum vitamin D3 levels were elevated, the percentage as well as the absolute 
CD4+ Τ cell counts were significantly raised as compared to winter (Figure 2A). For CD8+ Τ 
cells, this effect was less outspoken (Figure 2B). 
The composition and size of the naive and memory Τ cell pools are regulated by cytokines 
and Τ cell receptor (TCR) signalling from contact with major histocompatibility complex 
(MHC). Naïve Τ cells predominately express CD45RA and memory Τ cell express CD45RO. 
Interestingly, during spring and summer, we observed a relative increase in the percentage 
of CD4+CD45RA+ Τ cells (Figure 2C), with a corresponding drop in CD4+CD45RO+ Τ cell 
percentage (Figure 2D). Also, absolute CD4+CD45RA+ Τ cell counts were increased in 
spring and summer months, while the number of CD4+CD45RO+ Τ cells was not significantly 
changed. To investigate whether the increase in peripheral CD4+CD45RA+ Τ cells as 
observed in spring and summer could be attributed to recent thymic emigration or a higher 
proliferative capacity; we stained cells with Ki-67 and CD31. Ki-67 is a nuclear protein 
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Figure 2. Peripheral Τ cell (subset) 
numbers throughout the four 
seasons 
A) Percentage (of live gate) and 
absolute numbers of CDA* Τ cells. Β) 
Percentage (of live gate) and 
absolute numbers of CD8+ Τ cells, 
over time C) Percentage (within 
004* Τ cells) and absolute counts, of 
CD4*CD45RA* Τ cells. D) 
Percentage (within CD4* Τ cells) and 
absolute counts, of CD4*CD45RO* Τ 
cells. E) Percentage and absolute 
counts of Κι-67-expressing 
CD4 iCD45RA+ Τ cells. Whole blood 
samples obtained from 15 healthy 
volunteers during each season were 
analyzed for the respective markers 
using flow cytometry. Ki-67 analysis 
was performed on PBMC. Data show 
results of viable cells from 15 healthy 
donors. *P < 0.05 as compared to 
winter. 
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associated with cellular proliferation, while CD31 has been used as a marker for recent 
thymic emigrants (31 ). In spring and summer, an increased Ki-67-expressing population was 
found within the CD4+CD45RA+ Τ cells (Figure 2E). On the other hand, there were no 
significant differences in both the frequency of 004+0045ΚΑ+ Τ cell expressing CD31 as 
well as their level of expression between winter and summer (data not shown). 
The increase in vitamin D3 levels found in summer, as compared to winter was paralleled by 
a reduction in the percentage of CD25h'CD127" Treg within the CD4* Τ cell population 
(Figure 3A), however the absolute Treg numbers were not associated with the variation in 
vitamin D3 levels. Of note, the level of expression (mean fluorescence intensity, MFI) of 
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Figure 3. Seasonal variation in numbers 
and Foxp3 expression of Treg during 
the four seasons 
A) Percentage (within CD4* Τ cells) and 
absolute numbers of CD4+CD25hlCD127' 
Treg and B) level of Foxp3 expression 
(mean fluorescence intensity; MFI). Whole 
blood and PBMC isolated from 15 healthy 
volunteers during each season were 
analyzed for the respective markers using 
flowcytomelry. Data show results from 15 
healthy donors *P < 0 05 as compared to 
winter. 
Winter Spring Summer Autumn 
Seasonal variation in homing potential of peripheral blood CD4* Τ cells 
Peripheral Τ cell trafficking is regulated by specific chemokine receptors which are 
selectively expressed by the various Τ cells subsets. As 1,25(OH)2D3 has been 
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demonstrated to affect the homing capacity of the peripheral CD4+ Τ cell population in vitro 
and in vivo, we wondered if we could detect seasonal variation in homing receptors 
expression. We looked at the expression of homing markers on CD4+ Τ cells, as well as 
more specifically on the Treg population, and included chemokine receptors associated with 
migration to the skin (CCR4, CCR6 and CLA), gut (CCR9) and lymphoid tissues (CCR7). 
In summer, an increased skin homing potential of CD4* Τ cells was observed compared to 
winter, given that the percentage of CD4* Τ cells expressing CCR4 and CCR6 (Figure 4A 
and 4B) was significantly increased together with elevated expression levels (MFI) of CCR4, 
CCR6 and CLA (Figure 4A-C). Also, the percentage of CD4+ Τ cells expressing the gut 
homing marker CCR9 was increased in summer, as well as the level of expression (Figure 
4D). Similar observations were seen in the expression level of the chemokine receptor 
associated with lymphoid tissue homing, CCR7 (Figure 4E). 
The skin homing potential of the regulatory Τ cell subset mirrored that of the whole 
peripheral CD4* Τ cell population. In summer Treg displayed a heightened skin homing 
potential as seen by a significantly increased frequency of CCR4-expressing Treg (Figure 
5A), and higher expression levels (MFI) of CCR4, CCR6 and CLA (Figure 5A-C), when 
compared to winter. The level of expression (MFI) of chemokine receptors involved in gut 
homing, CCR9 (Figure 5D) and lymphoid tissue homing, CCR7 (Figure 5E) were also 
increased in summer. 
Reduced proinflammatory cytokine production by peripheral blood Τ cells in summer 
Intrigued by the increased CD4* Τ cell numbers in spring and summer, we also looked at 
functional characteristics of the cells by examining the cytokine-producing capacity of CD4+ 
Τ cells using intracellular cytokine staining for interferon (IFN)Y, IL-2 and IL-17. There was no 
significant effect on the percentage of IFNy-producing CD4+ Τ cells (Figure 6A), but the level 
of production on a per cell basis (MFI) was lowered in summer (p<0.05). The percentages of 
IL-2 and IL-17- secreting CD4+ Τ cells were reduced in summer (Figure 6B and 6C), with 
unchanged levels of production on a per cell basis (MFI). 
For CD8+ Τ cells we also found lowered levels of IFNy production (MFI) from spring to 
autumn (Figure 6D). The percentage of CD8+ Τ cells producing IL-2 was significantly 
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Figure 4. Skin, lymphoid tissue 
and gut homing receptor 
expression on CD4* Τ cells 
Percentage and level of expression 
(MFI) of A) CCR4, B) CCR6, C) CLA, 
D) CCR7 and E) CCR9 by CD4+ Τ 
cells during the different seasons of 
the year. Whole blood from 15 
healthy volunteers during each 
season was analyzed for the 
respective markers using flow 
cytometry. Data show results from 15 
healthy donors. *P < 0.05 as 
compared to winter. 
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Figure 5. Skin, lymphoid tissue 
and gut homing receptor 
expression on CD4+CD25hlCD127 
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Percentage of Treg (within CD4* Τ 
cells) and their level of expression 
(MFI) of A) CCR4, B) CCR6, C) CLA, 
D) CCR7 and E) CCR9 during the 
four seasons of the year. Whole 
blood from 15 healthy volunteers 
during each season was analyzed for 
the respective markers using flow 
cytometry. Data show results from 15 
healthy donors *P < 0.05 as 
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Figure 6. Seasonal 
variation in cytokine 
profile of CD4+ and CD8* Τ 
cells 
Percentage and the level of 
production on a per cell 
basls(MFI)of A) IFNy, B) IL-
2 and C) IL-17 by CD4+ Τ 
cells; and of D) IFNy and E) 
IL-2 by CD8+ Τ cells 
analyzed by flow cytometry. 
PBMC isolated from 10 
healthy volunteers and 
intracellular staining for 
cytokines was performed 
after the cells were 
stimulated with PMA plus 
ionomycin in the presence of 
brefeldin A. CD4+ Τ cells 
were defined as CD3*CD8". 
Data show results from 10 
healthy donors. *P < 0.05 as 
compared to winter. 
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Figure S1. Supplementary figure 
Gate setting for CD4+ and CD8+ Τ cells 
gated on CD45+ cells; and CD4*CD45RA+ Τ 
cells, CD4+CD45RO+ Τ cells and 
CD4+CD25hlCD127 regulatory Τ cells gated 
on CD4* Τ cells. Dotplots show surface 
staining for markers performed on whole 
blood. 
DISCUSSION 
There is growing evidence that vitamin D3 plays a pivotal role in infections and autoimmune 
diseases. Whilst UV-induced vitamin D3 production serves as the main source of vitamin D3 
in the body (5), it is not apparent whether seasonal variation in vitamin D3 can impact Τ cell 
immunity. We show for the first time that physiological elevation in vitamin D3 concentrations 
during summer is paralleled by changes in the peripheral Τ cell composition, with a notable 
shift in the naive and memory CD4+ Τ cell balance as a consequence of increased 
proliferation of naive CD4+CD45RA* Τ cells. 
By virtue of its stability and long half-life, 25(OH)D3 is the vitamin D metabolite that best 
reflects the vitamin D3 status (32). Here, we found a significant difference between winter 
(December to February) and summer (June to August) 25(OH)D3 levels. Serum 1,25(OH)2D3 
concentrations were also higher in summer as compared to winter. In our cohort of 15 
subjects residing at 520N from the Equator, this variation correlated with the amount of 
sunlight and ultraviolet Β radiation received in the study region. Vitamin D3 insufficiency at 
high latitudes has been implicated in the prevalence of autoimmune diseases such as 
multiple sclerosis and insulin-dependent diabetes (33;34). Therefore, we investigated 
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whether the peripheral Τ cell compartment might vary with physiological changes in vitamin 
D3 status throughout the year. 
We found higher percentages of peripheral CD4* and CD8+ Τ cells concomitant with a 
heightened vitamin D3 status during summer. Interestingly, we observed a higher proportion 
of CD4+CD45RA+ naive Τ cells in the spring/summer months with a corresponding drop in 
the percentage, but not in the absolute number, of CD4+CD45RO+ memory Τ cells. When 
investigated further, the expansion of CD4*CD45RA* naive Τ cells resulted from an 
increased proliferative capacity as seen by a higher absolute cell count and an increased 
population expressing the proliferative marker, Ki-67. One of the key targets of 1,25(OH)2D3 
are the CD4+ Τ cells. In vitro, 1,25(OH)2D3 inhibits Τ cell proliferation (35;36). Though few 
studies examined the differential effects on naïve and memory Τ cells, the inhibitory effect 
has been found to be more pronounced in the memory Τ cell compartment (37). 
1,25(OH)2D3 exerts a marked inhibitory effect on cells of the adaptive immune system and it 
has been consistently described that 1,25(OH)2D3 inhibits cytokines such as IFNy (21;38) 
and IL-17, as well as IL-2 (19;39), both under in vitro conditions and in animal models. Our 
data reveal that in healthy adult males residing at 52°N from the Equator, the percentages of 
IL-17- and IL-2-producing CD4* Τ cells were down-regulated in summer and the IFNy 
production on a per cell basis (MFI) in both CD4+ and CD8+ Τ cells was also reduced. 
Regulatory Τ cells are characterized by a constitutively high expression of the transcription 
factor, Foxp3. We observed that, although the percentage of peripheral Treg was lower in 
summer as compared to winter, there was no correlation between absolute numbers of Treg 
and vitamin D3 levels. This is in concert with findings of Smolders et al, who failed to detect a 
correlation between Treg numbers and serum 25(OH)D3 levels in patients with multiple 
sclerosis (40). Interestingly, they did find that higher 25(OH)D3 levels were associated with 
improved suppressive function. This fits our data on increased expression of Foxp3 in the 
Treg during summer. Morales-Tirado et al reported that in vitro, 1,25(OH)2D3 enhanced Treg 
function by increasing the expression of Foxp3 and that this was shown to be associated 
with modulation of cell cycle progression by vitamin D3 (41 ). 
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Τ cell migration is determined by the presence of specific selectins, chemokine receptors 
and integrins. Homing receptors are selectively expressed and regulated in different Τ cell 
subsets (23,42). Our results are suggestive of a vitamin D3 associated up-regulation of skin-, 
gut- and lymphoid tissue- homing expression on CD4* Τ cells, including Treg. Although not 
previously described in the context of physiological variation, 1,25(OH)2D3 has been reported 
to influence certain skin homing markers in human Τ cells. In vitro, it has been shown that 
addition of 1,25(OH)2D3 resulted in induction of CCR10, inhibition of CLA, but not CCR4 and 
CCR6 expression (38;43). In our study, we found that during summer an increased 
frequency of CCR4-expressing cells as well as an increased level of expression (MFI) of 
CCR4, CCR6 and CLA. These data suggest that in summer CD4+ Τ cells, including Treg, 
are better equipped to migrate to the skin. Also, we observed higher levels of CCR9 and 
thus heightened potential to migrate to the gut. Previously, 1,25(OH)2D3 was described not 
to affect gut-homing markers (25). However, it should be appreciated that the physiological 
up-regulation of vitamin D3 levels by UV light through the skin is likely to yield distinct effects 
from those obtained through supraphysiological doses employed in these in vitro studies. 
In the present study, we assessed a homogenous study population (healthy, adult males of 
normal BMI) to establish if and how the human peripheral Τ cell compartment varies with the 
season. Unique to previous in vitro and in vivo studies examining the role of 1,25(OH)2D3 on 
Τ cells, our current results suggest that physiological variation in serum vitamin D3 levels 
throughout the four seasons might influence CD4+ and CD8* Τ cell homeostasis and homing 
behavior. Given that serum 25(OH)D3 levels can be affected by various factors, our 
observations warrant future validation in a larger and more diverse population cohort to 
identify any possible differences in adaptive immune responses among the extreme of ages 
and different genders. Nevertheless, our data provide insight on previous epidemiological 
findings regarding the prevalence of certain autoimmune diseases and infections, which 
have been attributed to seasonal variation in sun exposure and serum 25(OH)D3 levels (10-
12),(44). Although not as extensively reported as vitamin D3 status, certain hormones and 
corticosteroids such as catecholamine and aldosterone seem to vary with seasons as well 
(45;46). It would be of interest to find out if these factors are associated with changes in 
immunological characteristics of Τ cell. 
In conclusion, we have demonstrated for the first time the existence of variations in adaptive 
immunity throughout the four seasons of the year in association with physiological changes 
in serum 25(OH)D3 levels in vivo. These novel findings further our understanding on the 
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seasonal variability between vitamin D3 and human peripheral Τ cell composition, and 
support the basis for conducting larger population-based studies to investigate the benefits 
of vitamin D3 supplementation in temperate regions during winter. 
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1,25-Dihydroxyvitamin D3 Inhibits Proliferation but not the 
Suppressive Function of Regulatory Τ Cells in the Absence of 
Antigen-Presenting Cells 
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ABSTRACT 
Vitamin D3 is known to induce regulatory Τ cell (Treg) by rendering antigen presenting cells 
(APC) tolerogenic, its direct effect on human naturally-occurring Treg is unclear. Here, we 
investigated if and how 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) can directly affect the 
proliferation and function of human naturally-occurring Treg in vitro. First, we demonstrated 
that these Tregs express vitamin D receptor that was up-regulated following anti-CD3/CD28-
bead stimulation. 1,25(OH)2D3 inhibited proliferation of Treg even when exogenous 
interleukin (IL)-2 was provided. Tregs were more susceptible to the inhibitory effect of 
1,25(OH)2D3 than conventional Τ cells (Tconv) 1,25(OH)2D3 neither affected the anergic 
state nor the suppressive function of Treg but induced a subtle increase in IL-10-secreting 
cells. The cell division inhibiting effect of 1,25(OH)2D3 on Treg was also demonstrated in vivo 
by supplementing vitamin D deficient HIV-1 infected patients with 2000 ID cholecalciferol 
(vitamin D3). Increased serum 1,25(OH)2D3 levels were associated with a drop in the number 
and percentage of Treg which may be attributed to a decrease in proliferating Foxp3+ Treg 
population. In conclusion, 1,25(OH)2D3 directly affects Treg growth and promotes IL-10 
production without apparent effects on activation status and suppressive phenotype whereas 
in vivo, high serum 1,25(OH)2D3 levels are associated with reduced Treg proliferation and a 
reduced number of Treg. 
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INTRODUCTION 
Vitamin D3 is mostly associated with its primary role in bone and calcium metabolism, but 
recent interest hinges on its potential as an immunomodulatory agent. Vitamin D3 is obtained 
by dietary intake or by cutaneous previtamin D3 biosynthesis upon ultraviolet (UV)B 
exposure. Previtamin D3 is subsequently hydroxylated into 25-hydroxyvitamin D3 (25(OH)D3) 
in the liver and further hydroxylated by 1 α-hydroxylase in the kidney into the active 
metabolite, 1,25(OH)2D3 (1). 1,25(OH)2D3 is the ligand for vitamin D receptor (VDR). Several 
mononuclear cells including Τ cells, express VDR (2;3) and can also produce 1,25(OH)2D3 
by expressing 1 α-hydroxylase (4;5). A role for vitamin D3 in immune regulation has been 
demonstrated both in vivo and in vitro; 1,25(OH)2D3 influences the growth, differentiation and 
cytokine production of various immune cells (6-8). As a result, 1,25(OH)2D3 has been 
proposed as a potential immunomodulatory agent in autoimmune diseases such as insulin-
dependent diabetes mellitus, multiple sclerosis, inflammatory bowel disease and rheumatoid 
arthritis (9-11), as well as in cancer (12) and infectious diseases such as HIV infection (13). 
Regulatory Τ cells are characterized by a CD4+CD25h' phenotype and signature transcription 
factor, forkhead box protein 3 (Foxp3). They are an integral part of the immune system and 
are crucial in the regulation of immune homeostasis (14). It has been demonstrated that the 
regulatory function of CD4+CD25* Treg is hampered in autoimmunity, allergy and infectious 
diseases, indicating that these cells play an important role in immune-mediated pathology. 
Over the past decade, there has been a streaming amount of evidence on the potential 
therapeutic application of Treg either in enhancing their regulatory activity in inflammatory 
diseases such as autoimmunity, allograft rejection, graft versus host disease and allergic 
diseases, or in blocking their suppressive activity in tumour immunity or vaccine 
development (15-18). 
Treg can either be derived from the thymus, the so-called naturally-occurring Treg (nTreg) or 
they can be induced de novo in the periphery from CD4+ Τ cells. Vitamin D3 interferes with 
the maturation and differentiation of dendritic cells and may induce a so-called tolerogenic 
phenotype (19;20). This implies that 1,25(OH)2D3can indirectly potentiate the differentiation 
of IL-10-producing CD4+CD25* regulatory Τ cells by altering the function of antigen 
presenting cells (21;22). 1,25(OH)2D3 can also act directly on CD4+CD25" Τ cells to generate 
Foxp3+ Τ cells expressing high levels of CTLA-4 that are capable of immune suppression 
(23). In mouse models, 1,25(OH)2D3 enhanced the proliferative capacity of CD4+CD25+ Treg 
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(24) and its ability to suppress Τ helper (Th)2 activity (25). However, there is limited 
information on the direct effects of 1,25(OH)2D3 on human naturally-occurring Treg. In 
patients with multiple sclerosis (MS), controversy exists on how serum 25-hydroxyvitamin D3 
levels correlate with peripheral nTreg pool (26;27) though it seems to be implicated in the 
enhancement of Treg suppressive function (27). 
In this study, we assessed the direct effect of 1,25(OH)2D3 on ex vivo stimulated human 
Treg. We show for the first time that human naturally-occurring regulatory Τ cells express 
VDR, and consequently that 1,25(OH)2D3 can exert its immunomodulatory effect directly on 
pre-existing Treg in the absence of APCs. The major effect of 1,25(01-1)203 on pre-existing 
Treg is inhibition of proliferation. Other properties associated with its suppressor capacity are 
left largely unaffected although IL-10 production by Treg was slightly enhanced. Our in vitro 
data on reduced proliferative capacity of Treg is supported by a clinical study whereby 
decreased numbers of peripheral blood Treg are found during the treatment of vitamin D 
deficient HIV-infected patients with cholecalciferol. 
MATERIALS AND METHODS 
Cell isolation 
Buffy coats were obtained from healthy donors (Sanquin Blood Bank, Region South East, 
the Netherlands) with written informed consent on scientific use, according to the Declaration 
of Helsinki. Peripheral blood mononuclear cells (PBMC) were isolated by density 
centrifugation with Lymphoprep (Axis-Shield AS, Oslo, Norway) and LeucoSep® (Greiner 
Bio-One, Frickenhausen, Germany). CD4+ Τ cells were purified from PBMC by negative 
selection using monoclonal antibodies (mAbs) directed against CD8 (RPA-T8), CD14 
(M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD56 (B159) and CD235a (GA-R2(HIR2) 
(BD-Biosciences, Erembodegem, Belgium) combined with sheep-anti-mouse-lg coated 
magnetic beads (Dynal Biotech, Invitrogen ASA, Oslo, Norway). Bead-cell complexes were 
removed using a magnetic holder. The resultant CD4+ Τ cell fraction, typically of > 90% 
purity was incubated with anti-CD25-PE (M-A251, BD Biosciences, NY, USA), anti-CD4-
ECD (SFCI12T4D11) and anti-CD27-PC5 (1A4CD27) conjugated antibodies (both from 
Beekman Coulter Corporation, Miami, USA). CD4+CD25hlCD27+ regulatory Τ cells and 
CD4*CD25ne9CD27* conventional Τ cells were isolated from purified CD4* Τ cells by high 
purity flowcytometric cell sorting (Altra Flow Cytometer, Beekman Coulter, Miami, USA). The 
isolated CD4+CD25h,CD27+ Treg (routine yield of > 98% purity) and CD4+CD25ne9CD27+ 
133 
conventional Τ cells (Tconv) were used immediately after isolation. A phenotypic analysis 
after isolation established that our target CD4+CD25h'CD27+ Treg population expressed high 
level of Foxp3 whereas CD127 expression was lacking. In some experiments, CD4+CD25* 
and CD4+CD25ne9 Τ cells were isolated from the negative isolated CD4+ population by 
MACS-sorting, using 10 μΙ anti-CD25 magnetic microbeads for every 107 CD4+ Τ cells 
(Miltenyi Biotec, Bergisch Gladbach, Germany). 
Cell proliferation assay 
To study the effect of 1,25(OH)2D3 on cell proliferation, 2.5 χ 104 Treg or Tconv were 
stimulated with 5 χ 103 anti-CD3/anti-CD28 mAb-coated microbeads (Dynal Biotech, 
Invitrogen ASA, Oslo, Norway) in 200 μΙ culture medium (RPMI-1640 supplemented with 
glutamax, 0.02 mM sodium pyruvate, 100 U/ml Penicillin, 100 pg/ml Streptomycin) (all from 
Gibco, Paisley, UK) and 10% human pooled serum (HPS). Exogenous recombinant human 
interleukin-2 (rhlL-2) 12.5 U/ml (Proleukine, Chiron, Amsterdam, the Netherlands) was 
added to the cell culture. The dose-response of 1,25(OH)2D3 (Fluka Biochemika, Sigma-
Aldrich, Missouri, USA), dissolved in absolute ethanol, was examined at 1, 10, 100 nM. No 
solvent effect was apparent in control experiments. Cell cultures were performed in 96-well 
round bottom plates (Greiner, Frickenhausen, Germany) and incubated in a 37°C, 95% 
humidity, 5% CO2 incubator. Cell proliferation was monitored by [3H] Thymidine incorporation 
using a gas scintillation Counter (Canberra Packard, Matrix 96 Beta-counter, Meriden, USA) 
on day 3, 4 and 5. The cells were pulsed with 0.5 pCi of [3H] Thymidine (Amersham 
Biosciences, Piscataway, NJ) during the last 16-18 hours of culture. [3H] Thymidine 
incorporation is expressed as mean (±SD) counts per 5 minute of triplicate measurements. 
Relative inhibition was calculated as: % inhibition= {1- ([3H] Thymidine incorporation co-
culture/ [3H] Thymidine incorporation control MLC) χ 100%}. 
Suppression assay 
The suppressive capacity of isolated or cultured Treg was studied in co-culture assays. In 
brief, graded doses of Treg were added in an increasing ratio to 2.5 χ 104 responder cells 
(Tconv) and stimulated with anti-CD3/anti-CD28 mAb-coated microbeads. Cell proliferation 
was examined by [3H] Thymidine incorporation, as mentioned above, on day 4 of cultures. 
Relative suppression was calculated as: % suppression= {1- ([3H] Thymidine incorporation 
co-culture/ [3H] Thymidine incorporation control MLC) χ 100%}. To study the suppressive 
capacity of Treg in the presence of 1,25(OH)2D3, co-cultures were conducted with or without 
the addition of 100 nM of 1,25(OH)2D3. 
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Flow cytometry 
Cells were phenotypically analyzed by four- and five-color flow cytometry (Coulter Epics XL 
and Coulter Cytomics FC 500, Beekman Coulter, Fullerton, USA) using Coulter Epics Expo 
32 software. Cells were washed with PBS with 0.2% bovine serum albumin (BSA) before 
being labeled with fluorochrome-conjugated antibodies (mAb). After incubation for 20 
minutes at room temperature, in the dark, cells were washed twice to remove unbound 
antibodies and analyzed. For cell surface staining, the following mAb were used: CD25-PE 
(M-A251, BD Bioscience, NY, USA), CD4-ECD (SFCI12T4D11) , CD27-PC5 (1A4CD27) 
(both from Beekman Coulter Corporation, Miami, USA), CD25-PC5 (B1.49.9), CD69-PE 
(TP1.55.3) (both from Immunotech, Marseille, France) and CD27-PE (M-T271, Dako, 
Glostrup, Denmark). Appropriate isotype control mAbs were used for marker setting. 
Intracellular cytokine staining was performed after 4 hours stimulation with PMA (12.5 ng/ml) 
and ionomycin (500 ng/ml) in the presence of brefeldin A (5 pg/ml; Sigma-Aldrich). Cells 
were fixed and permeabilized using Fix and Perm reagent (eBioscience, San Diego, USA) 
according to the manufacturer's recommendations. The following mAb were used for 
staining: anti-IFNY-PC7 (4S.B3, eBioscience, San Diego, USA) and anti-IL-2-PE (MQ1-
17H12), anti-IL-4-PE (8D4-8), anti-IL-10-PE (JES3-19F1); all from BD Bioscience, NY, USA 
Intracellular Foxp3 expression was analyzed after fixation and permeabilization using anti-
human FoxP3 (FCH101) mAb, FITC or PE labeled; all from eBioscience, San Diego, USA). 
Similarly, Ki-67 expression was examined by intracellular staining using anti-human Ki-67-
FITC mAb (B56, BD Bioscience, NY, USA) 
Vitamin D receptor expression on Τ cells was analyzed by an indirect staining method. After 
fixation and permeabilization of cell sample, cells were incubated with anti-human VDR mAb 
(NR1I1, R&D Systems, Minneapolis, USA) at 4°C for 30 minutes. Cells were then washed 
twice with permeabilization buffer (eBioscience, San Diego, USA) followed by incubation 
with goat-anti-mouse IgG-FITC (Dako, Glostrup, Denmark) in the dark, at 4°C for 30 minutes 
and analyzed by flow cytometry. Appropriate isotype (lgG2A mAb) and conjugate control 
staining were included. 
CFSE-based cell division analysis 
Cell division was studied by CFSE dilution analysis. To this end, high purity sorted cells, 
Treg (0.5-2 χ 106) and Tconv (10 χ 106) were labeled with 0.25-0.5 μΜ and 4 μΜ 
carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes) respectively. The cells were 
subsequently activated with anti-CD3/anti-CD28 mAb-coated microbeads with or without the 
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addition of 100 nM 1,25(OH)2D3. Cell division accompanied by CFSE dilution was analyzed 
by flow cytometry on days 1, 2 and 5. 
Stimulation assay to study Τ cell anergy 
To study Τ cell anergy, 2.5 χ 104 sorted Treg and 2.5 χ 10" Tconv were stimulated with anti-
CD3/anti-CD28 mAb-coated microbeads, 25 U/ml rhlL-2 and 10 ng/ml IL-15 (Biosource 
International, Camarillo, CA); with or without 1,25(OH)2D3. After expansion, the cells were 
harvested on day 7, washed and rested for 2 days in culture medium containing 5% HPS. 
Next secondary cell cultures were performed whereby cells were stimulated with anti-
CD3/anti-CD28 mAb-coated microbeads with and without the addition of 12.5 U/ml IL-2. Cell 
proliferation was examined by [3H] Thymidine incorporation, as described above, after 2 
days. 
In vivo study 
An observational study was done among vitamin D deficient HIV-1 seropositive patients 
visiting the Radboud University Nijmegen Medical Centre, The Netherlands. Vitamin D 
deficiency was defined as 25(OH)D3 levels below 25 or 35 nmol/L, depending on the 
season. We prospectively studied the effect of cholecalciferol supplementation on circulating 
Treg numbers by flow cytometry. The subjects were treated with a daily dose of 2000 IU 
cholecalciferol (vitamin D3) during the first 12 weeks and thereafter for at least 48 weeks with 
a dose of 1000 IU daily. At baseline and after 24 and 48 weeks serum 25(OH)D3, 1,25-
dihydroxyvitamin D3, parathyroid hormone (PTH) levels and circulating Treg were 
determined. This study was approved by the local ethics committee and written informed 
consent was given by all participating subjects 
Twenty subjects were included but two subjects discontinued cholecalciferol 
supplementation after 24 weeks for non-medical reasons. No adverse effects were reported 
or observed during the supplementation. 
25(OH)D3,1,25(OH)2D3 and parathyroid hormone determination 
Serum 25(OH)D3 was measured by high pressure liquid chromatography (HLPC) with UV 
detection, after prior extraction on small SepPak columns. Tritiated 25-hydroxyvitamin D3, 
collected from the HPLC system during passage of the UV peak, was used to correct for 
procedural losses. Serum 1,25(OH)2D3 was measured by radioreceptor assay (RRA) with 
prior extraction and chromatographic purification with correction for recovery. For PTH 
assays the ELSA-PTH assay by CIS BIO was used at first. This method was switched into 
the intact PTH assay performed by the Abbott Architect analyzer, when the CIS BIO assay 
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was no longer available. The Abbott Architect assay was recalibrated on the CIS BIO assay 
to give identical measurement results. 
Statistical analysis 
Statistical analysis was performed using the Statistical Product and Services Solutions 
(SPSS) package version 16.0. The Wilcoxon rank-sum test was used to compare differences 
between groups (unless otherwise stated). The level of significance was set at Ρ < 0.05. 
RESULTS 
Human regulatory Τ cells express VDR 
1,25(OH)2D3 can only exert its effect through binding to its receptor. Although the expression 
of VDR by Τ lymphocytes has been reported (2;3), no information is available on the 
expression of VDR by Treg. Using flow cytometric analysis, we showed that both freshly 
isolated CD4+CD25hl Treg as well as CD4+CD25ne9 conventional Τ cells express VDR 
(Figure 1A). VDR expression was increased upon activation with anti-CD3/anti-CD28 mAb-
coated microbeads in Treg (Figure 1B) as well as Tconv (Figure 1C). The highest levels of 
VDR expression by Treg and Τ conv were found were found on day 2 of culture. 
A) B) C) 
I > VDR 
Figure 1. Flow cytometry of VDR expression by Treg and Tconv 
A) Histogram overlay of VDR expression in Treg and Tconv with isotype staining. Histograms showing 
VDR expression (X-axis) in anti-CD3/anti-CD28 mAb-coated microbeads stimulated vs un-stimulated 
B) Treg and C) Tconv on day 2. Data are representative for 3 independent experiments performed 
with cells obtained from different donors. 
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Figure 2. 1,25(OH)2D) inhibits Treg and Tconv proliferation 
A) The effect of graded doses of 1,25(OH)2D3 on Treg or Tconv proliferation, stimulated with anti-
CD3/anti-CD28 mAb-coated microbeads and in the presence of IL-2. Cell proliferation as assayed by 
[3H] Thymidine incorporation at day 4 of culture and expressed as mean + SD. Data are 
representative for 5 independent experiments. B) Percentage growth inhibition of Treg and Tconv 
upon treatment with 1,25(OH)2D3 at 1, 10 and 100 nM was calculated. Data are the cumulative results 
of 5 independent experiments using cells isolated by high purity flowcytometric cell sorting. * Ρ < 0.05 
when comparing the degree of growth inhibition between Treg and Tconv cells. Effect of 1,25(OH)2D3 
(100 nM) on CD69 expression (Y-axis), in C) Treg and D) Tconv labeled with CFSE (X-axis), after 24 
or 48 hours post-activation. E) Cell division of Treg and Tconv as analyzed by CFSE dilution (X-axis) 
on day 5 with and without addition of 100 nM 1,25(ΟΗ^3. Data are representative for 3 independent 
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experiments performed with cells isolated by high purity flowcytometric cell sorting, obtained from 
different donors. 
1,25(OH)2D3 inhibits proliferation, but allows activation of Treg 
Having established that Treg express VDR, we assessed whether vitamin D3 can affect Treg 
proliferation in an APC-free system. Treg were stimulated with anti-CD3/anti-CD28 mAb-
coated microbeads, in the presence of exogenously added rhlL-2 and 1, 10 or 100 nM 
1,25(OH)2D3. Treg proliferation as analyzed by [
3H] Thymidine incorporation was clearly 
inhibited in a dose dependent fashion (Figure 2A). Even at a low concentration of 1 nM 
1,25(OH)2D3 there was a marked decrease in cell proliferation. Interestingly, we observed a 
significant difference in the inhibition of cell division between Treg and Tconv (Figure 2B and 
2E), indicating that Treg proliferation was more susceptible to the suppressive effect of 
vitamin D3. This difference between Treg and Tconv was consistently observed through all 
the concentrations of 1,25(OH)2D3 employed (Figure 2B). 
Since the addition of vitamin D3 significantly inhibited Treg proliferation, we wondered 
whether this compound also interfere with early Τ cell activation. To analyze this, we looked 
at cell activation status by measuring the expression of CD69, an inducible cell surface 
glycoprotein acquired very early during Τ cell activation. We found that treatment with 
1,25(OH)2D3 did not cause any difference in the expression of CD69 in Treg (Figure 2C) or 
Tconv (Figure 2D) within the first 24 to 48 hours post activation. Although 1,25(OH)2D3 
allowed activation of Treg, cell cycle progression was inhibited (Figure 2E). 
Vitamin Da treatment preserves Treg suppressor function, anergic phenotype and 
Foxp3 expression 
Treg are characterized by its suppressor function, anergic phenotype and constitutively high 
expression of the transcription factor Foxp3. Here, we assessed the influence of vitamin D3 
on the aforementioned Treg characteristics. To examine whether 1,25(OH)2D3 treatment 
interferes with the suppressor activity of Treg, freshly isolated Treg were stimulated with anti-
CD3/anti-CD28 mAb-coated microbeads in the presence of 1,25(OH)2D3 and cultured for 7 
days. Thereafter, the cells were allowed to recuperate and tested for their suppressor 
function in a co-culture assay. After this 'pre-treatment' with 1,25(OH)2D3p Treg kept their 
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Figure 3. Effect of 1,25(OH)2D3 on Treg suppressive function and phenotypic characteristics 
A) Treg were expanded with anti-CD3/anti-CD28 mAb-coated microbeads with or without 100 nM 
1,25(OH)2D3 for 7 days. The cells were harvested and rested for 2 days. Co-culture suppression 
assays were conducted to analyze the suppressor potential of these 1,25(OH)2D3-pretreated cells. 
Cell proliferation was determined by [3H] Thymidine incorporation at day 4. Results are expressed as 
percentage suppression= { 1 - ([3H] Thymidine incorporation co-culture/ [3H] Thymidine incorporation 
control MLC) χ 100%} (Y-axis). B) Suppression assay performed in the absence or presence of 100 
nM 1,25(OH)2D3. Percentage suppression (Y-axis) was measured and calculated as mentioned 
above. C) Treg and Tconv were expanded with anti-CD3/anti-CD28 mAb-coated microbeads with or 
without 100 nM 1,25(OH)2D3 for 7 days. The cells were harvested and rested for 2 days. Proliferative 
capacity of expanded cells upon restimulation with anti-CD3/anti-CD28 mAb-coated microbeads was 
determined in the absence or presence of IL-2 by [3H] Thymidine incorporation (Y-axis). D) 
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Representative histogram overlay depicting the expression of Foxp3 (Y-axis) in Treg and Tconv on 
day 8, as measured by flow cytometry. Data are representative for 5 or 6 independent experiments 
performed with cells isolated by high purity flowcytometric cell sorting, obtained from different donors. 
*P < 0.05 as compared to respective cell culture without the addition of 1,25(OH)2D3. 
of Treg was not affected when a high concentration of 1,25(OH)2D3 was present during the 
co-culture assay (Figure 3B). 
Another classical characteristic of Treg is that they exhibit anergic behavior in vitro. 
Classically, Τ cell anergy is defined as a low proliferative capacity upon stimulation with 
antigen only, which can be (partially) reversed by addition of exogenous IL-2. This feature 
was examined in restimulation assays. We found that independent of the provision of 
1,25(01-1)203 to the primary cell culture, Treg retained their anergic state (Figure 3C). In 
contrast to Tconv, Treg did not proliferate in the secondary culture upon stimulation in the 
absence of IL-2 while the addition of IL-2 to the secondary culture restored their proliferative 
capacity. 
Foxp3 expression was examined by flow cytometry 8 days after Treg stimulation with anti-
CD3/anti-CD28 mAb-coated microbeads in the presence of 1,25(ΟΗ)2θ3. 1,25(OH)2D3 did 
not affect Foxp3 expression in Treg. Neither the level of Foxp3 expression per cell as 
indicated by the mean fluorescence intensity (MFI) nor the percentage of cells expressing 
Foxp3 was affected (Figure 3D). 
Vitamin D3 increases the percentage of Treg producing IL-10 in an APC-free system 
Having established that 1,25(ΟΗ)2θ3 diminished the proliferative capacity of Treg but spared 
their suppressive function, we evaluated the influence of 1,25(ΟΗ)2θ3 on cytokine production 
(IL-2, IFNy, IL-4 and IL-10) in isolated Treg by intracellular flow cytometry. With the addition 
of 100 nM 1,25(OH)2D3, we found a statistically significant increase in the percentage of 
Treg producing IL-10 upon stimulation with anti-CD3/anti-CD28 mAb-coated microbeads, in 
an APC-free system (Figure 4A). IL-2 and IFNy production in both Treg and Tconv was 
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Figure 4. Effect of 1,25(OH)2D3 on cytokine production 
Intracellular staining for cytokines in A) Treg and B) Tconv. Treg and Tconv were stimulated with anti-
CD3/anti-CD28 mAb-coated microbeads with or without the addition of 100 nM 1,25(OH)2D3. At day 8 
of cultures, the cells were stimulated with PMA plus ionomycin in the presence of brefeldin A and 
intracellularly stained with antibodies directed against the cytokine as shown above. Data are 
representative for 5 independent experiments performed with cells isolated by high purity 
flowcytometric cell sorting, obtained from different donors. *P < 0.05 as compared to respective cell 
culture without the addition of 1,25(OH)2D3. 
In patients supplemented with cholecalciferol, the proliferative capacity of Treg was 
reduced and lower numbers of Treg were found 
Having established inhibitory effects of 1,25(OH)2D3 on Treg proliferation in vitro, we looked 
for evidence of this feature in vivo. To this end, we studied the effect of cholecalciferol 
(vitamin D3) supplementation on Treg cell division and Treg numbers in HIV-1 seropositive 
patients, who are known to have low serum 25(OH)D3 and 1,25(OH)2D3 levels (13). The 
subjects were supplemented with an oral daily dose of 2000 IU cholecalciferol during the first 
12 weeks and thereafter for at least 48 weeks with a dose of 1000 IU daily. At baseline and 
after 24 and 48 weeks after supplementation, we determined the numbers and proliferative 
capacity of circulating CD4+CD25hl Treg and the serum levels of 25(OH)D3, 1,25(OH)2D3, 
and parathyroid hormone . 
Upon supplementation of cholecalciferol, the serum 25(OH)D3 concentration significantly 
increased after 24 and 48 weeks as compared to baseline levels (Table 1). Also, 
1,25(OH)2D3 levels significantly increased after 24 weeks of supplementation, but were not 
significantly different from baseline at 48 weeks (Table 1, Figure 5A). As expected, 
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parathyroid hormone levels had an inverse relation to 1,25(OH)2D3 levels. Interestingly, the 
percentages and absolute numbers of CD4+CD25h'CD127Foxp3+ Treg were significantly 
lower after 24 weeks of supplementation, but recovered at 48 weeks when the dosage of 
cholecalciferol was lowered at week 12 (Figure 5B). This suggests a direct and inverse 
relationship between the levels of 1,25(OH)2D3 and the number of circulating Treg. Next, we 
analyzed the ex vivo proliferative capacity of Treg in supplemented patients by measuring 
the expression of the proliferation marker Ki-67 in CD4+Foxp3+ expressing Treg using flow 
cytometry (Figure 5C). At first, we compared the proliferation status of Treg in 8 subjects 
after 24 and 48 weeks supplementation of cholecalciferol, which corresponded to reduced 
1,25(OH)2D3 levels at week 48 as compared to week 24. We found an increased expression 
of Ki-67 in the Treg population (Figure 5D), but not in CD4* Tconv (i.e. Foxp3 cells) (Figure 
5E) at week 48 as compared to week 24. Together, these findings show that increased 
1,25(OH)2D3 levels concur with reduced proliferative capacity of Treg in vivo. 
Mdn (IQR) Mdn (IQR) Mdn (IQR) p-value p-value 
25-hydroxyvitamin D3 (nmol/L) 
1,25-dihydroxyvitamin Dj (pmol/L) 
Parathyroid hormone (pmol/L) 
Treg number (cells/L) 









































Table 1. Baseline data and week 24 and 48 data after cholecalciferol supplementation in 25-
hydroxyvitamin D3 deficient HIV-1 positive subjects 
DISCUSSION 
In this study, we showed a direct effect of 1,25(OH)2D3 on nTreg independent of APC. 
1,25(OH)2D3 dose-dependently inhibited Treg proliferation in vitro and high levels of serum 
25(OH)D3 and 1,25(OH)2D3 concur with low frequency of Treg in vivo. Apart from its 
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Figure 5. Effect of cholecalciferol supplementation in vitamin D, deficient HIV-infected patients 
A) Changes in serum 1,25(OH)2D3 concentrations and B) Treg numbers over time. *P < 0.05 as 
compared to baseline, **P < 0.05 as compared to week 24. The subjects were treated with a daily 
dose of 2000 IU cholecalciferol during the first 12 weeks and thereafter for at least 48 weeks with a 
dose of 1000 IU daily. C) Representative flow cytometry dotplot showing intracellular Ki-67 (X-axis) 
and Foxp3 (Y-axis) staining on CD4* gated Τ cells. Cumulative data showing the percentages of Ki-67 
expressing cells within the D) CD4*Foxp3+ and E) CD4+Foxp3 population at week 24 and week 48 in 
8 subjects, where serum 25(OH)D3 levels at week 48 was reduced as compared to week 24. *P < 
0.05 as compared to week 24. 
of Foxp3 in Treg or on the anergic characteristic and suppressive function in vitro, and even 
induced a slight increase in IL-10 production by Treg in an APC-free system. Also, we 
showed an inverse relationship between in vivo 1,25(OH)2D3 levels and Treg numbers In 
HIV-infected patients supplemented with cholecalciferol. So, whereas vitamin D3 may de 
novo induce Treg via the induction of tolerogenic DC (28;29) its direct effect on pre-existing 
Treg appears containment of the population size. 
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The active form of vitamin D, 1,25-dihydroxyvitamin D3, exerts its biological effect through 
VDR leading to modified gene expression. The vitamin D receptor is part of the steroid 
hormone nuclear receptor family that are expressed by various cell types including 
mononuclear cells. However, to our knowledge, no information is available regarding the 
expression of VDR by Treg. In this study, we demonstrated that Treg, like Tconv, do express 
VDR, and that the expression was up regulated upon Τ cell receptor (TCR) stimulation. This 
implies that 1,25(OH)2D3 may exert its immunomodulatory effects directly on Treg as we 
show here for cytokine production and proliferation arrest. The interplay between VDR and 
TCR signaling has not been widely studied. Although not specific to Treg, one possible 
mechanism involves TCR signaling via protein kinase p38 pathway which has been shown 
to induce up-regulation of vitamin D receptor and phospholipase C (PLC)-gammal in CD4+ 
and CD8* Τ cells (30). In addition, induction of PLC-gamma1 was found to be dependent on 
vitamin D and expression of the VDR and was vital for subsequent classical TCR signaling 
and Τ cell activation. 
Here, we showed clearly that 1,25(OH)2D3 inhibit the proliferation of human Treg freshly 
isolated from peripheral blood. Interestingly, we observed that in comparison to Tconv cells, 
1,25(OH)2D3 had a more pronounced repressive effect on Treg with regards to proliferation. 
Despite the fact that 1,25(OH)2D3 inhibited proliferation of Treg in vitro, it did not affect the 
number of Tregs that became activated upon stimulation with anti-CD3/anti-CD28 mAb-
coated microbeads, as indicated by the expression of CD69, nor did it induce cell death in 
Treg (data not shown). 
Our finding adds to the already described immunomodulatory effects of 1,25(OH)2D3 on APC 
and conventional Τ lymphocytes. In the presence of APC, 1,25(OH)2D3 can induce a 
regulatory phenotype by influencing their maturation (22;31), hereby facilitating the induction 
of regulatory cells via modulation of the APC. In pre-existing nTreg we showed that 
1,25(OH)2D3 inhibited its proliferation, but spared the suppressive phenotype and to some 
extent increased the number of IL-10 producing cells, notably in an APC-free system 
employed by the present study. With regard to conventional Τ cells, it has been shown that 
1,25(OH)2D3 and its analogues have the capacity to inhibit Τ cell proliferation (32-34) and to 
modulate cytokine production (35;36) when activated with mitogens. Secretion of IFNy and 
IL-17 was inhibited (23), and IL-4 and IL-10 production was enhanced (23;37-39) thereby 
favouring a bias towards Th2 differentiation. 
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In vivo we found suggestive evidence that cholecalciferol supplementation affect Treg 
numbers and proliferation. Increasing serum 25(OH)D3 and 1,25(OH)2D3 levels were 
paralleled by a drop in peripheral Treg numbers, while a subsequent reduction in 25(OH)D3 
levels resulted in recovery of Treg numbers. This variation in 25(OH)D3 and 1,25(OH)2D3 
levels concurred with changes in the number of dividing Foxp3+ cells, suggesting that 
regulation of Treg cell division was the underlying effect of cholecalciferol supplementation in 
vivo. Importantly, resting Tregs have recently been identified as a reservoir for HIV 
replication. In vitro activation of these cells led to a detectable viral production (40). The 
authors suggested that resting Tregs could release the virus when their anergy status is 
disturbed. We showed that vitamin D3 can inhibit Treg proliferation in vivo while in vitro, it 
preserved anergy. Therefore, 1,25(OH)2D3 could be possibly beneficial in diminishing the 
latent viral pool. Having said that, this postulation requires further verification. 
In conclusion, the present study demonstrated that nTreg express VDR which can be up-
regulated upon activation. The immediate effect of 1,25(OH)2D3 on nTreg is growth inhibition 
without interference on its suppressive capacity, anergy status or the Foxp3 expression. 
Also, in vitro 1,25(OH)2D3 skewed cytokine secretion in nTreg towards IL-10 producing cells 
in the absence of APC. As in vivo proof of principle that vitamin D3 inhibits Treg proliferation, 
we demonstrated that cholecalciferol supplementation in HIV-infected subjects restored 
1,25(OH)2D3 and 25(OH)D3 levels resulting in a decreased Treg numbers. 
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ABSTRACT 
Vitamin D3 is known to have an effect on the immune function. We investigated the 
immunomodulatory capability of vitamin D3 in human immunodeficiency virus (HlV)-infected 
patients and studied the expression of chemokine receptors on regulatory Τ cell (Treg). 
Vitamin Da-deficient HIV-1 seropositive subjects were treated with cholecalciferol (vitamin 
D3) at a daily dose of 800 IU for 3 months (n = 9) or a weekly dose of 25000 IU for 2 months 
(n = 7). Peripheral blood mononuclear cells (PBMC) were isolated and analyzed for skin-
homing (CCR4 and CCR10) and gut-homing (CCR9 and integrin Οιβ?) marker expression on 
Treg, by flow cytometry. Serum 25(OH)D3 and PTH levels were determined at baseline and 
after the treatment period. Weekly doses of 25000 IU cholecalciferol effectively achieved the 
optimal target serum 25(OH)D3 concentration of >75 nmol/L in HIV-infected patients. High 
dose cholecalciferol supplementation differentially influenced skin-homing markers on Treg 
with an increased level of CCR10 expression and while a reduction in CCR4 expression 
level was observed together with a lower percentage of Treg expressing CCR4. For both 
dosing regimens, there were no significant differences in the expression of gut-homing 
markers, CCR9 and integrin c^ß/. In conclusion, high dose vitamin D3 supplementation is 
needed to reverse vitamin D3 deficiency in HIV-infected individuals and this result in 
modulation of skin-homing markers but not gut-homing markers expression on Treg. At a 
standard dose of 800 IU/day, vitamin D3 is not effectively in achieving an optimal 25(OH)D3 




Vitamin D3 deficiency has also been identified as a highly prevalent entity among human 
immunodeficiency virus (HlV)-infected patients (1). The deficiency can be seen in both 
treated and untreated cohorts as well as HIV-infected patients compared to uninfected 
controls (2;3). Vitamin D3 has expanded its role beyond calcium and bone metabolism. The 
association of vitamin D3 deficiency with autoimmune conditions and infectious diseases 
provide the impetus to evaluate the impact of vitamin D3 supplementation on HIV disease 
and antiretroviral therapy. A well recognized effect of vitamin D3 has been its capacity to 
modulate Τ cell growth and function, and antigen presenting cell differentiation (4;5). It has 
been demonstrated that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibit Τ cell proliferation 
through suppression of interleukin (IL)-2 production (6;7). 1,25(OH)2D3 has also been shown 
to affect regulatory Τ cell (Treg) function and proliferation (8;9). Regulatory Τ cells, as 
characterized by the phenotype CD4+CD25h' and the transcription factor, forkhead box 
protein 3 (Foxp3), are crucial in the regulation of Τ cell homeostasis through its suppressive 
role on CD4+CD25" Τ cell response (10). This regulatory function of Treg is known to be 
hampered in autoimmunity, allergy and infectious diseases, indicating that these cells play a 
crucial role in immune-mediated pathology. However, little is known of the effects of vitamin 
D3 on Τ cell or Treg immunity in HIV-infected patients. This is so due to the limited number of 
studies carried out using vitamin D3 supplementation alone (11;12) or performed to assess 
its effects other than bone health in this group of patients. 
Human immunodeficiency virus-1 infection is characterized by progressive CD4* Τ cell 
depletion and immune dysfunction. Regulatory Τ cells are potential targets of HIV given that 
they express CD4 (13). HIV entry into target cells also requires cellular expression of the 
chemokine receptors CCR5 and CXCR4 in conjunction with CD4 (14). The role of Treg in 
regulating Τ cell activation during immune responses to pathogens such as chronic viral 
infections is a subject of great interest. Their effects can be beneficial or detrimental hinging 
on the balance between attenuating HIV-induced immune hyperactivation and mounting an 
immune response to HIV and mucosal pathogens. Chronic HIV infection also seems to alter 
the distribution of Tregs resulting in an apparent increased proportion in the peripheral lymph 
nodes and mucosal lymphoid tissues (15-18). Various chemokine receptors such as CCR4, 
CCR9, CCR10, CD62L and integrin a$7 are known to dictate the homing capacity of Τ cells 
as well as Tregs (19;20). Using CD4+CD25+ Tregs isolated from healthy subjects, Ji et al 
demonstrated that HIV-1 binds to Treg leading to an up-regulation of CD62L and integrin 
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α^β? expression (18). As a result, Tregs migrate to and accumulate in the peripheral lymph 
nodes and mucosal lymphoid tissues. 
Vitamin D3 has also been shown to affect the homing capacity of the peripheral CD4+ Τ cell 
population. Sigmundsdottir et al reported that 1,25(OH)2D3 induced the expression of skin-
homing chemokine receptors, CCR10 on CD4* Τ cells in vitro, at the expense of gut-homing 
markers, CCR9 and integrin (χ,β? (21). Given that both vitamin D3 (21) and HIV (15; 16; 18) 
can modulate the expression of chemokine receptors on Treg, it brings to mind whether the 
homing capability of Treg can be augmented by vitamin D3 during HIV infection. We 
investigate how cholecalciferol (vitamin Ds) in two different dosing regimen, 800 IU daily 
versus 25000 IU weekly, can impact Treg homeostasis in HIV-infected individuals and 
evaluate the expression of skin- and gut-homing markers in vivo and in vitro. 
MATERIALS AND METHODS 
Patients 
From April 2007 to August 2009, we conducted a pilot study in vitamin Ds-deficient HIV-
infected patients visiting the Radboud University Nijmegen Medical Centre, The Netherlands. 
Patients included were HIV-1 seropositive, vitamin D3 deficient and above 18 years old. 
Vitamin D3 deficiency was defined as 25(OH)D3 levels below 35 nmol/L (April to September) 
and below 25 nmol/L (October to March). The low-dose study cohort (n = 9) received a daily 
oral dose of 800 IU cholecalciferol for 3 months. The high-dose cohort (n = 7) received a 
weekly oral dose of 25000 IU cholecalciferol for 2 months. In the control group (n = 7) 
recruited from February to May 2009 and followed through until May to August 2009, no 
supplementation was administered. At baseline and after the treatment period, blood 
samples were taken for peripheral blood mononuclear cells (PBMC) isolation preceding flow 
cytometry analysis and serum vitamin D3 levels. The study was approved by the Ethical 
Committee on Human Experimentation of the Radboud University Nijmegen. A written 
consent was obtained from all participants to the study. PBMC were isolated as described 
below and subsequently used for flow cytometry analysis. 
In vitro study 
Buffy coats were obtained from healthy donors (Sanquin Blood Bank, Region South East, 
the Netherlands). Informed consent was obtained according to the Declaration of Helsinki. 
PBMC were isolated by density centrifugation with Lymphoprep (Axis-Shield AS, Oslo, 
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Norway) and LeucoSep® (Greiner Bio-One, Frickenhausen, Germany). CD4+ Τ cells were 
purified from PBMC by negative selection using monoclonal antibodies (mAbs) directed 
against CD8 (RPA-T8), CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD56 
(B159) and CD235a (GA-R2(HIR2) (BD-Biosciences, Erembodegem, Belgium) combined 
with sheep-anti-mouse-lg coated magnetic beads (Dynal Biotech, Invitrogen ASA, Oslo, 
Norway). The resultant CD4+ Τ cell fraction, typically of > 90% purity was incubated with 
anti-CD25-PE (M-A251, BD Biosciences, NY, USA), anti-CD4-ECD (SFCI12T4D11) and 
anti-CD27-PC5 (1A4CD27) conjugated antibodies (both from Beekman Coulter Corporation, 
Miami, USA). CD4+CD25h'CD27+ regulatory Τ cells (Treg) were isolated from purified CD4+ Τ 
cells by high purity flowcytometric cell sorting (Altra Flow Cytometer, Beekman Coulter, 
Miami, USA). The isolated CD4+CD25hlCD27+ Treg routine yield of > 95% purity were 
stimulated with anti-CD3/anti-CD28 mAb-coated Τ cell expander beads (Dynal Biotech, 
Invitrogen ASA, Oslo, Norway) in 200 μΙ culture medium (RPMI-1640 supplemented with 
glutamax, 0.02 mM sodium pyruvate, 100 U/ml Penicillin, 100 pg/ml Streptomycin) (all from 
Gibco, Paisley, UK) and 10% human pooled serum (HPS). Exogenous recombinant human 
interleukin-2 (rhlL-2) 12.5 U/ml (Proleukine, Chiron, Amsterdam, the Netherlands) was 
added to the cell culture. 1,25-dihydroxyvitamin D3 (Fluka Biochemika, Sigma-Aldrich, 
Missouri, USA) was dissolved in absolute ethanol and made up to a concentration of 100 nM 
in each well. No solvent effect was apparent in control experiments. Cell cultures were 
performed in 96-well round bottom plates (Greiner, Frickenhausen, Germany) and incubated 
for 3-4 days in a 37°C, 95% humidity, 5% CO2 incubator. 
Flow cytometry 
Cells were phenotypically analyzed by five-color flow cytometry (Coulter Cytomics FC 500, 
Beekman Coulter, Fullerton, USA) using Coulter Epics Expo 32 software. Cells were washed 
with PBS with 0.2% bovine serum albumin (BSA) before being labeled with fluorochrome-
conjugated antibodies (mAb). After incubation for 20 minutes at room temperature, in the 
dark, cells were washed twice to remove unbound antibodies and analyzed. For cell surface 
staining, the following mAb were used: CD127 PC5- or PC7-labeled (RDR5) (both from 
eBioscience); CD25-PE (M-A251), CD25-APC (2A3), CD49d-PE (9F10), CCR4-PC7 (1G1), 
(all from BD Biosciences); CD4 ECD- or PC7-labeled (SFCI12T4D11), CD4-PC5 (13B8.2), 
CD27-PC5 (1A4CD27), (all from Beekman Coulter Corporation); CCR9-PE (112509), 
CCR10-PE (314305) (both from R&D Systems) and CD27-FITC (M-T271; Dako). 
Appropriate isotype control mAbs were used for marker setting. 
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25(OH)D3 and parathyroid hormone levels 
Serum 25(OH)D3 was measured by high pressure liquid chromatography (HLPC) with UV 
detection, after prior extraction on small SepPak columns as previously described(2). 
Tritiated 25(OH)D3, collected from the HPLC system during passage of the UV peak, was 
used to correct for procedural losses. The within run precision was 2.6% at 69 nmol/l and 
between run precision was 6.2% at 69 nmol/L. For parathyroid hormone (PTH) assays the 
ELSA-PTH assay by CIS BIO was used at first. This method was switched into the intact 
PTH assay performed by the Abbott Architect analyzer, when the CIS BIO assay was no 
longer available. The Abbott Architect assay was recalibrated on the CIS BIO assay to give 
identical measurement results. 
Statistical analysis 
Statistical analysis was performed using the Statistical Product and Services Solutions 
(SPSS) package version 16.0. The Wilcoxon rank-sum test was used to compare differences 
between groups (unless otherwise stated). The level of significance was set at Ρ < 0.05. 
RESULTS 
We investigated the effect of low versus high dose cholecalciferol (vitamin D3) on serum 
25(OH)D3 and PTH levels in HIV-infected subjects. There were 3 study groups: the high-
dose cohort (n = 7) received weekly oral cholecalciferol supplementation at a dose of 25000 
IU for 2 months, the low-dose treatment arm (n = 9) was given 3 months of 800 lU/day 
cholecalciferol supplementation orally and the control group (n = 7) received no 
supplementation and was followed up from spring to summer. The patients' characteristics 
are presented in Table 1. 
High-dose cohort Low-dose cohort Non-treated cohort 
(n=7) (ii=9) (n=7) 
Medianage 33 39 37 























Table 1. Demographic data of the patients 
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High weekly dose of 25 000 IU cholecalciferol achieve the optimal target serum 
25(OH)D3 concentration in HIV-infected patients 
The baseline median serum 25(OH)D3 and PTH levels in the high-dose cohort (n=7) were 
30.0 nmol/L and 7.7 pmol/L respectively. After weekly cholecalciferol supplementation at 
25000 IU for 2 months, the median serum 25(OH)D3 and PTH levels were 138.0 nmol/L and 
6.7 pmol/L respectively (Figure 1A). In the low-dose cohort (n = 9), the baseline median 
serum 25(OH)D3 and parathyroid hormone (PTH) levels were 23.8 nmol/L and 7.2 pmol/L 
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Figure 1. Serum 25(ΟΙ-Ι)03 concentrations and parathyroid hormone (PTH) levels 
Serum 25(OH)D3 and PTH concentrations in A, B) high-dose, C, D) low-dose and E, F) control cohort 
before and after treatment. The high-dose cohort (n = 7) received a weekly oral dose of 25000 IU 
cholecalciferol for 2 months. The low-dose study cohort (n = 9) received a daily oral dose of 800 IU 
cholecalciferol for 3 months. In the control group (n = 7) recruited from February to May and followed 
through up for 2 to 3 months, no supplementation was administered. *P < 0.05 as compared to 
baseline. 
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serum 25(OH)D3 and PTH levels were 38.7 nmol/L and 3.8 pmol/L respectively (Figure 1B). 
The optimal target serum 25(OH)D3 of 75 nmol/L was achieved in 86% (6/7) of the high-dose 
study cohort but only 2 subjects (22%) in the low-dose treatment group attained this target 
concentration. 
From February to May 2009, seven HIV-infected subjects were recruited and no vitamin D3 
supplementation was given to this group. They were monitored for the effect of seasonal 
variation of vitamin D3 status after 2 to 3 months. In spring, the median serum 25(OH)D3and 
PTH levels were 33.0 nmol/L and 6.6 pmol/L respectively and in summer, the median serum 
25(OH)D3and PTH levels were 48.5 nmol/L and 5.7 pmol/L respectively (Figure 1C). 
Modulation in the skin-homing capacity of Treg can only be observed in high dose 
vitamin D3 supplementation 
In the next set of experiments, we investigated whether vitamin D3 supplementation can 
modulate the homing capability of Treg in HIV-infected patients. For this purpose, we 
evaluated the skin-homing markers, CCR4 and CCR10 as well as gut-homing markers, 
CCR9 and integrin cuß? using flow cytometry (Figure 2). 
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Figure 2. Representative flow cytometry dotplots for homing markers expression in HIV-
infected patients treated with high dose cholecalciferol 
Gate setting forCCRIO, CCR4, CCR9 and integrin cuß?; cells were gated on CD4+CD25hl regulatory Τ 
cells. Dotplots show surface staining for markers analyzed on PBMC. 
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A significant increase in the CCR10 expression (mean fluorescence intensity, MFI) by Treg 
was seen in the high-dose cohort after treatment (Figure 3A). In the same study group, a 
decrease in the skin-homing chemokine receptor, CCR4 expression level (MFI) was 
observed together with a lower percentage of Tregs expressing CCR4 (Figure 3C). 
However, in the low-dose treatment group no change in both skin-homing markers could be 
observed after 3 months (data not shown). 
We verified our in vivo findings by performing the analysis on regulatory Τ cells isolated from 
healthy volunteers and tested the in vitro effects of vitamin D3 using supraphysiological dose 
of 1,25(OH)2D3. Treg were stimulated with anti-CD3/anti-CD28 mAb-coated microbeads, in 
the presence of exogenously added rhlL-2 and 100 nM 1,25(OH)2D3 and analyzed after an 
incubation period of 4 days. The percentage of Tregs expressing CCR10 was significantly 
increased (Figure 3B). A significantly elevated level of expression (MFI) of CCR10 by Treg 
was also apparent. On the other hand, there was no significant effect observed for the 
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Figure 3. In vivo and in vitro effects of vitamin D3 on skin-homing markers CCR10 and CCR4 
expression by regulatory Τ cells 
Percentage and level of expression (mean fluorescence intensity, MFI) of skin-homing marker A) 
CCR10 and C) CCR4 by Treg in high-dose treatment group. PBMC from the study cohort were 
analyzed for the respective markers using flow cytometry; cells were gated on CD4+CD25h' Treg. 
Percentage and level of expression (MFI) of B) CCR10 and D) CCR4 on high purity flowcytometrically 
sorted-CD4*CD25h'CD127' Treg from healthy individuals. Cells were stimulated with anti-CD3/anti-
CD28 mAb-coated microbeads in the presence or absence (carrier) of 100 nM 1,25(OH)2D3 for 3-4 
days and analyzed for the respective markers using flow cytometry. Data show results from 5 to 6 
independent experiments performed with cells obtained from different donors. *P < 0.05 as compared 
to baseline or respective untreated cell culture without the addition of 1,25(OH)2D3. 
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Vitamin Da has no effect on gut-homing markers in vivo and in vitro 
There were no changes in the frequency and expression levels (MFI) of the gut-homing 
markers, CCR9 and integrin c^ß? with either low daily dose (data not shown) or high-dose 
pulsed therapy with vitamin D3 in HIV-infected patients (Figure 4A and 4C). Similarly, we 
looked at the expression of these markers in vitro, using Tregs isolated from healthy 
volunteers and stimulating these cells with anti-CD3/anti-CD28 mAb-coated microbeads and 
tested the effect of 100 nM 1,25(OH)2D3. Parallel to our in vivo observation, vitamin D3 has 
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Figure 4. Effects of vitamin D3 on gut-homing marker CCR9 and integrin αΛ$7 expression by 
regulatory Τ cells in vivo and in vitro 
Percentage of Treg expressing A) CCR9 and C) integrin (ITG) a$7, and A) level of CCR9 expression 
(MFI) by Treg in high-dose treatment group. PBMC from the study cohort were analyzed for the 
respective markers using flow cytometry; cells were gated on CD4+CD25h' Treg. Frequency of B) 
CCR9 and D) integrin (ITG) a$7 expression, and B) level of CCR9 expression (MFI) by 
CD4*CD25h'CD127 Treg isolated by high purity flowcytomelric cell sorting Cells were stimulated with 
anti-CD3/anti-CD28 mAb-coated microbeads and incubated in the presence or absence (carrier) of 
100 nM 1,25(OH)2D3 for 3-4 days and analyzed for the respective markers using flow cytometry Data 
show results from 5 to 6 independent experiments performed with cells obtained from different 




In this study, we used two different doses of vitamin D3 supplementation to investigate its 
effect on regulatory Τ cell trafficking in patients infected with HIV-1. We employed the 
standard recommended dose of 800 IU/day (22) versus a high dose regimen of 25000 
lU/week cholecalciferol (vitamin D3) in this study. In the high-dose study cohort, skin-homing 
marker CCR10 expression on Treg was increased while CCR4 expression and the 
percentages of CCR4-expressing cells were decreased. On the other hand, there were no 
notable differences in the expression of either the skin- or gut-homing markers in the low-
dose treatment group. The lack of effect seen in the low-dose cohort could be related to the 
lack of treatment efficacy with a standard dose of 800 IU cholecalciferol per day in this 
specific patient population. We saw that only 22% (2/9) of the patients in this cohort 
responded with a significant drop in PTH level and achieve serum 25(OH)D3 level of >75 
nmol/L. This effect is similar to that achieved by UV exposure during summer in the study 
region (Figure 1C). 
High-dose pulsed therapy seems effective in correcting vitamin D3 deficiency in 86% (6/7) of 
HIV-infected patients. The median serum 25(OH)D3 was elevated by 3-fold, from 33.0 
nmol/L to 138.0 nmol/L after 2 months. There is limited knowledge on the immunological 
influence of vitamin D3 supplementation in HIV-infected patients or the effective dose in this 
specific group of patients. In a cohort of 56 children (age 6 to 16) randomized to receiving a 
bi-monthly supplementation of 100,000 IU cholecalciferol (with daily doses of calcium) or 
placebo, serum 25(OH)D3 concentrations were higher in the treated group but no differences 
in CD4 count or viral load over a 12-month period were observed (11). In another study 
carried out in 40 patients with multiple sclerosis (MS), the efficacy of low dose cholecalciferol 
(800 IU or less) and high dose ergocalciferol (50,000 IU for 7-10 days and subsequently 
once or twice weekly) was being compared (23). Parallel to our observation, the low dose 
cholecalciferol treatment was unable to reverse the deficiency in MS patients while switching 
the patients to a high dosage of vitamin D2 resulted in a significant increase in their serum 
25(OH)D3 level. Of note, these patient cohorts share two things in common with ours in 
terms of geographical location (northern hemisphere) and both have an underlying 
immunopathology of different nature. The fact that we did not detect any significant 
differences in chemokine receptors expression by Treg in the low-dose cohort implies that it 
would be worthwhile using a higher dose to study the immunomodulatory effects of vitamin 
D3 in patients with an underlying immune dysfunction. In fact, it has been suggested that a 
higher 25(OH)D3 level (>100 nmol/L) may be required to sustain the immune function (24). 
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Homing receptors are selectively expressed and regulated in different Τ cells subset (19;25). 
Skin-homing Τ cells express CLA and by their binding to vascular E-selectin initiates the Τ 
cell rolling interactions on vascular endothelium, the first step in the migration process. 
Migration to the skin also involves CCR4 for the transition of blood to the dermis and CCR10 
from the dermis to the epidermis, and interactions of integrin cußi with VCAM and of LFA-1 
with ICAM-1. In human Τ cells, 1,25(OH)2D3 has been reported to down-regulate CLA 
expression but not CCR4, CCR6 and CCR7 (26). In vitro, it has been shown that addition of 
1,25(OH)2D3 after cells were activated resulted in an induction of CCR10 and inhibition of 
CLA expression (27). In the present study, high dose cholecalciferol supplementation in HIV-
infected individuals differentially augments the expression of skin-homing markers, CCR4 
and CCR10 on Treg. In vivo vitamin D3 up-regulates CCR10 expression and depresses 
CCR4 expression as well as the frequency of CCR4-expressing Treg. Parallel to our in vivo 
observation, CCR10 expression on Treg was elevated in vitro while the effect on CCR4 was 
not significant. The eventual result could still be a preferential homing of Treg to the skin as 
influenced by 1,25(OH)2D3. One should consider that even though both CCR10 and CCR4 
are implicated in lymphocyte-trafficking to the skin, there may be a certain degree of overlap 
in the two pathways with either alone being sufficient for skin homing (28). It has been 
shown that Τ cell accumulation within the skin was not impaired in CCR4-deficient mice 
(29;30). Lehtimaki reported that Treg are able to infiltrate the skin of CCR4-/- mice as 
evident by an increased number of Treg and enhanced Foxp3 mRNA in an oxazolone-
induced inflamed skin model (29). Hence even though we observed a depressed CCR4 
expression alongside an elevated CCR10 expression on Treg in HIV-infected subjects 
supplemented with high weekly dose of cholecalciferol, it is tempting to speculate that the 
net effect of vitamin D3 may be a preferential homing of Treg to the skin. 
The integrin cuß? and CCR9 are expressed by Τ cells which migrate to the gut. As previously 
described, retinoic acid and vitamin D3 which are selectively produced in the gut and skin 
respectively, differentially modulate the expression of gut- and skin- homing markers (31). 
Retinoic acid has been associated with up-regulation of CCR9 and integrin cLiß? expression 
while reducing the expression of CCR10 on Τ cells. On the other hand, 1,25(OH)2D3 does 
not affect the gut-homing markers but increased CCR10 expression (31). Here, we did not 
observe any in vivo or in vitro effect by 1,25(OH)2D3 on the expression of CCR9 and integrin 
cuß?. Of note, it has been demonstrated that the HIV-1 envelope protein gp120 binds to cuß? 
(32). As a result, CD4+CCR5hla4ß7h' Τ cells are highly susceptible to infection by HIV-1 and 
gp120 engagement of αιβ? is thought to facilitate infection at the point of transmission. 
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In light of the importance of vitamin D3 in regulating the immune function, interventions to 
improve vitamin D3 status in HIV-infected patients continues to warrant attention. Our 
findings serve as a caution to clinicians that treatment with a standard dose of 800 ID per 
day cholecalciferol may be inadequate to reverse the deficiency in HIV-infected individuals 
or to serve any immunomodulatory effects. The effect from a high weekly pulsed -dose 
therapy with vitamin D3 in HIV-infected individuals is suggestive of induction of skin-homing 
potential on Treg. 
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Summary and Discussion 

SUMMARY AND DISCUSSION 
Since the uncovering of an extra-renal source of 1 α-hydroxylase (1) and the expression of 
vitamin D receptor (VDR) by immune cells (2) almost 30 years ago, 1,25(OH)2D3 has 
displayed a far-reaching effect on human health. However, it was not until recent years that 
the physiological relevance of vitamin Ds-mediated immunity became more apparent and 
consequently the pursuit in vitamin D research is ever more intense. Annual citations in the 
PubMed database on vitamin D in 2010 were approximately 3600, doubling the volume as 
compared to a decade ago. 
In this thesis, we explored the role of vitamin D3 from three angles: its interaction with 
pathogens, the impact of its physiological variation on immunity and disease, and finally its 
immunomodulatory effect on the regulatory arm of the immune response. The observations 
and results of the studies presented in Chapter 2 through Chapter 8 are briefly described 
and further discussed below. 
In Chapter 2 of this thesis, we summarized the current knowledge on the role of vitamin D3 
as regulator of the immune system with specific reference to protective mechanism against 
pathogens. The net result of 1,25(OH)2D3 action on Τ cell is skewing towards regulatory Τ 
cell (Treg) differentiation and away from Τ helper (Th)1 and Th17 polarization. This is 
essential in curtailing an excessive and unchecked proinflammatory host response in certain 
situations such as sepsis and chronic infections. The recent discovery of its ability to 
promote production of the antimicrobial peptide cathelicidin underlines a protective 
mechanism by vitamin D3 in infections. Cathelicidin enhances microbial killing through 
disruption of the bacterial membrane and can also activate other antimicrobial pathways 
within infected cells. Over the past two decades, there is growing epidemiological evidence 
that suboptimal vitamin D3 status is correlated with the prevalence of many diseases not 
previously associated with this nutrient. Higher vitamin D3 status is positively associated with 
increased protection from infection with influenza, tuberculosis (TB) and respiratory tract 
viruses. However, such data amounts only to circumstantial evidence. As low vitamin D3 
levels may be itself a consequence of the disease process, evidence for vitamin D3 affecting 
disease pathogenesis must come from interventional studies. We discussed the clinical data 
from randomized placebo-controlled trials (RCT) in order to identify its therapeutic potential 
in infections such as TB, viral influenza and human immunodeficiency vims (HIV) infection. 
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From the studies we reviewed, vitamin D3 supplementation can potentially modify the clinical 
course and susceptibility to tuberculosis, and decrease the prevalence of viral respiratory 
tract infection. However, well-designed RCT are needed to elucidate the optimal vitamin D3 
doses as adjunctive therapy. 
The earliest recorded use of vitamin D was in 1849 when British physician, Dr Williams used 
cod liver oil to treat tuberculosis (known as phthisis at that time; defined as a disease 
characterized by wasting) (3). Although this is no longer the standard of care, the application 
of vitamin D3 in TB has since been re-visited most extensively amongst other infectious 
diseases. There have been numerous RCT (4-6) reported in recent years, as well as a 
comprehensive illustration of its underlying immunomodulatory mechanism (7). In Chapter 
3, we demonstrated that 1,25(OH)2D3 down-regulates the proinflammatory cytokine 
response in vitro when human leukocytes are stimulated with M. tuberculosis. Upon further 
evaluation, this appeared to be a consequence of suppression of Toll-like receptor (TLR) 2, 
TLR4, Dectin-1 and mannose receptor expression. On the other hand, production of the 
protective antimicrobial peptide cathelicidin was enhanced by vitamin D3. Even though Th1 
cytokines are vital for an effective immunity against M. tuberculosis, a disproportionate 
proinflammatory response often leads to excessive tissue damage (8). Taken together, 
these two effects complement each other by suppressing prolonged inflammation associated 
with TB and thereby prevent immune-mediated tissue damage, while offering protection 
through the antibacterial effect of vitamin Ds-induced cathelicidin. Moving forward, strategies 
to manipulate vitamin D3 therapy such that an antimicrobial effect can be achieved in TB 
without an excessive proinflammatory response would be an uphill task. Further studies are 
warranted to optimize this in vitro model and translate it into in vivo studies and to titrate the 
vitamin D dosages so that it can attain the desired clinical outcome. Moreover, it is 
reasonable to hypothesize that this 'dual action' of vitamin D3 may be of value in other 
chronic infections such as Candida albicans, where cathelicidin seems to exert a protective 
role (9). 
Our knowledge on the potential influence of vitamin D3 on fungal infection is limited (10), 
while vitamin D3 has been tested extensively as a preventive agent in viral influenza (11-13) 
and tuberculosis (4;6;14;15). In Chapter 4, we employed an in vitro Candida albicans model 
and showed that 1l25(OH)2D3 down-modulates the proinflammatory cytokine response 
through suppression of TLR2, TLR4, Dectin-1 and mannose receptor expression. We have 
illustrated a novel role for 1,25(OH)2D3 in the host innate response to C. albicans, but its 
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clinical relevance in C. albicans and other fungal infection merits further investigation. In line 
with the observations from Chapters 3 and 4, the challenge is to characterize and analyze 
the effects of vitamin D3 on the cytokine profile in these patients, from acute infection 
through the persistent phase. Such information will provide insights on how best to tailor 
vitamin D3 therapy to exert an anti-inflammatory effect without compromising antimicrobial 
activities. However, it is prudent to consider the possible effects that antimicrobial therapy 
may have on vitamin D3 metabolism. The enzymes involved in vitamin D3 metabolism, such 
as 1 α-hydroxylase, 25-hydroxylase and 24-hydroxylase, are part of the cytochrome 
(CYP)450 enzyme system. Many antimycobacterial, antifungal and antiretroviral drugs are 
known to induce or inhibit the CYP450 iso-enzymes so there is a potential risk for interaction 
with the metabolism of vitamin D3 and ultimately the systemic or local vitamin D3 
concentration (16). 
With an understanding that 1,25(OH)2D3 modulates proinflammatory cytokine production 
during infection in vitro, and before we validate these findings in vivo, it is worthwhile to 
establish how physiological variation in vitamin D3 status can modulate the immune 
response. Seasonal variation in vitamin D3 status with reduced sunlight exposure during 
certain periods of the year is thought to be responsible for the high prevalence of vitamin D3 
insufficiency among populations residing at higher latitudes. Not surprisingly, a positive 
latitude gradient for disease prevalence of certain cancers (17) as well as autoimmune 
diseases such as multiple sclerosis (MS) (18) and insulin-dependent diabetes mellitus (19) 
have been recorded. In Chapters 5 and 6, we presented novel findings on how seasonal 
variation in serum 25(OH)D3 concentrations can influence the innate and adaptive immunity 
in healthy adults. In Chapter 5, a significantly elevated serum 25(OH)D3 concentration 
during summer suppressed the proinflammatory cytokine response in healthy individuals. 
This effect was found to be related to a diminished expression of TLR2 and TLR4. In 
Chapter 6, we found seasonal changes in the peripheral Τ cell composition, phenotype and 
function. It would be useful to relate some of these observations with previous 
epidemiological findings on the prevalence of autoimmune diseases and infections, which 
coincide with the seasonal variation in vitamin D3 status. Therefore the appropriate course of 
action would be to verify these results in larger population-based studies, as well as in 
patient cohorts. Noteworthy, it has been suggested that a serological response to influenza 
vaccine is more frequent among prostate cancer patients with higher serum 25(OH)D3 levels 
(20). The season of birth can influence the risk of developing MS, and children born to 
mothers who were exposed to low levels of ultraviolet radiation in the first trimester have an 
increased risk of developing the disease later in life (21). The proposition that vaccine 
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responses may vary with the season and that the severity of specific autoimmune diseases 
may improve during summer merits further investigation. Ultimately, the gain of this type of 
information may improve decision-making in public health policies on vitamin D3 
supplementation. 
The final part of this thesis addressed the immunological impact of 1,25(OH)2D3 on 
regulatory Τ cells. Vitamin D3 is known to manipulate the differentiation and maturation of 
dendritic cells, inhibit Τ cell proliferation and alter cytokine production. Vitamin D3 inhibits the 
generation of Th1 and Th17 responses, while it induces Tregs by rendering dendritic cells 
tolerogenic. However, its immediate effect on human naturally-occurring Treg is less 
apparent. In Chapter 7, we addressed the effects of 1,25(OH)2D3 on Tregs in the absence of 
antigen presenting cells. In vitro 1,25(OH)2D3 could directly inhibit the proliferation of human 
naturally-occurring Tregs with limited effects on cytokine production, while preserving its 
suppressive function. One striking observation was that Treg proliferation was more 
susceptible to the suppressive effect of 1,25(OH)2D3 as compared to conventional Τ cell 
(Tconv). Our experiment revealed that Treg, similarly to Tconv, express VDR, and that the 
expression is induced upon Τ cell receptor (TCR) stimulation. This highlights the fact that 
1,25(OH)2D3 can affect Tregs directly. Therefore, the interplay between VDR and TCR 
signaling (22) in Treg is pivotal in outlining the mechanistic role of 1,25(OH)2D3 and deserves 
further attention. 
Human immunodeficiency virus infection is a disease of CD4+ Τ cells pathology. To study 
the impact of 1,25(OH)2D3 on Treg during disease state, we looked at how cholecalciferol 
(vitamin D3) supplementation can modify Treg phenotype in HIV-infected individuals. 
Reported as a pilot study in Chapter 7, reduced Treg numbers were seen in parallel with an 
elevated serum 25(OH)D3 levels when vitamin D3 deficient HIV-infected patients were 
supplemented with 2000 IU cholecalciferol daily. Apart from suppressed proliferation, we 
postulated the possibility of redistribution of circulating Tregs and examined how 
1,25(OH)2D3 may augment their trafficking potential in vivo. In Chapter 8, we illustrated that 
high-dose pulsed therapy with 25 000 IU cholecalciferol supplementation, differentially 
modulated skin-homing markers on Tregs with an increased level of CCR10 expression and 
reduced CCR4 expression. A significant finding was that cholecalciferol supplementation 
administered at 25 000 IU weekly promoted restoration of serum 25(OH)D3 levels more 
effectively as compared to a standard dose of 800 IU daily. This brings to mind the 
fundamental question of defining an adequate vitamin D3 dose for immunomodulatory 
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activities. Current target serum 25(OH)D3 concentration and dosage recommendation for 
vitamin D3 are governed by its therapeutic application in bone and calcium homeostasis (23). 
The dose required for achieving the same serum 25(OH)D3 concentration in patients with an 
underlying immune-mediated pathology may differ from healthy individuals. Furthermore, the 
optimal dosage as immunotherapy may differ among various diseases and remains to be 
determined. 
Vitamin D3 displays a multitude of activities and is known to be involved in a variety of 
diseases. It influences process such as immune regulation, host defense, inflammation, and 
cell proliferation. The findings in this thesis offer new perspectives on its immunological 
effects, as we seek to learn more about its mechanism of actions in various conditions and 
to translate it into clinical application. Having said that, several hurdles must be overcome to 
validate the benefits of vitamin D3 therapeutics. Many of its mechanisms in human pathology 
are not clearly elucidated and the molecular pathways involved are likely difficult to identify 
because vitamin D3 influences in parallel a variety of biological processes. The versatility of 
vitamin D3 also makes it challenging to determine the optimal dose needed to confer a 
beneficial outcome in different disease states. 
Epidemiological data suggest that the association between vitamin D3 deficiency and various 
pathologies is widespread, but conclusive data from interventional studies are missing for 
many diseases. Moving forward, randomized placebo-controlled trials taking into account 
variation in ethnicity, geographical location and seasonal variability in vitamin D3 status are 
needed to effectively decipher its therapeutic value. In addition, we propose that at least a 
few major questions need to be addressed: the dose to be administered, the time frame for 
potential benefits, the serum 25(OH)D3 concentrations to be sought for maximal clinical 
efficacy, the stage of disease most susceptible to this intervention, and the role of genetic 
variation in controlling responses to vitamin D3. The assessment of immunological functions 
would be of value in correlating with clinical outcomes. As much as we have advanced in our 
discovery of the non-classical roles of vitamin D3, new challenges present as we continue to 
unravel its clinical roles, in the hope of rejoicing in the 're-birth' of vitamin D3 when we are 
able to translate this knowledge into clinical benefits. 
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Nederlandse Samenvatting en Discussie 
Sinds de ontdekking dat er ook buiten de nier 1 α-hydroxylase bronnen zijn (1) en er bekend 
werd dat ook immuuncellen de vitamine D receptor (VDR) tot expressie kunnen brengen (2), 
bijna 30 jaar geleden, heeft 1,25(OH)2D3 een wijdverbreid effect gehad op de 
volksgezondheid. Met name de afgelopen jaren werd de relevantie van vitamine D3 
gemedieerde immuniteit steeds duidelijker en is er groeiende aandacht voor vitamine D. 
Jaarlijkse citaties in de database van PubMed op de zoekopdracht 'vitamine D' in 2010 
leverde ongeveer 3600 hits op, dit is een verdubbeling ten opzichte van een decennium 
geleden. 
In de studies beschreven in dit proefschrift is de rol van vitamine D3 bestudeerd vanuit drie 
invalshoeken: de interactie met ziekteverwekkers, de impact van de fysiologische variatie op 
immuniteit en ziekte en ten slotte het immuunmodulerende effect op de regulerende arm van 
de immuunrespons. De waarnemingen en de resultaten van de studies zijn gepresenteerd in 
hoofdstuk 2 tot en met hoofdstuk 8 van dit proefschrift. Hieronder volgt een korte 
beschrijving van de inhoud: 
In hoofdstuk 2 van dit proefschrift wordt de huidige kennis over de rol van vitamine D3 als 
regulator van het immuun systeem samengevat, met specifieke venwijzing naar 
beschermend mechanisme tegen ziekteverwekkers. Het netto resultaat van het effect 
1,25(OH)2D3 op Τ cellen in vitro is de sturing richting regulatoire Τ cel (Treg) differentiatie en 
weg van Τ helper (Th)1 en Th17 polarisatie. Dit is essentieel om een ontspoorde 
ontstekingsreactie in bepaalde situaties zoals sepsis en chronische infecties onder controle 
te houden. De recente ontdekking dat vitamine D3 de productie van het antimicrobiële 
peptide cathelicidin kan bevorderen onderstreept een beschermend mechanisme door 
vitamine D3 in infecties. Cathelicidin verbetert microbiële killing door het verstoren van het 
bacteriële membraan en kan ook andere antimicrobiële routes in geïnfecteerde cellen 
activeren. In de afgelopen twee decennia is er steeds meer epidemiologisch bewijs dat 
suboptimaal vitamine D3 status is gecorreleerd met de prevalentie van vele ziekten, die 
eerder niet in verband werden gebracht met vitamine D3. Een hoog vitamine D3 waarde is 
positief geassocieerd met een betere bescherming tegen besmetting met influenza, 
tuberculose (TB) en virussen aan de luchtwegen. Dit soort studies zijn slechts indirect 
bewijs. Lage vitamine D3 waardes zouden ook een gevolg kunnen zijn van het ziekteproces. 
Om experimenteel te bewijzen dat vitamine D3 inderdaad de Pathogenese van een ziekte 
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kan beïnvloeden dienen interventie studies te worden uitgevoerd. Wij bediscussiëren de 
klinische gegevens uit gerandomiseerde placebo-gecontroleerde studies (RCT) om het 
therapeutisch effect vast te stellen in infecties zoals tuberculose, virale influenza en humaan 
immuundeficiënt virus (HIV) infectie. Uit de studies die we bestudeerden, bleek dat vitamine 
D3 suppletie het ziekteverloop en de gevoeligheid voor tuberculose bepalen en de 
prevalentie van virale luchtweginfecties verminderen. Goed ontworpen RCT zijn echter nodig 
om de optimale vitamine D3 doses die geschikt is als therapeutisch adjuvant op te helderen. 
Het eerste geregistreerde gebruik van vitamine D was in 1849 toen de Britse arts, Dr 
Williams levertraan gebruikte voor de behandeling van tuberculose, op dat moment bekend 
als phthisis; gedefinieerd als een ziekte die wordt gekenmerkt door wegkwijnen (3). Hoewel 
dit niet meer de standaard benadeling is, heeft de toepassing van vitamine D3 in TB zich 
volop uitgebreid voor de behandeling van andere besmettelijke ziekten. Er zijn talrijke RCT 
(4-6) gemeld in de afgelopen jaren, evenals een uitgebreide illustratie van de onderliggende 
immuunmodulerende mechanismen (7). In hoofdstuk 3, laten we zien dat 1,25(OH)2D3 de 
proinflammatoire cytokine reactie onderdrukt in vitro, wanneer humane leukocyten worden 
gestimuleerd met M. tuberculosis. Na verdere evaluatie bleek dit een gevolg te zijn van de 
onderdrukking van Toll-like receptor (TLR) 2, TLR4, Dectin-1 en mannose receptor 
expressie. Tevens vonden we dat vitamine D3 de productie van het beschermende 
antimicrobiële peptide cathelicidin verhoogde. Hoewel Th1 cytokines van vitaal belang zijn 
voor een effectieve immuniteit tegen M. tuberculosis, leidt een ongecontroleerde 
proinflammatoire reactie vaak tot weefselschade (8). Samengevat, deze twee effecten vullen 
elkaar aan, enerzijds het onderdrukken van een langdurige ontsteking geassocieerd met TB 
en daarmee het voorkomen van immuun-gemedieerde weefselschade, anderzijds 
bescherming door de antibacteriële werking van het door vitamine Ds-geïnduceerde 
cathelicidin. Voor de toekomst ligt er de uitdagende taak om vitamine D3 therapie te 
manipuleren zodanig dat er een antimicrobiële werking kan worden bereikt in TB zonder 
overmatige ontstekingsreactie. Verdere studies zijn gerechtvaardigd om het in vitro model te 
optimaliseren en te vertalen naar in vivo onderzoek en de doseringen van vitamine D3 
zodanig te titreren, zodat het de gewenste klinische resultaten kan bereiken. Bovendien, lijkt 
het redelijk te veronderstellen dat de 'dubbele actie' van vitamine D3 van waarde kan zijn in 
andere chronische infecties zoals Candida albicans, waar cathelicidin ook een 
beschermende rol lijkt te hebben (9). 
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Onze kennis over de potentiële invloed van vitamine D3 op schimmelinfectie is beperkt (10) 
terwijl vitamine D3 uitgebreid is getest als een preventief middel bij virale influenza (11-13) 
en tuberculose (4;6;14;15). In hoofdstuk 4, tonen we in een in vitro Candida albicans model 
aan dat 1,25(OH)2D3 de proinflammatoire cytokine respons verminderd door middel van 
onderdrukking van TLR2, TLR4, Dectin-1 en mannose receptor expressie. We hebben een 
nieuwe rol voor 1,25(OH)2D3 bloot gelegd in de aangeboren immuunreactie tegen 
C. albicans. Echter, de klinische relevantie in C. albicans en andere schimmelinfecties 
vereist verder onderzoek. In overeenstemming met de gerapporteerd bevindingen in de 
hoofdstukken 3 en 4, is het nu de uitdaging om de gevolgen van vitamine D3 op het cytokine 
profiel in patiënten, van acute infectie tot aan de persisterend fase te karakteriseren en te 
analyseren. Dergelijke informatie zal inzicht geven over de optimale wijze van vitamine Ds 
therapie, met als doel ontsteking te remmen zonder verlies van antimicrobiële werking. Het 
is wel van belang aandacht te besteden aan de mogelijke gevolgen die antimicrobiële 
therapie op het vitamine D3 metabolisme kan hebben. De enzymen die betrokken zijn bij 
vitamine D3 metabolisme, zoals 1 α-hydroxylase, 25-hydroxylase en 24-hydroxylase, maken 
deel uit van de cytochroom P450 (CYP450) enzymsysteem. Van veel antimycobacteriële, 
schimmeldodende en antiretrovirale geneesmiddelen is bekend dat zij de CYP450 iso-
enzymen remmen, dus er is een potentieel risico voor interactie met het metabolisme van 
vitamine D3 en uiteindelijk de lokale of systemische vitamine D3 concentratie (16). 
Nu we weten dat 1,25(OH)2D3 de productie van proinflammatoire cytokines in ons in vitro 
infectie model moduleert, is het van belang deze bevindingen in vivo valideren. Echter voor 
het zover is, is het van belang om vast te stellen hoe fysiologische variatie de vitamine D3 
status en de immuunreactie kan moduleren. Seizoensvariatie in vitamine D3 status met 
verminderde zonlicht gedurende bepaalde periodes van het jaar wordt beschouwd als 
verantwoordelijk voor de hoge prevalentie van vitamine D3 insufficiëntie onder de bevolking 
woonachtig op hogere breedtegraden. Een positieve correlatie tussen breedtegraad en 
ziekte prevalentie van bepaalde kankers (17) en immuunziekten zoals multiple sclerose (MS) 
(18) en insuline-afhankelijke diabetes mellitus (19) is geconstateerd. In de hoofdstukken 5 
en 6, presenteren we nieuwe bevindingen hoe seizoensvariatie de serum 25(OH)D3 
concentraties en de aangeboren en adaptieve immuniteit bij gezonde volwassenen kunnen 
beïnvloeden. In hoofdstuk 5 tonen we aan dat een aanzienlijk verhoogde 25(OH)D3 
serumconcentratie tijdens de zomer, proinflammatoire cytokine reactie in gezonde individuen 
onderdrukt. Dit effect wordt gerelateerd aan een verminderde expressie van TLR2 en TLR4. 
In hoofdstuk 6 vonden we seizoensgebonden veranderingen in de perifere Τ cel 
samenstelling, fenotype en functie. Het is waardevol om enkele van deze bevindingen te 
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relateren aan eerder resultaten van epidemiologisch onderzoek naar de prevalentie van 
auto-immuun ziekten en infecties, die mogelijk met de seizoensvariatie in vitamine D3 status 
samenvallen. Daarom zou het goed zijn om deze resultaten te controleren in grotere 
bevolking gebaseerde studies, evenals in patiënt cohorten. Het is opmerkelijk dat er is 
gesuggereerd dat een serologische reactie op griepvaccin vaker onder prostaatkanker 
patiënten met hogere serum 25(OH)D3 niveaus voorkomt (20). Het seizoen van geboorte 
kan het risico van het ontwikkelen van MS beïnvloeden en kinderen van moeders die 
werden blootgesteld aan lage niveaus van ultraviolette straling in het eerste trimester 
hebben een verhoogd risico van het ontwikkelen van de ziekte later in het leven (21). De 
stelling dat vaccinatie reacties kunnen variëren met het seizoen en dat de ernst van de 
specifieke auto-immune ziekten tijdens de zomer verbeteren, verdient verder onderzoek. 
Uiteindelijk, zal deze informatie besluitvorming verbeteren in het volksgezondheidsbeleid 
met betrekking to vitamine D3 suppletie. 
Het laatste deel van dit proefschrift is gericht op het immunologische effect van 1,25(OH)2D3 
op regulatoire Τ cellen. Van vitamine D3 is bekend dat het de differentiatie en de rijping van 
dendritische cellen manipuleert, de Τ cel proliferatie remt en cytokine productie wijzigt. 
Vitamine D3 remt de generatie van Thl en Th17 reacties en induceert Treg op een indirecte 
wijze doordat vitamine D3 tolerogene dendritische cellen induceert. Het directe effect van 
vitamine D3 op natuurlijk voorkomende Tregs is echter minder duidelijk. In hoofdstuk 7 
beschrijven we de effecten van 1,25(OH)2D3 op Tregs in de afwezigheid van antigeen-
presenterende cellen. In vitro kan 1,25(OH)2D3 direct de proliferatie van humaan natuurlijk 
voorkomende Tregs beïnvloeden met beperkte effecten op cytokine productie en het behoud 
van de onderdrukkende functie remmen. Een opvallende observatie was dat Treg proliferatie 
meer vatbaar was voor het onderdrukkende effect van 1,25(OH)2D3 in vergelijking tot 
conventionele Τ cellen (Tconv). Uit ons experimenten bleek dat in Treg, op dezelfde manier 
als in Tconv, de expressie van de VDR kon worden geïnduceerd door Τ cel receptor (TCR) 
stimulatie. Dit wijst erop dat 1,25(OH)2D3 rechtstreeks Tregs kan beïnvloeden. Daarom is het 
samenspel tussen de VDR en TCR signalering (22) in Treg cruciaal in de mechanistische rol 
van 1,25(OH)2D3 en verdient dit nadere aandacht. 
Human immunodeficiency virusinfectie is een ziekte van CD4+ Τ cellen. Om de impact van 
1,25(OH)2D3 te bestuderen op Treg tijdens ziekte, hebben we bestudeerd hoe cholecalciferol 
(vitamine D3) suppletie het Treg fenotype in Hl V-geïnfecteerde individuen beïnvloedt. Zoals 
gerapporteerd als een pilot-studie in hoofdstuk 7, vonden wij verminderde absolute 
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aantallen Treg in het perifere bloed, en daarnaast vonden we een verhoogde serum 
25(OH)D3 niveau, wanneer vitamine D3 deficiënte HlV-geïnfecteerde patiënten dagelijks 
werden gesupplementeerd met 2000 IU cholecalciferol. Naast de verminderde Treg 
proliferatie in vivo, hebben de mogelijkheid getoetst of 1,25(OH)2D3 de distributie van 
circulerende Treg kan beïnvloeden in vivo door een verandering in migratie marker 
expressie patroon. In hoofdstuk 8, tonen we aan dat een hoge dosis pulse therapie met 
25000 IU cholecalciferol suppletie, de expressie huid-'homing' markers op Tregs differentieel 
moduleert, met een verhoogd level van CCR10 expressie en verminderd CCR4 expressie. 
Een belangrijke bevinding was dat wanneer cholecalciferol suppletie van 25000 IU wekelijks 
toegediend wordt, dit het serum 25(OH)D3 niveau effectiever bevorderd in vergelijking met 
een dagelijks standaard dosis van 800 IU. Dit doet denken aan de fundamentele vraag van 
het definiëren van een voldoende vitamine D3 dosis voor immuun modulerende activiteiten. 
De huidige doelstelling van 25(OH)D3 serumconcentratie en de aanbevolen dosering voor 
vitamine Ds worden beheerst door de therapeutische toepassing ervan in bot en calcium-
homeostase (23). De dosis die nodig is voor het bereiken van dezelfde serum 25(OH)D3 
concentratie bij patiënten met een onderliggende immuun-gemedieerde pathologie wijkt af 
van gezonde individuen. Bovendien, de optimale dosering als immunothérapie verschilt 
tussen de verschillende ziekten en zal moeten worden bepaald. 
Vitamine D3 leidt tot een uiteenlopende hoeveelheid biologische effecten en is betrokken bij 
diverse ziekten. Het beïnvloedt processen zoals immuunregulatie, host defense, ontsteking 
en celproliferatie. De bevindingen in dit proefschrift bieden nieuwe perspectieven voor het 
moduleren van immunologische effecten, we proberen meer te leren over het mechanisme 
onder verschillende omstandigheden en dit te vertalen naar klinische toepassingen. Dit 
gezegd hebbend, er moeten eerst nog verschillende hindernissen worden overwonnen om 
de voordelen van vitamine D3 therapie te valideren. Veel van de mechanismen in menselijk 
pathologie zijn nog niet duidelijk en de moleculaire pathways die betrokken zijn, zijn nog 
maar amper geïdentificeerd, vooral omdat vitamine D3 een verscheidenheid aan biologische 
processen beïnvloedt. De veelzijdigheid van vitamine D3 maakt het uitdagend om de 
optimale dosis te bepalen die nodig zijn in andere staat van ziekte. 
Epidemiologische gegevens suggereren dat de associatie tussen vitamine Ds-deficiëntie en 
verschillende pathologieën wijdverbreid is, maar afdoende gegevens uit interventionele 
studies voor vele ziekten ontbreken. Wat we nodig hebben zijn gerandomiseerde placebo-
gecontroleerde studies die rekening houden met variatie in etniciteit, geografische locatie en 
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seizoensgebonden variabiliteit in vitamine D3 status om daarna effectief de therapeutische 
waarde te ontcijferen. Bovendien stellen wij voor dat ten minste een paar belangrijke 
vraagstukken moeten worden aangepakt: de dosis die moet worden toegediend, het 
tijdschema van toediening, de serum 25(OH)D3 concentraties die nodig zijn voor maximale 
klinische werkzaamheid, het stadium van de ziekte dat het meest vatbaar is voor deze 
interventie en de rol van genetische variatie in het controleren van reacties op vitamine D3. 
Het analyseren van immunologische functies is van groot belang in correlatie met de 
klinische resultaten. Hoeveel we ook al hebben bereikt in het blootleggen van de "niet-
klassieke rol" van vitamine D3, nieuwe uitdagingen presenteren zich als we doorgaan met 
het ontrafelen van de klinische relevantie van deze stof. Tezamen maakt dat, dat we kunnen 
uitkijken naar een 'wedergeboorte' van vitamine D3, zeker wanneer wij in staat blijken om 
deze kennis te vertalen naar een verbetering van klinische protocollen en behandeling. 
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Last but not least, I present the most challenging 'chapter" of my thesis. It took me the longest time 
because there are so many emotions, and some of which are pretty difficult to pen down. With my 
sincere heart, I would like to convey my deepest gratitude to all you wonderful people... 
In spring 2007, I packed my bag and came along with my husband Louis, to Nijmegen. Louis was 
eager to find me a job while we spend the next couple of years here in this quaint town. Through 
Prof Mihai Netea, I was most fortunate to have met Prof André van der Ven and that was how this 
journey begins Prof André van der Ven, you are one person whom I am most indebted to. 
Without any prior knowledge about who I am or what I can do, you did not hesitate to give me a 
chance to work in your team. To date, this is one kind act that has been deeply engraved in my heart 
and I will be eternally grateful to you. You have also been very concerned about my well-being as 
well as that of Louis and we are truly honoured to have known you. 
Prof Irma Joosten, you have been most instrumental in all my research work and my manuscripts. 
Like Andre, you took a chance when you granted me the opportunity to not only work in your 
laboratory but later on, to even pursue a doctoral degree. For that, I am truly gratified. I have learnt 
a lot from yourself and it is your invaluable guidance and tutoring that has seen me through this 
endeavour. Irma, from the bottom of my heart, I am thankful to you for the trust and the 
mentorship all these years. 
My initial impression of Dr Hans Koenen was 'Mr Nice Guy' and this image remains unchanged. 
Given that I had absolutely no prior knowledge on immunology, you have been most patient and 
kind when coaching me all these years. There has not been a single instance that you lost your cool 
when things were not proceeding smoothly. Hans, it has been a blessing that you are my mentor and 
it is due to your cordial personality that I had not become adverse to the subject during times of 
difficulties. I am also touched by your concern over Louis and Clement (and now Damian) from time 
to time. 
Prof Mihai Netea, for all your help right from the moment you picked us up at Nijmegen Station in 
March 2007, we express our heartfelt gratitude. You are without doubt one of the most talented 
people we have met but your approach towards people around you has been most admirable and 
we are still learning how to emulate your humility. Our most sincere thanks to you and Romana for 
the benevolence showered upon our family and we certainly wish that the upkeeping of our 
friendship will remain a good reason to bring us back to Nijmegen every now and then. 
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If I may consider myself as a by-product of Louis' scholarship, I am certainly indebted to the Ministry 
of Health and the Agency for Science, Technology and Research (A*STAR)/National Medical Research 
Council, Singapore. Very importantly, I sincerely thank Prof Jos van der Meer and Prof Bart-Jan 
Kullberg for your help to overcome the issues with our stay permit in the initial days. It was the most 
critical huddle to surmount before we could begin our research work with peace of mind. 
I am truly honoured to be working alongside many experienced analysts and researchers in both the 
laboratory of medical immunology (LMI) and the department of medicine (AIG). Esther (Fasse), you 
have been most kind in many ways to myself and my family. Since the days you initiated me to the 
laboratory, you have been a constant help, not only in the laboratory but also on other matters 
which I have troubled you with. I express my heartfelt appreciation to you for helping with the 
translation of the Dutch summary for my thesis and for agreeing to be the paranimfen. 
Esther (van Rijssen), my sincere thanks to you for helping me all along, sharing some of your skills 
and results with me, and even carrying out some of the experiments after I had returned to 
Singapore. Jorieke, Diana, you were the first people whom I shared the room with. I recall how 
dependent I was when I first joined and kept asking the both of you for advice on many things. You 
have been most kind to share your knowledge with me and that has helped me a lot in the early 
days. Vivian, Marina, Bram, Jos, Elena, Sip and Arnold, you have all been such gracious friends in the 
laboratory. Henk, I thank you for showing me how to performing qPCR. Rob, you have always been 
so obliging to help me with 'cell sorting' and for that I am truly gratified. Some of my work would not 
have been possible if not for your involvement. Ronald, I am grateful for your assistance with some 
of my experiments during my pregnancy. 
Meta, you were one of the first persons we got to know when we first landed in Radboud and you 
have been such a caring friend all along. We hope that there will be more opportunities to see one 
another given that you have to travel to Bandung for your research work these days. Sharon, I am 
grateful for all the hard work you had put in for the study on vitamin D supplement in HIV patients. 
Marjolein, I am also thankful for your help during the course of this study. Marije, thank you for your 
help in one of my experiments and we wish you every success in your work. Johanna and Trees, I 
appreciate your time and effort in showing me how to perform qPCR and ELISA. 
To all our friends in LMI and AIG, I am happy to be a part of the team and I thank each and every one 
of you for your help and concern especially during my pregnancy. Louis and I will remember your 
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kindness and the greetings we exchanged along the corridors. You form part of the sweetest 
memories from Nijmegen which we consistently reminiscence. 
Throughout the three years in Nijmegen, we were most blessed to be in the companionship of many 
gracious friends. Xuehui and Xinhui (and now Andy), you have been as our dear friends for the 
longest time and we are deeply touched by your kindness in so many ways. Xuehui, I truly enjoyed 
the times I had working alongside you in the laboratory, sharing 'cells' and helping each other out. I 
convey my deepest gratitude to you for always obliging to help during flow cytometry analysis 
(whenever the schedule for the 'FC500' was extremely tight), for performing the 3H-thymidine assay 
when I was pregnant, and for taking up the role as the paranimfen. 
James and Beryl, God has showered us with abundant blessings and He bestowed upon us this 
friendship which we treasure dearly. We got acquainted at the Radboud Guesthouse in the earlier 
days of our stay in Nijmegen and came to know each other better when James joined the AIG 
laboratory, we hope that our friendship will carry on in many years to come. We pray for God's 
continual blessings upon yourselves and your family, and especially for Hosanna. 
Fr Joop, we were indeed fortunate to stumble upon the Dorminicuskerk on the first weekend that 
we were in Nijmegen. That day, we were an hour late for the English-speaking mass due to the 
switch to day-light saving time. You extended a warm welcome to us and henceforth we became a 
part of this unique multi-national Catholic student community in Nijmegen. Fr Joop, it is through 
your efforts that we have a place to gather and listen to God's words and to celebrate church 
festivities. It was also our blessing to be surrounded by the warmth of the many religious whom 
passed through Radboud University and the companionship of many friends from all over Europe, 
Africa and Indonesia. 
Alena, you have always been my soul mate since we knew each other at the Dorminicuskerk. I miss 
the times we chatted over a cup of coffee in our apartment. Your friendship is the greatest gift from 
God and we pray that God will shower you with many blessings in life. 
Alieke and Fazin, you have been a role model for the both of us in many ways. We are full of 
admiration for your strength and perseverance. We constantly keep you in our prayers. Thank you 
Fazin, for your help to ease my toothache back in 2009. 
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Viviane and family, through the years we have been receiving countless help from all of you, the 
warmth and the generosity from fellow countrymen has been most comforting to us. Chloe, it has 
been a great joy to know you as a friend, a sweet and kind girl. Ching Wei & Jerald, Nicole & Alfons, it 
has always been such a joy to meet up during festive season and exchange our experience on taming 
the little ones. 
Papa and Mummy, I owe what I have achieved to you, for all that you have provided for me all these 
years. I realised only in recent years the autonomy you have given me is invaluable, I thank you for 
your trust in me. To my brothers, Puay Meng & Bow and Puay Ning, it is a blessing to come together 
as siblings and I hope we continue to treasure this kinship in many years to come. Uncle Francis and 
family, thank you for taking care of my parents and my brothers all these years, and especially during 
the times when I was away from home. 
Clement and Damian, I dedicate the spirit of this book to the both of you. When you believe in 
yourselves and as long as you remain focused, you can achieve your goals in life. You are the most 
precious gifts from God and you have enriched our lives tremendously over that past three years. It 
is indeed amazing that papa and mama have you to share our joy on both occasions of our thesis 
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